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proteCtion of the human body: the immune response
The human body is continuously exposed to various pathogens. To protect itself 
against these potential threats, the human body possesses a combination of 
mechanisms to either inhibit the entrance of the pathogens, or to neutralize 
and quickly remove pathogens that do enter the human body. These defense 
mechanisms can be subdivided into three different layers of protection.
The firsT layer of proTecTion: physical and chemical barriers
The first layer of protection, is composed of a physical and chemical barrier, which 
prevent the initial entrance of pathogens into the human system. The major 
physical barrier is the epithelial lining on the outside of our body, i.e. skin tissue and 
the mucosal membranes of our gut and lungs. The cells in this epithelial lining are 
tightly connected (e.g. via tight junctions, gap junctions or adherens junctions), 
thereby preventing pathogens to penetrate through the epithelium.1,2 In addition, 
air flow around the skin, peristaltic movement of the bowel, and movement of 
cilia on the apical side of epithelial cells mechanically remove pathogens from 
the human body. Thirdly, in addition to these physical barriers, chemical barriers 
are formed, which include mucus, sweat, saliva and tears. These fluids contain 
antimicrobial proteins, contain a high salt concentration and have a low pH, which 
together inhibit attachment and proliferation of pathogens.3 Finally, the human 
body is colonized with commensal microbiota. These bacteria do not only occupy 
potential niches and thereby prevent the attachment of harmful pathogens, but 
are also essential for epithelial cell proliferation and differentiation, and support 
the second and third layers of protection.4 (Figure 1).
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Figure 1. First layer of protection: 
A physical and chemical barrier.
The physical barrier is composed of a tight 
epithelial lining near the exterior of the 
human body, closely connected via structures 
including tight junctions. The chemical barrier 
is composed of mucus, tears and sweat 
containing low pH, high salt concentration 
and containing antimicrobial proteins. The 
commensal microbiota and cilia on top of 
epithelial cells further prevent pathogen 
adherence.  
The second layer of proTecTion: The innaTe immune response
In case a pathogen does enter the human body, an immune response is needed 
to eliminate it.5 Cells and molecules of the vertebrate immune system are able 
to recognize foreign particles and to initiate a cascade of responses for pathogen 
neutralization and removal. Important mediators of the second layer of protection 
are soluble proteins that form the complement system,6 and innate immune cells. 
These innate cells carry receptors that recognize conserved pathogenic structures, 
such as pathogen-associated, microbe-associated or damage-associated molecular 
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patterns on bacteria, fungi, parasites or damaged host cells.7-9 Various innate cell 
populations can be discriminated, each with a distinct role in the immune response 
(Figure 2).10,11 First of all, pathogenic threats can be fought directly by two types of 
innate cells, i.e natural killer (NK) cells and eosinophils. NK cells recognize and kill 
pathogen-infected cells,12,13 whereas eosinophils locally release anti-pathogenic 
toxins upon infiltration of extracellular pathogens.14 Secondly, mast cells can 
release chemokines and pro-inflammatory cytokines that induce the dilation of 
blood vessels, thereby mediating the recruitment of additional innate immune 
cells from blood, including monocytes, neutrophils, basophils and dendritic cells 
(DCs).15 Basophils start to release their granule content, which stimulates further 
recruitment of innate cells.15 Monocytes migrate into tissue and differentiate into 
macrophages that, together with the newly recruited neutrophils, take up pathogens 
by phagocytosis and destroy the pathogens internally in endosomal structures.16,17 
Finally, DCs take up the pathogen, and migrate through the lymphatic system into 
secondary lymphoid tissues. In these tissues, B and T lymphocytes are activated 
and form the third layer of protection.18 DCs thereby perform a crucial bridging 
function between the second and third layers of protection. 
NK cell eosinophil mast cell macrophage
neutrophil
DC
basophil monocyte
1. direct
killing
2. chemokines 3. phagocytosis 4. presentation
pathogenexterior
blood
Figure 2. Second layer of protection: 
Innate immune responses.
Innate leukocytes possess four basic 
mechanisms to fight pathogen infections: 
1) direct killing of pathogen-infected cells 
by NK cells; or removal of free pathogen in 
the local tissue by eosinophils;
2) production of chemokines by mast cells 
and basophils;
3) phagocytosis and internal pathogen 
killing by macrophages and neutrophils;
4) phagocytosis and antigen presentation 
by dendritic cells (DCs) to initiate adaptive 
immune responses. 
The Third layer of proTecTion: The adapTive immune response
B and T lymphocytes form the third line of defense: the adaptive immune response 
(Figure 3). These cells carry specialized receptors, i.e. the B-cell receptor (BCR) or 
T-cell receptor (TCR). In contrast to other proteins, these receptors differ between 
each newly generated B and T cell, and together these cells can recognize an 
enormous diversity of structures, i.e. epitopes. Mature B and T cells circulate 
through blood and lymphatic vessels between lymphoid tissues. B cells recognize 
soluble antigens dispersed into the lymph nodes via the lymphatic system. T cells, 
however, only recognize an antigen when it is presented on specialized protein 
complexes called the human leukocyte antigens (HLA’s; also known as the major 
histocompatibility complex (MHC) proteins), by DCs that migrated from local 
tissue into the lymph nodes. Upon recognition of specific antigen, a B or T cell 
becomes activated, resulting in extensive clonal proliferation and differentiation 
into effector cells.  
Two major types of T lymphocytes exist: cytotoxic and helper T cells. Cytotoxic T 
cells recognize antigens presented on HLA proteins A, B or C (HLA-class I), which 
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are expressed on all cells of the body except for red blood cells. Presented in the 
groove of these HLA-class I molecules are intracellular peptides.19 By scanning 
the antigens presented in these HLA-class I molecules, cytotoxic T cells are 
able to scan the content of a cell. In case of a viral infection, intracellular viral 
peptides will also be presented in HLA-class I molecules on the cell membrane 
and can be recognized by cytotoxic T cells. Local recognition of virus-infected 
cells by activated cytotoxic T cells subsequently triggers the release of cytotoxic 
molecules resulting in the direct killing of the infected cells.20 The TCR – HLA-class 
I interaction is stabilized by the co-receptor molecule cluster of differentiation 8 
(CD8), expressed on the cytotoxic T cell, which is therefore also referred to as 
CD8+ T cell. Helper T cells recognize peptides presented on HLA proteins DP, DQ 
or DR (HLA-class II). Different from HLA-class I molecules, HLA-class II molecules 
present peptides taken up from the cell’s exterior, such as bacterial antigens. As 
antigen uptake and presentation in the groove of HLA-class II proteins can only be 
performed by specialized cells called antigen-presenting cells (APCs), helper T-cell 
interactions are limited mainly to cells of the immune system.20,21 Activated helper 
T cells function predominantly in stimulating the activation of surrounding antigen-
specific B and cytotoxic T lymphocytes.22 The TCR – HLA-class II interaction is 
stabilized by the co-receptor CD4, and helper T cells are therefore also referred 
to as CD4+ T cells.
Upon antigen recognition, and proper stimulation by helper T cells, B cells undergo 
extensive clonal expansion and can differentiate into plasma cells, which secrete 
large amounts of soluble variants of the BCR: immunoglobulins (Igs). These Igs can 
bind the pathogen and thereby prevent it from binding and infecting cells, thereby 
neutralizing the pathogenic threat. Furthermore, they can stimulate phagocytosis 
of the pathogen by phagocytic cells, such as neutrophils and macrophages, or 
they can induce antibody-dependent cytotoxicity, both processes resulting in the 
destruction of the pathogen.20  
The antigen-specific B- and T-cell responses are highly effective in controlling 
an infection. However, upon primary infection, the selective activation followed 
by extensive proliferation and maturation of lymphocytes takes several days. 
Therefore, the host depends largely on the immediate innate immune response 
in the first days after primary infection. Importantly, after primary infection with 
a pathogen and subsequent clearance by the immune system, a selected set of 
antigen-experience lymphocytes involved in this response remain present in the 
circulation as “memory” lymphocytes.  In case of a subsequent encounter with the 
same pathogen, these memory lymphocytes are able to recognize the pathogen 
and to respond more quickly than naive B and T cells. The adaptive immune 
responses thereby provide immunological memory. Consequently, the pathogenic 
threat can be removed before the development of clinical symptoms and the host 
is functionally immune for this specific pathogen. 
hematopoiesis
All immune cells, or leukocytes, are continuously generated throughout life from 
tissue-specific, pluripotent hematopoietic stem cell (HSC) in the bone marrow. This 
process is called hematopoiesis and involves a branched multi-step differentiation 
process in which the HSC proliferates and differentiates into each of the leukocyte 
lineages. First, the progenitor cells becomes restricted towards either the myeloid 
or lymphoid lineage. Myeloid progenitors can still differentiate into mast cells, 
monocytes, granulocyte subsets (i.e. neutrophilic, basophilic and eosinophilic 
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granulocytes), certain DC subsets, erythrocytes (red blood cells) and thrombocytes 
(platelets). Mast cells originate directly from myeloid progenitors. Monocytes and 
granulocyte subsets develop via an intermediate myeloblast cell stage. Monocytes 
leave the bone marrow into the circulation, but upon their migration into tissue 
differentiate further into macrophages. 
Lymphoid progenitors can differentiate into B, T and NK lymphocytes, and certain 
DC subsets (Figure 4). Commitment and differentiation into the B- or NK-cell 
lineages takes place in bone marrow, whereas early progenitors exit the bone 
marrow and migrate into the thymus where they develop into T cells (reviewed 
in 23).  
antigen-independent b-Cell and t-Cell antigen reCeptor formation
In contrast to myeloid cell development, B- and T-cell differentiation is a 
lengthy process in which the cells undergo various stages of differentiation and 
proliferation.24-28 These stages are required to ensure regulated rearrangement 
of genetic elements in the genes encoding the BCRs and TCRs.27,29 The BCR is 
composed of four peptide chains; two identical Ig heavy chains (IgH) and two 
identical Ig light chains (IgL). The latter are either of the Lambda (Igλ) or Kappa 
(Igκ) isotype (Figure 5A).29 The TCR is composed of only two TCR chains, being 
lymph node
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Figure 3. Third layer of 
protection: Adaptive immune 
responses.
A) Soluble antigen and antigen-
loaded DCs migrate to secondary 
lymphoid structures, including 
the lymph nodes. Lymphocytes 
enter the lymph node via the 
blood circulation. DCs activate 
helper T cells (Th). Together 
they activate cytotoxic T cells 
(Tc) and B cells. Cytotoxic T cells 
migrate into the tissue, where 
they induce death of virus-
infected cells. B cells differentiate 
in immunoglobulin-producing 
plasma cells. Immunoglobulins 
disperse into tissue where they 
neutralize antigens. B) Initiation 
of adaptive immune responses 
follows three phases: 1. Selection 
of antigen-specific B cells, Th cells 
and Tc cells. 2. Proliferation and 
differentiation of antigen-specific 
lymphocytes. Th cells stimulate 
B-cell and Tc-cell proliferation 
and differentiation. B cells 
differentiate into immunoglobulin 
producing plasma cells. Activated 
cytotoxic T cells release cytotoxic 
granules upon antigenic trigger. 3. 
Memory formation. A selection of 
lymphocytes remain after pathogen 
clearance to provide immunological 
memory.
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either composed of one TCRα and one TCRβ chain (TCRαβ+ T cells; comprising 
~95% of all T cells), or of one TCRγ paired with one TCRδ chain (TCRγδ+ T 
cells; comprising ~5% of all T cells) (Figure 5B). Each BCR and TCR contains a 
constant domain (or backbone), providing stability to the receptor and anchoring 
it in the cell membrane, and a variable domain, which is unique in each B or T 
cell and is responsible for the specific recognition of antigens. An adult adaptive 
human immune system contains approximately 1012 different lymphocytes. As it 
is not possible to code this large number of TCRs or BCRs in the human genome, 
the variable domains of BCRs and TCRs are formed in a process called V(D)
J-recombination (Figure 5C). 
V(D)J recombination is a highly structured and step-wise process in which the BCR 
and TCR are developed via a number of maturation steps.24-28,30,31 In the human 
genome, the gene IGH (coding for the B-cell IgH chain), and the genes TCRB and 
TCRD (coding for the TCRβ and TCRδ proteins, respectively) are all composed of 
multiple non-identical copies of three different gene segments; a Variable (V) gene 
segment, a Diversity (D) gene segment and a Joining (J) gene segment.32-34 For 
each of the IGH, TCRB and TCRD loci, V(D)J recombination starts with the random 
selection of one D and one J gene segment, which are then brought in close 
TCRαβ+
Thymus
CD4+
TH cell
CD8+
TC cell
TCRγδ+
Bone marrow
Blood/ Periphery
immature B-cell
pro-B cell
mature 
B-cell
Hematopoietic
Stem cell
lymphoid prog.myeloid prog.
NK cell
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TCRγδ+
V(D)J
baso-
phil
monocyteeosino-
phil
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neutro-
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Figure 4. Schematic representation of the hematopoietic differentiation pathways.
Hematopoietic stem cells differentiate into a myeloid progenitor or lymphoid progenitor. Myeloid progenitors give 
rise to innate immune cells. They differentiate directly into mast cells, or via a myeloblast stage into neutrophils, 
basophils, eosinophils, monocytes and selected dendritic cell (DC) subsets (dashed line). Monocytes differentiate 
into macrophages upon migration into tissue. Lymphoid progenitors give rise to selected DC subsets (dashed 
line), NK cells and B cells in bone marrow, and T cells in the thymus. T-cell precursors differentiate further into 
TCRαβ+ T cells or TCRγδ+ T cells. All lymphocytes undergo V(D)J recombination (V(D)J) to develop a functional 
antigen receptor. TCRαβ+ T cells further differentiate into CD4-expressing helper T cells (Th) and CD8-expressing 
cytotxic T cells (Tc). For simplicity, erythrocytes and thrombocytes are excluded from the figure. Figure adapted 
from Rieger et al.23
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proximity. Next, the DNA in between the two segments is removed and excised in 
the form of a circular excision product and the D and J segments are rearranged 
into a DJ recombination product. Subsequently, this DJ segment is recombined 
to one V segment in a similar process, resulting in a VDJ recombination product. 
Together this VDJ segment forms a first exon of the IgH, TCRβ or TCRδ proteins. The 
resulting V(D)J exon is subsequently transcribed, spliced towards a downstream 
constant (C) region and translated into a functional protein (Figure 5C). A similar 
process occurs for the IGL, TCRA and TCRG gene loci encoding the IgL, TCRα and 
TCRγ proteins respectively, though these loci contain only V and J gene segments 
and consequently require only V to J recombination.34,35 This largely random 
selection of V, (D) and J gene segments ensures high combinatorial diversity of 
BCRs and TCRs. Still, to even further increase the variability in BCRs and TCRs, 
random nucleotides are inserted or deleted at the sites of V(D)J recombination, 
resulting in a high junctional diversity.36-38 Together, the combinatorial diversity 
and junctional diversity enable the formation of a repertoire of more than 1012 
unique lymphocytes.29
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Figure 5. B-cell receptor and T-cell receptor formation.
A) The B-cell receptor (BCR) is composed of two identical Ig heavy (IgH) and two identical Ig light (IgL) peptide 
chains. Each IgH chain is composed of a Variable (V), Diversity (D), Joining (J) and Constant (C) region (the 
latter composed of four domains). Each IgL is composed of a V, J and C region. The BCR is anchored in the cell 
membrane by anchoring molecules CD79a and CD79b. B) The T-cell receptor (TCR) is composed of a combination 
of a TCRα and a TCRβ peptide chain (left), or a combination of a TCRγ and TCRδ peptide chain (right). The TCRβ 
and TCRδ chains are composed of V, D, J and C regions. The TCRα and TCRγ chains are composed of V, J and 
C regions. The TCR is anchored in the cell membrane by anchoring molecules CD3ε, CD3δ, CD3γ and CD3ζ. C) 
V(D)J recombination starts with the rearrangement of a D to a J segment, followed by a V to DJ rearrangement, 
resulting in a V(D)J exon. Upon functional rearrangement, the DNA is transcribed, the VDJ exon is spliced towards 
the C region, and translated into a functional protein. 
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antigen-dependent b-Cell maturation 
affiniTy maTuraTion and class-swiTch recombinaTion
After V(D)J recombination, a functional BCR is produced and expressed on the 
cell membrane of the naive B cell, which exits the bone marrow and migrates to 
secondary lymphoid organs. Upon antigen encounter, the naive B cell becomes 
activated and, in case of a protein antigen, recruits antigen-specific CD4+ helper 
T cells through the presentation of antigenic peptides in HLA-class II proteins. 
Interactions between B cells and CD4+ helper T cells trigger clonal proliferation 
and formation of germinal centers. Germinal centers are specialized lymphoid 
tissue structures that support two important B-cell maturation processes: BCR 
affinity maturation and class switch recombination (CSR). BCR affinity maturation 
is a process to optimize the BCR variable domain for more optimal recognition 
of the antigen (Figure 6). During extensive proliferation, B cells induce point 
mutations, i.e. somatic hypermutations (SHM), particularly targeting the V(D)J 
exon of their IgH and IgL chains, under the control of activation-induced cytidine 
deaminase (AID).39,40 Subsequently, B cells expressing BCRs with higher affinity 
for the antigen are positively selected, resulting in increased overall affinity of the 
B-cell pool responding to a specific antigen.41-44
CSR is a process to change the constant region of the BCR and thereby adapt its 
effector functions. In naive B cells the constant region of the IgH chain anchors 
the BCR in the B-cell membrane. Upon antigen encounter, however, the activated 
B cells differentiate into Ig-secreting plasma cells. The constant region of the Ig 
(also known as the Fc-tail), mediates its specific effector function. Nine different 
immunoglobulin isotypes exist in humans: IgM, IgD, IgG (IgG1, IgG2, IgG3, IgG4), 
IgA (IgA1, IgA2) and IgE (Figure 6).29 In naive B cells the V(D)J exon is by default 
spliced towards the downstream constant region Cμ or by alternative splicing 
toward the Cδ, resulting in a BCR of the IgM or IgD isotype, respectively, both of 
which are expressed on naive B cells. During CSR, a switch region upstream of 
the Cμ exons recombines with a switch region upstream of one of the Cγ, Cα or Cε 
exons (Figure 6). This results in a new recombination product, replacing the IgM 
and IgD constant regions for either an IgG, IgA or IgE constant region (extensively 
reviewed in 45,46). Each of these Ig isotypes have their own predominant effector 
functions, as discussed in the following paragraph.
immunoglobulin-producing plasma cells
Following proliferation, SHM and CSR, germinal center B cells differentiate either 
into plasma cells or memory B cells. Plasma cells are the effector B cells that, 
by producing Igs, directly fight the invading pathogen. As each Ig isotype has a 
distinct constant region; i.e. Fc-tail, each of them can be recognized by a distinct 
Fc receptor, subsequently inducing distinct downstream effector functions.29 The 
nature of the pathogen and the combination of cytokines produced by the CD4+ 
helper T cells, together define the selection of a certain isotype.46,47 IgM is the first 
isotype to be expressed upon naive B-cell activation. Part of the IgM expressing cells 
does not undergo a germinal center response, but differentiates in extrafollicular 
niches, such as the marginal zone of the spleen. Consequently, IgM expressing 
cells can respond quickly to a pathogen trigger, but the IgM molecules contains 
low levels of SHM and consequently low affinity maturation. Although this low 
affinity can be (partially) overcome by forming large pentamer molecules, thereby 
C
ha
pt
er
 1
General Introduction
15
increasing binding efficiency, highly specific, long-lasting antibody responses will 
predominantly be of an Ig isotype different from IgM. Since B cells can undergo 
consecutive CSR steps (Figure 6), effector functions of the highly-specific Ig 
molecules can be adapted to specific needs.
IgG is the most predominant immunoglobulin in the circulation. It is mainly 
present as monomer and is easily transferred into local tissue, via binding to the 
neonatal Fc-Receptor, thereby providing protection throughout the human body.48 
In a similar process, IgG can also be transferred through the placenta and provide 
a fetus with maternal protection.49 IgG coated pathogens can be recognized by Fcγ 
receptors, which either activate the complement system, stimulate phagocytosis, 
or induces antibody-dependent cellular cytotoxicity by NK cells and other cytotoxic 
cells. These actions result in the direct destruction of the pathogen.50 IgA is 
predominantly localized at mucosal tissues lining the outside of the human body. 
Via binding of polymeric IgA to the polymeric Ig receptor on epithelial cells, it 
can be transported through the epithelial layer into mucus layers or excretions.51 
One of these IgA containing excretions is human breastmilk. IgA can thereby be 
passively transferred from a mother to her newborn’s intestinal mucosa, providing 
early maternal protection to the child. In contrast to IgG, IgA is less capable of 
inducing antibody-dependent cytotoxicity. It, however, predominantly functions in 
blocking pathogen binding to host cells.52 IgE predominantly functions by activating 
mast cells through the cross-linking of Fcε receptors on these cells, resulting in the 
release of granule content, including histamines and other inflammatory proteins. 
IgE antibodies function in response to parasitic infections, but are also known for 
their function in allergic responses. 
V DJ Cµ Cδ CεΨε ΨγCγ3 Cγ1 Cγ2 Cγ4Cα1 Cα2
Sµ SεSγ3 Sγ1 Sγ2 Sγ4Sα1 Sα2
. . . . .
IgM
IgG2
. . . . .
. . . . .
IgG1
. . . 
. .  
. . . . .
Figure 6. Class switch recombination and somatic hypermutation.
The human IGH locus contains 9 functional constant (C) regions. Apart from the Cδ region, each of the constant 
regions is preceded by a switch (S) region. RNA splicing of the V(D)J exon to the Cμ results in a B-cell receptor 
(BCR) of the IgM isotype. During class switch recombination, a switch region (in this figure Sμ) recombines with 
a downstream switch region (e.g Sγ1), which result in a new RNA splicing product and the production of a BCR 
of a different isotype (e.g. IgG1). During extensive proliferation, point mutations (somatic hypermutations; red 
dots) are introduced in the V(D)J exon to increase the affinity of the BCR. Consecutive switching to a downstream 
switch region (e.g. Sγ2), enables a further switching towards a more downstream BCR Ig isotype (e.g. IgG2).
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memory b cells
Memory B cells are able to respond fast upon subsequent encounter with the same 
antigen, providing long-lasting immunity to the host. Eight different memory B-cell 
populations can be defined (Figure 7). Five memory B-cell populations develop 
via classical T-cell dependent germinal center responses: IgM+IgD- (IgMonly), 
CD27-IgG+, CD27+IgE+, CD27+IgG+ and CD27+IgA+ memory B cells. All five 
have proliferated significantly and show high levels of SHM, indicative of affinity 
maturation. Still, CD27+IgG+ and CD27+IgA+ memory B cells underwent more 
proliferation and acquired more SHM than IgMonly, CD27-IgG+ and CD27+IgE+ 
memory B cells, suggesting that these cells underwent multiple cycles of affinity 
maturation.53-55 Besides these classical germinal center-dependent memory B-cell 
populations, three other populations have been identified: IgM+ memory B cells 
still co-expressing IgD (natural effector B cells) and CD27-IgA+ and CD27-IgE+ 
memory B cells. All three populations show low levels of proliferation and SHM, and 
can be detected in peripheral blood of immunodeficient patients who are unable to 
form germinal centers.54-57 Together, this indicates a germinal center-independent 
(T-cell independent) origin of these populations. Natural effector B cells have been 
suggested to develop in the marginal zone of the spleen and are also referred 
to as marginal-zone B cells.57-59 The CD27-IgA+ and CD27-IgE+ memory B-cell 
populations have been suggested to originate from mucosal tissues.54,55 
Altogether, plasma cell formation, antibody production and memory development 
result from maturation of a selected set of naive B cells, thereby restricting the 
BCR repertoire, but increasing pathogen-specific responsiveness.
Figure 7. Memory B-cell formation.
Naive mature B cells can undergo T cell–independent (TI) or T cell–dependent (TD) immune responses. TI 
responses occur locally in the mucosal tissue, inducing the formation of CD27-IgE+ and CD27-IgA+ cells, or 
systemically in the splenic marginal zone, inducing natural effector B cells. TI responses are characterized by 
low proliferation and B-cell receptor (BCR) maturation levels as compared with TD responses. TD responses 
occur in germinal center structures. Primary germinal center responses induce the formation of CD27+IgM+, 
CD27-IgG+ and CD27+IgE+ memory B cells with intermediate proliferation and BCR maturation. Secondary TD 
germinal center responses induce the formation of CD27+IgG+ and CD27+IgA+ memory B cells that underwent 
even stronger proliferation and BCR maturation. Figure adapted from Berkowska et al.54
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antigen-dependent t-Cell maturation
The majority of T cells produce a TCR using a TCRα and TCRβ chain, thereby 
forming an TCRαβ+ T cell. Within these cells, around 65% comprises CD4+ helper 
T cells, whereas the remaining 35% are CD8+ cytotoxic T cells.22,60
CD4+ TCRαβ+ T-cell effecTor responses
When a naive CD4+ T cell recognizes an antigenic peptide presented in HLA-class 
II proteins by an APC, further co-stimulation via CD40 expressed on the cell 
membrane of the APC, and CD40Ligand on the CD4+ T cell, induces the activation 
and maturation of both cell types.61 This induces the upregulated expression 
of co-stimulatory molecules on the APC, and the production and secretion of 
signaling molecules, i.e. cytokines, to the surroundings by both the cell types. 
The upregulated co-stimulatory molecules, such as CD80, CD86 or CD70, can 
stimulate and stabilize a subsequent interaction between an APC and an antigen-
specific CD8+ T cell.62-65 The cytokines, including interferon γ, interleukin (IL)-2, 
IL-12 and IL-15,22,63,66-68 furthermore stimulate proper activation of CD8+ T cells 
(Figure 8A). 
In addition, B cells are able to present antigenic peptides in HLA-class II molecules, 
thereby enabling a cognate interaction with an antigen-specific activated CD4+ T 
cell in a germinal center. During this germinal center response (paragraph ‘Antigen-
dependent B-cell maturation’), the CD4+ T cell stimulates B-cell maturation and 
differentiation via CD40 – CD40L interaction and the production of cytokines 
including IL21 and IL4 (Figure 8B).41-43 An activated CD4+ T cell can thereby 
provide help to both antigen-specific CD8+ T cells and B cells.
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Figure 8. Helper T-cell functions.
A) An antigen-specific helper T (Th) cell initiates a cognate interaction with a dendritic cell (DC) presenting 
antigenic peptides in HLA-class II molecules. This initiates the upregulation of co-stimulatory molecules, which 
stabilize a subsequent cognate interaction between the DC, presenting antigen in HLA-class I molecules, and an 
antigen-specific cytotoxic T (Tc) cell. Furthermore, both the Th cell and DC produce cytokines to stimulate further 
Tc-cell differentiation. B) A B cell can present antigenic peptides in HLA-class II molecules to antigen-specific Th 
cells. Subsequent signaling via co-stimulatory molecules and the production of cytokines by the Th cell, stimulate 
the B cell towards plasma cell (pc) differentiation. 
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CD8+ TCRαβ+ T-cell effecTor responses
When a naive CD8+ T cell recognizes an antigen presented in HLA-class I 
molecules, the additional co-stimulation provided by APCs, together with the 
cytokine production of both APCs and CD4+ T cells, results in its full activation (as 
described above). Activated CD8+ T cells then migrate towards the site of infection 
where they scan the cell membranes of cells in the surrounding tissue in search 
for cells that present their cognate antigen. Upon antigen encounter, the CD8+ T 
cell induces the death of its infected target-cell, predominantly via the release of 
toxic granules containing perforins and granzymes, or FAS – FASLigand dependent 
cell death.69-71 
TCRγδ+ T-cell responses
TCRγδ+ T cells are different from TCRαβ+ T cells, not only in the TCR chains they 
use, but also with respect to their development and responses. Though details of 
their development and function still remain largely unknown, two major subsets 
of TCRγδ+ T cells can be defined: Vδ1+ and Vδ2+ T cells. Vδ1+ T cells predominate 
in the intestine and have been described to recognize stress-antigens (e.g. MHC-
class I–related molecules MICA and MICB),72,73 whereas Vδ2+ T cells predominate 
in blood and recognize low molecular mass phospho-antigens.72,74 Antigen 
recognition might be independent of presentation in HLA-class I or II molecules,73 
and does not require clonal expansion. Besides cytotoxic functions, TCRγδ+ T cells 
have also been described to produce cytokines or chemokines and to perform 
a function in antigen presentation. Altogether, their quick, diverse, and stress-
induced response make them important in stress-surveillance.75,76
memory T cells
Upon pathogen clearance, the majority of effector T cells die by apoptosis to 
dampen the T-cell response and to prevent excessive effector T-cell accumulation 
after multiple pathogen encounters.77,78  Instead, subsets of T cells remain present 
after pathogen clearance, in the form of memory T cells. The total pool of memory 
T cells is highly diverse, with the development of each memory T cell depending on 
the specific strength of TCR-triggering and/or cytokine stimulation,79-81 and each 
possessing its own migration capacities, requirements for optimal stimulation and 
potential effector functions (Figure 9).77,82-91
One of the first proteins described to be differentially expressed in different 
T-cell subsets is the protein tyrosine phosphatase CD45. Naive T cells express 
CD45RA (an isotype of CD45), but upon antigen encounter and T-cell activation, 
the CD45RA switches isotype into CD45RO. Although the exact role of the CD45 
isotypes is still largely unclear, this CD45-isotype-switch correlates with induced 
T-cell activation and proliferation.92 Memory T cells can express either CD45RO, 
or re-express the CD45RA isotype, the latter being considered as having more 
effector cell properties.93,94
Similarly, depending on their function and predominant localization throughout the 
human body, T-cell subsets show differential expression of chemokine receptors 
(CCRs) and adhesion molecules.86 Naive T cells express molecules important 
in lymph node homing, including CCR7 (also known as CD197) and L-selectin 
(also known as CD62L). Part of the CD45RO+ memory T cells express similar 
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proteins, and have been designated “central memory” T cells (Tcm).82,83 Due to the 
maintained expression of CCR7 and L-selectin, these Tcm cells circulate through 
the blood, lymphatics system and secondary lymphoid tissues. The remaining 
CD45RO+ memory T cells and the CD45RA+ memory T cells, however, lack the 
expression of both markers, but express other chemokine receptors, e.g. CCR5, 
CXCR1 or CX3CR1, which enable their migration into local tissue, such as the 
skin or intestine.77,84-87,91,94 Both of these memory populations are referred to as 
effector memory T cells (Tem), either CD45RO+ (TemRO) or CD45RA+ (TemRA)
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Figure 9. CD8+ T-cell responses.
A) Activated naive T cells differentiate into central memory T cells (Tcm) or effector memory T cells, the latter 
being either CD45RO+ (TemRO) or CD45RO- (TemRA). Tcm cells circulate the lymphatics and blood circulation and 
lymphoid structures. TemRO and TemRA cells migrate into tissue and kill virus-infected cells. B) T-cell subsets 
expression levels of proteins involved in co-stimulation, cell survival and regulation of activation; cell migration 
and adhesion;  and cytokine production and cytotoxic function. White, not expressed; light blue, intermediate 
expression; dark blue, strong expression.
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The various memory T-cell subsets each possess distinct functional properties and 
different requirements for co-stimulation and survival. Naive T cells express high 
levels of survival factors, such as IL-7R (CD127), and different co-stimulatory 
molecules including CD27 and CD28, to enable their optimal activation upon 
antigen encounter.84,85,87,94 Similarly, the systemic and lymph node localization of 
Tcm cells, will enable them to quickly recognize a subsequent infection with the 
same antigen, and to perform a central function in the induction of an adaptive 
immune response. In line with this function, Tcm cells maintain the expression 
of IL-7R, CD27 and CD28. Effector memory T cells gradually lose these survival 
factors and co-stimulatory molecules upon further differentiation (from early 
towards late differentiated TemRO or TemRA cells), but (especially cytotoxic T 
cells) show increased effector molecule production, including granzymes and 
perforin,70,89 FASL (CD95L), and the cytokines IFNγ and TNFα, increasing their 
cytotoxic potential.84,88,89 Increasing differentiation is, however, also correlated 
with an increased expression of inhibitory molecules, including killer cell lectin like 
receptor G1 (KLRG1), Programmed death 1 (PD-1 or CD279) and CD57,95-97 and 
with increasing T-cell proliferative exhaustion.81,84,95-97 
The exact differentiation pathway through which the various memory T-cell 
populations are generated remains debated.91 Memory cells might develop from 
effector cells that escaped activation-induced cell death, or via a pathway independent 
from effector cell formation.98 Furthermore, a consecutive differentiation pathway 
from naive T cells, via Tcm cells towards Tem cells has been described, in which 
Tcm cells might provide a renewing pool of cells continuously replenishing the 
Tem populations and in which effector memory T cells progressively lose co-
stimulation, proliferative capacity and responsiveness.79,80,84,89,99 Others, however, 
described a parallel differentiation,100 or even a two-directional interchanging 
phenotype in which effector memory cells can regain expression of lymph node 
homing potential, self-renewal and functional properties comparable to central 
memory T cells.101
Still, irrespective of the differentiation pathway, the extensive characterization of 
the distinct memory T-cell subsets by markers described above (Figure 9) – which 
are still a selection of the available expression profiles in literature – enables 
detailed functional discrimination of memory T-cell subsets.  
maturation of the Childhood immune system
During fetal development, a fetus resides in the protected environment of the 
uterus, shielded from the vast majority of external pathogens. Thus, the fetal 
immune system is largely immature and mainly composed of innate leukocytes 
and naive lymphocytes.102-104 Maturation of the immune system largely occurs 
in the first few years of life, in response to environmental pathogens and other 
antigens. Important partial immune protection for the first few months of life, will 
be provided by the mother. Already during pregnancy maternal IgG molecules, 
can be transferred to the child through the placenta and can provide protection to 
the child.49 Also after birth the mother can pass on immune protection to her child 
via breastfeeding. Breastfeeding contains various particles, including maternal IgA 
and IgG molecules and cytokines, which passively provide the child with immune 
protection for the time of breastfeeding duration.105 
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While receiving short-term passive protection via its mother, a child will have 
to develop its own protective immunity, mainly in the form of memory B and T 
cells. During childhood, the number of lymphocytes is relatively large, compared 
to adults.102,104 With each naive lymphocyte having a unique antigen receptor, 
the combined BCR and TCR repertoires are enormous, with a high potential to 
mount responses to all distinct types of pathogens. As each pathogen induces a 
distinct functional response, associated with the expansions of distinct lymphocyte 
populations and the generation of distinct memory lymphocyte pools, the 
combination of pathogens we encounter in the environment eventually shapes the 
composition and antigen-receptor repertoire of our immune system. 
With increasing age, the production of naive lymphocytes declines, together with a 
reduction in the size and functionality of the thymus. Consequently, the repertoire 
of new naive lymphocytes will become smaller in adults.106 Adults, therefore, 
largely depend on their memory lymphocyte pools, produced as a result of the 
many pathogen-encounters during the first few years of life, to protect them 
from the recurrence of clinical illness.107-113 The formation of a stable memory 
lymphocyte pool during childhood, and the maintenance hereof in adulthood, is 
therefore essential for long-term immune protection. A disbalance in the immune 
system can result in clinical complications, ranging from lack of protection, to the 
development of excessive immune responses, and can even lead to auto-immune 
diseases. 
persistent viral infeCtions
Most of the encountered pathogens are eventually cleared by the immune 
system. Several viruses, however, escape from clearance by the immune system. 
Even though these can be seemingly well-controlled by the host, they can 
persist life-long, and cause complications in case of immunosuppression. Such 
persistent viruses include members of the family of herpesviruses and the human 
immunodeficiency virus (HIV). 
herpesviruses 
Herpesviruses are double-stranded DNA viruses, and many are highly prevalent 
in the human population.114 To date, 8 herpesviruses have been identified to 
infect humans. Four of these include the cytomegalovirus (CMV), Epstein Barr 
virus (EBV), herpes simplex virus (HSV) type 1 and varicella zoster virus (VZV). 
Seroprevalence for these viruses is high, varying between around 30 to >90% in 
adults.115,116 Infection predominantly occurs during childhood and is mostly mild 
or even asymptomatic. However, infection in neonates and immunocompromised 
individuals might result in severe clinical complications. HSV-1 and VZV are two 
neurotropic viruses, meaning that they reside in sensory neurons.117,118 HSV-1 
can induce cold sores, recurring in situations of weakened immune surveillance. 
VZV induces chicken pox in children and can recur as shingles in most adults. 
CMV is able to infect a broad range of cell types including monocytes, epithelial 
cells, endothelial cell and to a lesser extend leukocytes.119-121 CMV infection in 
endothelial cells also induces the attraction of neutrophils. CMV is transferred to 
these neutrophils, after which they recirculate and promote further dissemination 
of the virus.122 EBV infects and persists in B cells.123,124 EBV targets B cells through 
interactions with complement receptor 2 (CR2; CD21), HLA-class II co-receptor 
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surface molecules, or the Beta-1 integrin.125-127 Even though all B cells express 
these molecules, EBV persists preferentially in memory cells.123,128 Both CMV and 
EBV are able to induce infectious mononucleosis. CMV is, due to its tropism for 
endothelial cells, furthermore associated with vascular complications.129,130 EBV 
is associated with increased development of malignant complications, including 
Burkitt lymphomas.131
The human immunodeficiency virus
HIV is a retrovirus responsible for inducing the acquired immunodeficiency 
syndrome (AIDS). HIV infects cells through binding to the CD4 proteins expressed 
on the membrane of the target cell, and therefore the predominant target cells are 
the CD4+ T cells and monocytes/macrophages. HIV infection is characterized by 
CD4+ T-cell depletion. HIV-infected adults in whom the CD4+ T-cell numbers drop 
below 200 cells/μl of blood are eventually diagnosed with AIDS.
HIV uses co-receptors CCR5 and CXCR4, or integrin α4β7 for cell entry.132-140 The 
integrin α4β7 is more recently described to form a complex with the CD4 protein 
on the cell membrane and CD4+α4β7+ T cells have been observed to be enriched 
for metabolically active cells expressing high levels of CCR5.138 By targeting 
α4β7+ cells, HIV thereby seems to increase its chance for effective infection. 
Furthermore, HIV is able to interact with DC-specific C-type lectin (DC-SIGN) on 
local DCs and CD21 on B cells, two cell types that are themselves not permissive 
for HIV infection, but that facilitate HIV virus transfer towards secondary lymphoid 
structures and into close proximity of CD4+ T cells.141,142 Moreover, HIV seems 
to preferentially infect HIV-specific CD4+ T cells, most likely due to prolonged 
presence of both actively replicating HIV particles and HIV-specific CD4+ T cells in 
lymphoid structures.143 The latter might even further impair HIV clearance. 
immune evasion by persistent viral infeCtions
Persistent viruses have developed various strategies to avoid their detection 
and destruction by the host’s immune system. Although describing all the 
immunomodulatory effects of the viral proteins involved in immune evasion will 
be beyond the scope of this thesis (these have been extensively reviewed in 144-
149), five major evasion strategies, used by herpesviruses and the HIV virus, will 
be addressed here (Table 1). 
First, especially RNA viruses, including the HIV virus, have a high mutation rate 
of their viral genome, resulting in very high antigenic variability of the virus. 
Consequently, immune responses need to be continuously adapted to these 
mutating viruses. This provides the virus with a survival-advantage. DNA viruses, 
including the herpesviruses, seem to depend less on this evasion strategy as their 
DNA templates are more stable. 
Second, CMV, EBV, HSV-1, VZV and HIV all inhibit antigen presentation by the 
infected host cell, masking them from the immune system. This is achieved through 
the low production of viral proteins during their state of latency. Furthermore, 
these viruses inhibit host HLA expression using mechanisms that can vary 
from decreasing HLA protein production, HLA stability, HLA transport to the cell 
membrane or HLA maintenance at the cell membrane.150-155 Finally, viruses might 
limit the generation of presentable peptides by inhibiting host cell protease activity 
C
ha
pt
er
 1
General Introduction
23
Table 1. Evasion strategies used by different persistent viruses
Immune evasion strategy Persistent virus
CMV EBV HSV1 VZV HIV
1  High mutation rate and antigenic variability ± ± ± ± +
2  Inhibiting virus peptide presentation
         reducing protein expression during latency + + + + +
         preventing HLA expression + + + + +
         inhibiting proteases and TAP function + + + ? ?
3  Inhibiting immune cell activation
         inhibiting CD8+ T/ NK cell killing + + + ? +
         inhibiting humoral immunity + + + + +
4  Reducing cytokine/chemokine production + + + ? +
5  Predominant tropism Broad 
range 
of cells
B cells CD4+ 
T cells, 
macro-
phages
Neuronal 
cells
TAP, transporter associated with antigen processing; +, virus possesses the evasion strategy; ±, 
virus can perform evasion strategy, but is less common; ?, evasion strategy not (yet) defined for the 
specific virus.
or the TAP protein (transporter associated with antigen processing).145,151,156-159 
Third, persistent viruses might directly inhibit the activation of immune cells; 
inhibiting cellular responses by avoiding NK cell and CD8+ T cells activation,160-163 
or humoral responses by inhibiting antibodies from binding to their Fc-receptor 
and inducing antibody-dependent or complement-dependent cytotoxicity.144
Fourth, persistent viruses possess many mechanisms to affect cytokine and 
chemokine production or their subsequent signaling function, thereby regulating 
the balance between immune-activating molecules and immune-inhibiting 
molecules (reviewed in 144,148). 
The last, important mechanism that can contribute to immune evasion is the 
selective tropism in certain host cell types. HSV-1 and VZV, for example, induces 
latency mainly in neuronal cells, which are protected from immune targeting, 
because of their importance and incapability to renew. EBV and HIV directly 
target lymphocyte populations. Killing the virus-infected cells, either by the virus 
itself, or as a result of an anti-viral immune response, therefore directly leads to 
destruction of the body’s own immune system, eventually weakening the anti-
viral immune responses. 
Combined, the various evasion strategies, of which the ones described in this 
thesis are only a limited selection, enable the persistent viruses to escape from 
virus clearance and to induce long-term latency in the host.
immunologiCal ConsequenCes of persistent viral infeCtion
As persistent viruses are continuously present, they also apply a constant pressure 
on the immune system. Consequently, important changes in the immune system 
have been correlated to the presence of a persistent viral infection. Some of these 
being common to persistent viruses, others being virus-specific (Figure 10).  
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direcT desTrucTion of The immune sysTem
Some persistent viruses directly target the immune system and reside in immune 
cells. These viruses thereby directly affect the immune system and immune cell 
functioning (Figure 10a.). The two strongest examples hereof are the EBV and 
HIV viruses. EBV directly targets B cells, inducing persistence preferentially in 
memory B cells.123,128 It is thought that this is the result of EBV infection in naive 
B cells that are driven into an immune response, after which the virus persists 
in the long-lived memory B-cell compartment.123,164-166 Recent studies, however, 
indicate that both activated naive and memory B cells can be infected,167 and 
that EBV can establish persistence in the absence of fully functional germinal 
center activity.128,168 The true effect of EBV on B cells, is therefore still a matter of 
debate. Furthermore, although primary EBV infection induces a strong expansion 
of memory B cells that normalizes within 1 week after the appearance of clinical 
complications, long-term consequences of EBV persistence in memory B cells are 
still unknown.169 
HIV directly targets CD4+ T cells, focusing on activated, CCR5-expressing 
T cells,132-140 and even HIV-specific CD4+ T cells.143 While HIV thereby directly 
impairs the CD4+ T-cell functioning, it furthermore affects the function of CD8+ 
T cells and B cells, both of which need CD4+ T-cell help for optimal activation 
(as discussed earlier). B cells can furthermore be directly affected by HIV via 
direct binding and signaling of HIV to the B cell,141 or via the transfer of HIV 
proteins, such as Nef (negative factor) onto B cells, reducing B-cell class switching 
towards IgG and IgA.170 (extensively reviewed in 171-173) Both CD4+ T-cell 
help-dependent and independent B-cell defects have been described, including 
hypergammaglobulinemia,174,175 a reduction of CD27+ class-switched memory B 
cells,170,175,176 and an expansion of an aberrant, anergic B-cell population expressing 
low level of CD21 (CD21low B cells).177,178 
Current combined antiretroviral therapy (cART) can nowadays effectively reduce 
HIV virus loads in peripheral blood and recover CD4+ T-cell numbers to near-normal 
levels in both HIV-infected adults and children, suggesting that the treatment 
is effectively inhibiting viral replication and inducing immune recovery.179-182 HIV 
thereby is changing from a lethal into a chronic disease. Still, full recovery of all 
immune defects is in adults not obtained, and long-term consequences of HIV 
infection and cART treatment in HIV-infected children remain largely unknown. 
overcrowding The immune sysTem
The continuous presence of persistent viruses and the repeated cycles of activation 
and reactivation of virus production result in a continuous triggering of the 
immune system and a constant activation and stimulation of memory lymphocyte 
responses. Clinical consequences hereof have been best described for CMV and 
EBV infection. Memory lymphocyte pools directed against these viruses have 
been described to accumulate over time,84,99 resulting in very large populations in 
especially the elderly. In these elderly they seem to occupy such a large part of 
the immune system that they overcrowd memory lymphocytes against different, 
unrelated pathogens, resulting in the loss of immunity (Figure 10b.)183-187 Still, 
these effects are not consistently observed,188-191 and despite high CMV and EBV 
seropositivity rates in elderly, only a minority develops clinical complications. 
Furthermore, childhood infection with these viruses is mostly asymptomatic and 
C
ha
pt
er
 1
General Introduction
25
might even be protective against the development of allergic or autoimmune 
diseases.192,193 The reason for the different clinical outcome in children and adults, 
the discrepancy in literature on adult infection, as well as why only the minority 
of CMV- and/or EBV-infected elderly present clinical complications, remain largely 
unknown.
immune eXhausTion
Another important consequence of the continuous immune activation is immune 
exhaustion, also known as immunosenescence, a process that is also largely 
correlated to aging.81,194,195 Immune exhaustion is a state in which cells show 
high replication history, reduced proliferative potential and reduced functional 
responsiveness (Figure 10c.). Exhaustion has been predominantly described for 
CD8+ T cells and correlates with shortened telomere length, reduced expression of 
co-stimulatory molecules, e.g. CD27 and CD28, increased expression of inhibitory 
receptors, e.g. CD57, KLRG1 and PD-1, and reduced cytotoxic potential (see also 
Figure 9).84,85,95-97
Immune exhaustion has also been described for a B-cell population expressing low 
levels of CD21. Increased numbers of these CD21low B cells have been observed in 
various conditions of chronic immune activation, including immunodefi ciencies,196 
autoimmune diseases,197 and persistent viral infection with HIV.198 In HIV-infected 
individuals, these CD21low B cells express increased levels of inhibitory receptors 
(including FcRL4), reduced replication potential, altered expression of homing 
receptors guiding them more towards infl amed tissue, and functional exhaustion.198 
They thereby share many characteristics with exhausted T cells. The presence 
of these CD21low B cells correlates with the presence of detectable HIV-viremia, 
suggesting that continuous viral exposure also induces exhaustion of B cells. 198 
The ability of HIV to directly interact with B cells through binding of the CD21 
protein, has been suggested to increase the chance of close contact between HIV 
particles and B cells, and enhance the induction of B-cell exhaustion.141 This is 
even further underlined by the fi nding that CD21low B cells are enriched for HIV-
specifi c cells, as recognition of HIV particles by BCRs could prolong the interaction 
period and subsequently enhance immunomodulatory effects and the induction of 
immune exhaustion.198
healthy persistent viral infection
overcrowding exhaustion
apoptosis
cell depletion
proliferation 
effector function
inhibitory receptors
a. b. c.
Figure 10. Immunological consequences of persistent viral infection.
Persistent viral infections can affect the immune system via three different mechanism: a. the targeted depletion 
of immune cells; b. the induction of extensive antiviral immune responses that overcrowd the pool of non-
related immune cells; and c. extensive stimulation of the immune system which induces functional exhaustion, 
characterized by reduced proliferative potential and effector functions, but increased susceptibility to apoptosis 
and increased expression of inhibitory receptors. 
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aims of this thesis
The importance of a well-functioning immune system can be appreciated in 
cases of either insufficient immune protection, such as immunodeficiency 
or immunosenescence, or excessive immune responses leading to clinical 
complications, such as autoimmune or allergic diseases. An optimal collaboration 
between the various cell types of the immune system is crucial for providing long-
term protection of the host without eventually losing control. Understanding the 
mechanism behind this delicately balanced immune system will largely contribute 
to the field of immunology and might have implications for situations varying from 
vaccine strategies, the treatment of autoimmune or allergic diseases and even 
cancer therapy.
Most of the priming of the immune system is achieved during childhood, when 
the majority of the antigens encountered are still seen by the immune system 
for the first time. The research presented in this thesis aimed to further unravel 
the development and shaping of the immune system during childhood, focusing 
predominantly on the adaptive immune compartment. This in order to understand 
the mechanism by which children become optimally prepared for adulthood. 
Chapter 2 focuses on the homeostasis during healthy immune development. 
In this chapter, we describe the different dynamics of the innate and adaptive 
immune compartments during their simultaneous development from birth until 6 
years of age, and identify various environmental factors that associate to these 
dynamics. Chapter 3 describes the effects of breastfeeding on the immune 
maturation at the age of 6 months. Chapter 4 focuses on persistent herpesvirus 
infections, describing ethnic differences in herpesvirus seroprevalence. Chapter 
5 describes the presence of CMV- and EBV-associated T-cell expansions in 6-year-
old children and their effect on the total T-cell compartment. Chapter 6 focuses on 
the effect of EBV infection and persistence in memory B cells on the composition 
and functioning of the memory B-cell compartment in young children. In Chapter 
7, we studied the effectiveness of current cART treatment in HIV-infected children 
and adolescents to enable B- and T-cell development. 
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ABSTRACT 
baCkground. Blood leukocyte subsets in young children are highly dynamic, 
resulting in wide reference ranges. This is likely related to variable exposure to 
external antigens, and the generation of immunological memory following primary 
antigen responses. However, it is unclear which external determinants affect the 
dynamics of innate leukocytes, and naive and memory lymphocyte subsets.
methods. Using 6-color flow cytometry and linear mixed effect modeling, we 
defined the dynamics of 62 leukocyte subsets from birth to 6 years of age in 1,182 
children with one to five measurements per individual. Subsequently, we defined 
the impact of prenatal maternal lifestyle-related, prenatal maternal immune-
mediated, birth characteristics and bacterial/viral exposure-related determinants 
on these leukocyte dynamics. 
results. Hierarchical clustering of leukocyte subset dynamics revealed four major 
age-related patterns that each contained functionally similar leukocyte populations. 
Innate leukocyte numbers were high at birth and were predominantly affected by 
maternal low education level. Naive lymphocytes peaked around 1 year, while 
most memory lymphocyte subsets more gradually increased during the first 1 to 4 
years of life. Dynamics of CD4+ T cells were predominantly associated with gender, 
birth characteristics, and persistent infections with cytomegalovirus (CMV) or 
Epstein Barr virus (EBV). CD8+ T cells were predominantly associated with CMV 
and EBV infections. TCRγδ+ T cells were associated with premature rupture of 
membranes and CMV infection. B-cell subsets were predominantly associated with 
gender, breastfeeding and Helicobacter Pylori carriership.
ConClusions. Our study identifies specific dynamic patterns of leukocyte subset 
numbers, as well as determinants that affect these patterns, thereby providing 
new insights into the shaping of the childhood immune system.
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INTRODuCTION
The immune system in young children is highly dynamic in composition and cell 
numbers.1-6 Innate cell numbers, such as neutrophils and NK cells, are higher 
in neonates than in children or adults,1,5,7 and already display dynamic changes 
within the first few days after birth.1,5,6 Furthermore, B and T cells are mostly naive 
in infants, while protective immunity is gradually built up in the form of increasing 
numbers of memory B and T cells during the first 5 years of life after which these 
numbers stabilize.2-4,8-11 
Age-associated changes in leukocyte numbers have been extensively studied in 
the past two decades, and findings were quite consistent.1-5,8-14 Both short-term 
follow-up of selected leukocyte subsets in infants in the first year of life,5,6,12,13,15 
and cross-sectional studies in children and adults,3,4,6,10,11,14 have shown age-
related differences in B- and T-cell numbers, whereas innate leukocyte subset 
numbers are quite stable. Still, it is difficult to make correlations between various 
leukocyte lineages, due to either the restricted numbers of analyzed subsets or 
the short-term follow-up. Furthermore, the determinants that drive the kinetics 
in immune development remain less well studied. Likely, various environmental 
determinants affect the development of certain leukocyte subsets during the first 
years of life, such as prenatal maternal life style and immune-mediated diseases, 
birth characteristics, and bacterial and viral exposure.16-26 Studying the impact of 
environmental determinants on the dynamics of childhood immune development 
requires large cohorts of healthy young children, with multiple measurements per 
individual. 
We investigated which external determinants, related to the prenatal maternal 
lifestyle, prenatal maternal immune-mediated diseases, birth characteristics or 
bacterial/viral exposure-related characteristics, influence the dynamics of blood 
leukocyte populations from birth until 6 years of age. This concerned a total of 
62 leukocyte populations, including innate leukocyte subsets, naive and memory 
B-cell and T-cell subsets and TCRγδ+ T-cell subsets. 
PATIENTS AND METHODS
study subjeCts
This study was embedded in the Generation R Study, a prospective population-
based cohort study from fetal life until young adulthood.27,28 The current study 
focused on a subgroup of 1,182 two-generation Dutch children, born between 
August 2003 and August 2006. Peripheral blood was obtained at birth (cord blood; 
n=220), and median age of 6 months (5-9m; n=376), 14 months (13-17m; 
n=241), 25 months (22-30m; n=257) and 72 months (61-95m; n=916). Detailed 
immunophenotyping was performed at 1-5 time points per child, resulting in a 
total of 2,010 data points. Written informed consent was obtained from parents, 
according to the Medical Ethics Committee guidelines of Erasmus MC. 
immunophenotyping
Absolute numbers of leukocytes, NK cells, T cells and B cells were obtained 
with a diagnostic lyse-no-wash protocol, using a BD FACSCalibur. Six-color flow 
cytometry was performed to quantify 62 well-defined leukocyte populations 
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Table 1. Definition of leukocyte subsets
n=
62
n=
31 Name population Phenotype definition
Innate leukocytes
1 Granulocytes SSChighCD45+
2 CD15+ granulocytes SSChighCD45+CD15+
3 1’ Neutrophils SSChighCD45+CD16+
4 2’ Eosinophils SSChighCD45+CD16-
5 Monocytes FSCinterSSCinterCD45+
6 3’ classical monocytes FSCinterSSCinterCD45+CD14+CD16-
7 4’ intermediate monocytes FSCinterSSCinterCD45+CD14+CD16+
8 5’ Non-classical monocytes FSCinterSSCinterCD45+CD14-CD16+
9 6’ Nk cells SSClowCD45+CD3-CD16+or CD56+
lymphocytes
10 T cells SSClowCD45+CD3+
11 TCRαβ+ T cells SSClowCD3+TCRγδ-TCRαβ+
12 ∟CD4+ TCRαβ+ T cells SSClowCD3+TCRγδ-TCRαβ+CD8-CD4+
13 ∟CD8+ TCRαβ+ T cells SSClowCD3+TCRγδ-TCRαβ+CD8+CD4-
14 TCRγδ+ T cells SSClowCD3+TCRγδ+TCRαβ-
15 ∟CD8+ TCRγδ+ T cells SSClowCD3+TCRγδ+TCRαβ-CD8+CD4-
16 ∟CD4+ TCRγδ+ T cells SSClowCD3+TCRγδ+TCRαβ-CD8-CD4+
17 ∟Vδ1-Vδ2- TCRαβ- T cells SSClowCD3+TCRαβ-Vδ1-Vδ2-
18 ∟Vδ2+ T cells SSClowCD3+TCRαβ-Vδ1-Vδ2+
19 7’ ∟Vδ1+ T cells SSClowCD3+TCRαβ-Vδ1+Vδ2-
20 ∟Vγ9+ T cells FSClowSSClowCD3+TCRαβ-Vγ9+
21 8’ ∟Vδ2+Vγ9+ T cells FSClowSSClowCD3+TCRαβ-Vδ2+Vγ9+
22 CD4+ T cells SSClowCD45+CD3+CD4+CD8-
23 9’ ∟CD4+ Tnaive FSClowSSClowCD3+CD8-CD197+CD45RO-CD27+CD28+
24 ∟CD4+ Tmem FSClowSSClowCD3+CD8-    CD197- & CD197+CD45RO+
25 10’ ∟CD4+ Tcm FSClowSSClowCD3+CD8-CD197+CD45RO+CD27+CD28+
26 ∟CD4+ TemRO FSClowSSClowCD3+CD8-CD197-CD45RO+
27 11’   ∟CD4+ early TemRO FSClowSSClowCD3+CD8-CD197-CD45RO+CD27+CD28+
28 12’   ∟ CD4+ interm TemRO FSClowSSClowCD3+CD8-CD197-CD45RO+CD27-CD28+
29 13’   ∟CD4+ late TemRO FSClowSSClowCD3+CD8-CD197-CD45RO+CD27-CD28-
30 ∟CD4+ TemRA FSClowSSClowCD3+CD8-CD197-CD45RO-
31 14’   ∟CD4+ early TemRA FSClowSSClowCD3+CD8-CD197-CD45RO-CD27+CD28+
32 15’   ∟ CD4+ interm TemRA FSClowSSClowCD3+CD8-CD197-CD45RO-CD27-CD28+
33 16’   ∟CD4+ late TemRA FSClowSSClowCD3+CD8-CD197-CD45RO-CD27-CD28-
34 CD8+ T cells SSClowCD45+CD3+CD4-CD8+
35 17’ ∟CD8+ Tnaive FSClowSSClowCD3+CD8+CD197+CD45RO-CD27+CD28+
36 ∟CD8+ Tmem FSClowSSClowCD3+CD8+    CD197- & CD197+CD45RO+
37 18’ ∟CD8+ Tcm FSClowSSClowCD3+CD8+CD197+CD45RO+CD27+CD28+
38 ∟CD8+ TemRO FSClowSSClowCD3+CD8+CD197-CD45RO+
39 19’   ∟CD8+ early TemRO FSClowSSClowCD3+CD8+CD197-CD45RO+CD27+CD28+
40 20’   ∟CD8+ interm TemRO FSClowSSClowCD3+CD8+CD197-CD45RO+CD27+CD28-
41 21’   ∟CD8+ late TemRO FSClowSSClowCD3+CD8+CD197-CD45RO+CD27-CD28-
42 ∟CD8+ TemRA FSClowSSClowCD3+CD8+CD197-CD45RO-
43 22’   ∟CD8+ early TemRA FSClowSSClowCD3+CD8+CD197-CD45RO-CD27+CD28+
44 23’   ∟CD8+ interm TemRA FSClowSSClowCD3+CD8+CD197-CD45RO-CD27+CD28-
45 24’   ∟CD8+ late TemRA FSClowSSClowCD3+CD8+CD197-CD45RO-CD27-CD28-
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(Table 1), which included NK-cell, monocyte, granulocyte, naive and memory 
B-cell, naive and memory TCRαβ+ T-cell and TCRγδ+ T-cell subsets (Supplemental 
Table 1). Flowcytometric analyses were performed on an LSRII (BD Biosciences) 
using standardized measurement settings.29
determinants
Information on 26 dichotomized determinants was obtained (Table 2).27,28 Six 
of these were related to prenatal maternal life style, and were evaluated using 
questionnaires in the first, second and third trimester of pregnancy:28 maternal age 
(above 35y defined as a group with increased risks during pregnancy), education, 
net household income, smoking or alcohol use during pregnancy, and maternal 
body mass index before pregnancy (>25 defined as above healthy range). Three 
determinants were related to prenatal maternal immune-mediated diseases: 
maternal atopy defined by questionnaire data,28 and serum anti-thyroid peroxidase 
IgG (anti-TPO) and anti-tissue transglutaminase IgA antibody (TG2A) levels.30 
Three birth-related determinants included gender, gestational age (preterm birth 
<37w) and birth weight (low birth weight <2,500g). Fourteen determinants 
related to bacterial or viral exposure included three perinatal determinants, i.e. 
premature rupture of membranes, birth season and mode of delivery; and eleven 
postnatal determinants, i.e. breastfeeding and breastfeeding duration, having 
siblings, antibiotics usage and presence of upper or lower respiratory tract infection 
in the first year of life (obtained using questionnaires at the child’s age of 2, 3, 
6 and 12 months);28 Helicobacter pylori (H. pylori) carriership, and seropositivity 
(IgG) for cytomegalovirus (CMV), Epstein Barr virus (EBV), herpes simplex virus 1 
(HSV-1) and varicella zoster virus (VZV) were defined at the age of 6 years.26,31,32 
We did not include the postnatal determinants of housing conditions, pets, day 
care, home environment or other potential sources for differences in antigenic or 
microbial pressure, because of incomplete data sets. 
Table 1 (continued)
n=
62
n=
31 Name population Phenotype definition
46 B cells SSClowCD45+CD19+
47 25’ Bnaive SSClowCD19+CD27-IgD+
48 Bmem SSClowCD19+        IgD- & CD27+IgD+ 
49 ∟CD27- Bmem SSClowCD19+CD27-IgD-
50 ∟CD27+ Bmem SSClowCD19+CD27+IgD-
51 ∟IgM+ Bmem SSClowCD19+CD27+IgM+
52 26’ ∟Natural effector SSClowCD19+CD27+IgM+IgD+
53 27’ ∟IgMonly SSClowCD19+CD27+IgM+IgD-
54 ∟IgA+ Bmem SSClowCD19+IgA+
55 28’ ∟CD27-IgA+ SSClowCD19+CD27-IgA+
56 29’ ∟CD27+IgA+ SSClowCD19+CD27+IgA+
57 ∟IgG+ Bmem SSClowCD19+IgG+
58 30’ ∟CD27-IgG+ SSClowCD19+CD27-IgG+
59 31’ ∟CD27+IgG+ SSClowCD19+CD27+IgG+
60 CD21low B cells SSClowCD19+CD38lowCD21low
61 Igλ+ B cells SSClowCD19+Igκ-Igλ+
62 Igκ+ B cells SSClowCD19+Igκ+Igλ-
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statistiCal modeling
To model leukocyte dynamics between birth and the age of 6 years, linear mixed 
effect analyses were performed on the relationship between the age of the children 
and the size of individual leukocyte populations. By including random-effects in 
the model, this approach enabled modeling of cross-sectional data, with further 
improvement of the accuracy by incorporating longitudinal follow-up data from 
individual children. To capture the trend in the data more precisely, we included 
a natural spline with different knots (0-3 knots) into the models. Basically, the 
number of knots is inversely related to the smoothness of the curve. Positions of 
the knots in the 1-knot model was defined as the 50th percentile (25.5 months), 
the 2-knots model at 33rd and 66th percentiles (14.1 and 70 months); the knots in 
the 3-knot model were defined manually at 6, 14 and 24 months, focusing around 
the time points of data inclusion. Model selection was performed by likelihood 
ratio test. 
Next, for each leukocyte population the effect of all 26 determinants on the models 
was assessed by first adding each determinant univariately into the model and 
analyzing fixed effect estimates. To correct for potential multiple testing errors, a 
correction for the four groups of determinants was performed, and consequently 
only determinants with an effect of p<0.0125 were defined as significant. 
Subsequently, for each leukocyte population, the determinants with a significant 
effect were combined in a multivariable model to correct for possible confounding 
effects. The p-value for significance for the multivariable analyses was p<0.05. 
Up to 3 determinants were added per model. Statistical analyses were performed 
in R (version R-3.2.1).33 
Clustering analyses
To cluster patterns of leukocyte subsets kinetics, the modelled data of each 
population was normalized into zero mean and unit standard deviation (z-score), 
using the following calculation:
 z-score= (population size (at month x) - average population size (at months 0-72))  
      (standard deviation of population size (at months 0-72))
The normalized leukocyte models were subsequently clustered using agglomerative 
(‘bottom-up’) Ward’s hierarchical clustering, at each step clustering two clusters 
with minimum between-cluster distance, using the Euclidean distance measure. 
RESulTS
linear mixed effeCt modeling of leukoCyte-subset Cell numbers versus the 
Child’s age
To study the dynamics of different leukocyte subsets in young children, 2,010 
measurements were performed in 1,182 children between birth and 72 months 
(6y) of age to quantify 11 leukocyte subsets: four major innate leukocyte subsets 
(monocytes, neutrophils, eosinophils and NK cells), naive B cells (Bnaive) and 
memory B cells (Bmem), naive and memory CD4+ T cells (CD4+ Tnaive; CD4+ 
Tmem), naive and memory CD8+ T cells (CD8+ Tnaive; CD8+ Tmem), and TCRγδ+ 
T cells. All four innate leukocyte subsets followed a similar profile, starting with 
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high numbers at birth, which quickly declined within the first 6 months of age 
and subsequently remained stable (Figure 1A). In contrast, naive B-cell and T-cell 
numbers strongly increased after birth, peaked around 6-14 months of age and 
subsequently decreased to stable levels around the age of 2-6 years (Figure 1B). 
Memory B-cell and T-cell numbers slowly increased within the first 6-14 months 
of life, after which numbers declined marginally and stabilized from ~3 years 
onwards (Figure 1B). Total TCRγδ+ T-cell numbers increased until 6 months and 
remained quite stable at these levels (Figure 1C).
Figure 1. Dynamics of innate leukocyte and naive and memory lymphocyte populations in children 
between birth and 6 years of age. 
A) Dynamics of monocytes, neutrophils, eosinophils and NK cells. B) Dynamics of naive and memory B-cell 
and T-cell subsets C) Dynamics of TCRγδ+ T cells. Flow cytometry plots depict population definitions in one 
representative 6-year-old individual. Graphs depict absolute numbers of cells in blood of 1,182 children with in 
total 2,010 measurements (gray dots). Linear mixed effect models were generated for each population (solid 
black line) and represented with the 90% confidence interval (CI) of the model (dashed black lines). For clarity, 
only direct follow-up time points within one individual were connected with gray lines; i.e. 0-6m, 6-14m, 14-25m 
or 25-72m. 
0
500
1000
1500
2000
2500
3000
3500
0 12 24 36 48 60 72 84 96
age (months)
NK cells
0
500
1000
1500
2000
2500
3000
3500
ce
lls
/µ
l
ce
lls
/µ
l
   Monocytes
A
0
5000
10000
15000
20000
25000
30000
Neutrophils
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
Eosinophils
CD45
C
D
16
CD3
C
D
16
+C
D
56CD45
S
S
C
granulocytes
lymphocytes
0 12 24 36 48 60 72 84 96
0 12 24 36 48 60 72 84 96
0 12 24 36 48 60 72 84 96
granulo
mono
neutro
phils
eosino
phils
NK cells
lympho
age (months)
0
1000
2000
3000
4000
5000
ce
lls
/µ
l
ce
lls
/µ
l
ce
lls
/µ
l
Bnaive
0
100
200
300
400
500
600
700
800
0 12 24 36 48 60 72 84 96
age (months)
Bmem
0
500
1000
1500
2000
2500
0 12 24 36 48 60 72 84 96
age (months)
CD4+ Tmem
0
500
1000
1500
2000
2500
CD8+ Tmem
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
CD4+ Tnaive
0
500
1000
1500
2000
2500
3000
CD8+ Tnaive
B
C
model
90% CI
 linked data points
data points
0
200
400
600
800
1000
1200
1400
0 12 24 36 48 60 72 84 96
ce
lls
/μ
l
age (months)
TCRγδ+ T cells
CCR7
C
D
45
R
O
TCRαβ
TC
R
γδ
CD27
Ig
D
CD3+
0 12 24 36 48 60 72 84 96
0 12 24 36 48 60 72 84 960
0 12 24 36 48 60 72 84 96
0 12 24 36 48 60 72 84 96
Bnaive
Tnaive
Tmem
Bmem
γδ T cells
CCR7
C
D
45
R
O
CD19
C
D
3
CD3
C
D
8
lympho
CD4+
CD8+
T cells
B cells
Tnaive
Tmem
Chapter 2
44
C
ha
pt
er
 2
Thus, innate leukocytes, naive lymphocytes and memory lymphocytes seem to 
display three distinct patterns in cell numbers versus the child’s age, but patterns 
seemed common to subsets within each of these lineages. 
distinCt dynamiCs of innate leukoCytes, and naive and memory b and t Cells
To evaluate whether functionally similar immune populations would follow similar 
dynamics with increasing age, we extended our analysis to 62 leukocyte subsets, 
including 31 phenotypically non-overlapping subsets, using a more detailed 
classification of innate cells, and naive and memory B and T cells (Table 1), in the 
same children. Linear mixed effect models were generated as described above 
and presented with the raw data points in Supplemental Figures 1-5. 
Hierarchical clustering of the total 62 leukocyte populations resulted in 4 distinct 
clusters of leukocyte dynamics, in which functionally related populations, as 
well as populations with phenotypic overlapping definitions clustered together 
(Figure 2A). To test the effect of including populations with overlapping population 
definitions on the clustering, an additional clustering was performed on a selection 
of 31 non-overlapping populations (Table 1 and Supplemental Figure 6). The 
resulting clusters showed similar dynamics (Figure 2B and Supplemental Figure 
6B) with only 3 populations being assigned to a different cluster, indicating that 
the overlapping populations did not overtly skew our clustering approach. 
Cell numbers of all populations in the first cluster were high at birth, followed 
by a sharp decrease within the first 6 months of life, after which they stabilized 
(Figure 2B). This cluster exclusively contained innate leukocyte subsets, including 
the initially defined NK cells, monocytes, neutrophils and eosinophils (Figure 
1A). All defined innate leukocyte subsets clustered within cluster 1, except for 
the intermediate monocytes, and except for the non-classical monocytes in the 
clustering of 31 non-overlapping populations (Supplemental Figure 6). 
The populations in the second cluster strongly increased shortly after birth, peaked 
before 14 months of age, followed by a long-term gradual decrease. Populations 
in cluster 2 included the three major naive lymphocyte subsets defined in Figure 
1B: Bnaive, CD4+ Tnaive and CD8+ Tnaive. Also the total B and T cells, the 
intermediate monocytes and the Vδ1+ T cells clustered in cluster 2, as well as the 
non-classical monocytes in the clustering in Supplemental Figure 6. Furthermore, 
5 memory populations also showed this pattern: CD4+ central memory T cells 
(Tcm) and CD8+ Tcm cells, early differentiated CD8+ CD45RO- effector memory T 
cells (CD8+ early TemRA), CD27-IgA+ memory B cells and natural effector memory 
B cells. 
The populations in cluster 3 and 4 gradually increased in cell number and peaked 
either at 14 months (cluster 3) or after ~4 years (cluster 4). Clusters 3 and 4 
contained only memory B-cell and T-cell subsets, and the TCRγδ+ T-cell subsets. 
Cluster 3 contained the three major memory populations described in Figure 1B: 
Bmem, CD4+ Tmem and CD8+ Tmem. In particular, these memory populations 
included the early and intermediate CD8+ TemRO subpopulations and the IgMonly, 
CD27+IgA+ and CD27-IgG+ memory B-cell subsets. Cluster 4 contained total TCRγδ+ 
T cells and the Vδ2+ and the Vγ9+ T-cell subsets, as well as the intermediate CD8+ 
TemRO and TemRA cells, most of the CD4+ effector memory T-cell subsets and the 
CD27+IgG+ memory B cells. CD8+ late TemRO and TemRA cells clustered in cluster 
3 in the analysis of all 62 populations (Figure 2) and in cluster 4 when only the 31 
non-overlapping populations were included (Supplemental Figure 6).
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Figure 2. Hierarchical clustering of leukocyte subset dynamics in early childhood. 
A) Absolute numbers of the 62 populations were calculated between 0-72 months of age using the linear mixed 
models. For each population, the data was converted to zero mean and unit standard deviation (z score). The 
resulting patterns of all 62 subsets were subjected to Ward’s hierarchical clustering. 
(Figure 2 continues on next page)
assoCiations between external determinants and leukoCyte subset dynamiCs 
in the four Clusters
To study which external determinants were associated with the four distinct 
age-related patterns of leukocyte numbers (Figure 2), we analyzed 6 prenatal 
maternal life style-related determinants, 3 prenatal maternal immune-mediated 
determinants, 3 birth characteristics, and 14 bacterial/viral exposure-related 
determinants (Table 2). We observed 1 prenatal maternal life style-related 
determinant, no prenatal maternal immune-mediated determinants, gender, 
and 9 bacterial/viral exposure-related determinants that showed a significant 
association with the dynamics of one or more of the 62 leukocyte populations 
after multivariable correction (Table 2). All of these 11 determinants also showed 
a significant association with the 31 non-overlapping leukocyte subsets.
Within cluster 1, 5 determinants were associated to changes in the kinetics of 
one or more of the leukocyte subsets. The strongest association was observed 
with maternal education level, both for the analysis of the total 62 populations 
(37.5%, Figure 3A,C) and the 31 non-overlapping populations (40%, Figure 
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Figure 2. Hierarchical clustering of leukocyte subset dynamics in early childhood. (continued)
B) Average patterns +/- 1 standard deviation of the subsets in each of the 4 major clusters. A comparable 
hierarchical cluster analysis on 31 non-overlapping subsets is presented in Supplementary Figure 6.
3B,D). Specifi cally, low maternal education was associated with a reduction in 
the patterns of eosinophils and classical monocytes (Figure 4). Female gender 
was associated with a signifi cant increase in the pattern of neutrophils, and the 
phenotypically overlapping CD15+ granulocyte population. Having more than 1 
sibling was associated with a reduction, and CMV infection with an increase, in 
NK cells. Antibiotics usage in the fi rst year of life was associated with an increase 
in non-classical monocytes.  Prenatal maternal immune-mediated determinants, 
and the bacterial/viral exposure-related determinants breastfeeding, respiratory 
tract infection or bacterial/ persistent viral infections did not affect any of the 
populations within cluster 1.
Bacterial/ viral exposure-related determinants were more frequently found to 
affect cell numbers in clusters 2, 3 and 4 than in cluster 1 (Figure 3A-B). None 
of the determinants included in our study affected the patterns of more than 
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25% of the populations in cluster 2 (Figure 3C-D). However, female gender was 
associated with an increase in the patterns of CD4+ naive and Tcm cells, and 
consequently in the phenotypically overlapping CD4+TCRαβ+ and total CD4+ 
T cells. Whereas breastfeeding for more than 6 months was associated with a 
reduction in the pattern of total IgA+ and CD27-IgA+ memory B cells, H. pylori 
carriership was associated with an increase in these populations. Furthermore, H. 
pylori carriership was associated with an increase in total Igκ+ B cells and TCRαβ+ 
T cells. CMV and EBV were both associated with an increase in the strongly related 
total and TCRαβ+ CD8+ T cells, and CMV with an increase in Vδ1+ T cells. HSV-1 
seropositivity was associated with a decrease in the large population of naive B 
cells, and consequently with total B cells and Igκ+ and Igλ+ B-cell subsets. 
In cluster 3, CMV and EBV seropositivity were most strongly associated with 
changes in lymphocyte dynamics (Figure 3C). Both viruses were associated with 
an increase in CD8+ intermediate and late TemRO cells, and the phenotypically-
related total CD8+ TemRO and total CD8+ Tmem populations. In addition, CMV was 
associated with an increase in CD8+TCRγδ+ T cells, and CD8+ late TemRA cells, 
and the phenotypically-related total CD8+ TemRA population. EBV was associated 
with an increase in CD8+ early TemRO cells, and a decrease in total Bmem, and 
the CD27- and CD27+ Bmem subsets. The effects on CD8+ late TemRO and TemRA 
cells were still present in the analysis of 31 non-overlapping population, even 
though these were now included in cluster 4 (Figure 3D).
In cluster 4, gender, premature rupture of membranes, CMV and EBV were most 
strongly associated with changes in lymphocyte dynamics (Figure 3C-D). Female 
gender was associated with an increase in the patterns of CD27+IgG+ memory B 
cells, and CD4+ early TemRO cells, and with a reduction in total TCRγδ+ T cells and 
CD4+ late TemRA populations. Premature rupture of membranes was associated 
with an increase in CD4+ late TemRO and Vδ2+ and Vγ9+ T-cell subsets. CMV 
and EBV seropositivity were both associated with an increase in total CD4+ and 
CD4+ late TemRO and TemRA cells, as well as CD8+ intermediate TemRA cells. In 
addition, CMV was associated with increased CD4+ intermediate TemRO cells, and 
EBV with an increase in CD4+ early TemRO cells. 
Altogether, we identified multiple determinants that had a significant effect on the 
dynamics of leukocyte subset numbers within one or more of the four distinct age-
related patterns. Still, considerable variation of effects could be observed within 
individual clusters.
effeCts of external determinants on leukoCyte dynamiCs within distinCt 
leukoCyte lineages
As clusters 2, 3 and 4 each contained various B-cell and T-cell populations, each 
with distinct humoral or cellular functions, we next studied the effects of the 26 
determinants on the patterns of individual subsets within the innate leukocytes, 
TCRγδ+ T-cell, naive and memory B-cell, naive and memory CD4+ T-cell and naive 
and memory CD8+ T-cell and lineages (Figure 4). 
Within the B-cell lineage, low maternal educational level was the only prenatal 
maternal life style-related factor that was associated with a change in B-cell 
dynamics, and was associated with a reduction in the patterns of total memory B 
cells. None of the prenatal maternal immune-mediated diseases were associated 
with leukocyte dynamics in any of the cell lineages. Of the birth characteristics, 
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Figure 3. External determinants associated with leukocyte dynamics in the four clusters. 
Twenty-six determinants were studied for having an independent effect on the linear mixed effect models of 
each of the 62 leukocyte populations (A and C) and each of the 31 non-overlapping leukocyte subsets (B and 
D). Subsequently, all determinants with a significant individual effect were added to a multivariable linear 
mixed effect analysis to correct for confounding effects. A and B) Relative distribution of significant effects by 
determinants within the groups: prenatal maternal life style, prenatal maternal immune-mediated diseases, birth 
characteristics or bacterial/ exposure-related determinants. Analyses were independently performed for all 62 
defined subsets (A) and the subgroup of 31 non-overlapping subsets (B). C and D) Frequencies of populations 
within a cluster that were affected by individual determinants. In C. all 62 leukocyte populations and all 26 studied 
determinants are presented. In D., the independent analysis on the 31 non-overlapping populations is depicted 
containing only the determinants that affected one or more cell types. Abbreviations: PROMM, premature rupture 
of membranes; RTI, respiratory tract infection. Numbers in each bar refer to the number of each population as 
indicated in Figure 2. 
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female gender was associated with an increase in the patterns of CD27+IgA+ and 
CD27+IgG+ memory B cells, though these effects were not reflected in the total 
memory B-cell populations. Breastfeeding for more than 6 months was associated 
with a selective reduction in the pattern of CD27-IgA+ memory B cells, antibiotics 
usage in the first year of life was associated with a selective increase in the pattern 
of CD27-IgG+ memory B cells, and H. pylori carriership was associated with an 
increase in the patterns of both CD27-IgA+ and CD27+IgA+ memory B cells. EBV 
infection was associated with a reduction in the pattern of total memory B cells, 
though not with a specific memory B-cell subset, HSV-1 infection was associated 
with a selective reduction in the pattern of naive B cells.
Within the CD4+ and CD8+ T-cell lineage, female gender was associated with an 
increase in the patterns of CD4+ naive, Tcm and early TemRO cells, although 
these effects were not reflected in the total CD4+ memory T-cell populations. 
In contrast, female gender was associated with a decrease in the patterns of 
CD4+ and CD8+ late TemRA cells. Whereas premature rupture of membranes was 
associated with an increase in CD4+ late TemRO cells, child birth via caesarian 
section was associated with a reduction in the pattern of CD4+ early TemRO cells. 
Breastfeeding, antibiotics usage and H. pylori carriership were not associated 
with CD4+ or CD8+ T-cell dynamics. Persistent viral infection with CMV and EBV 
strongly associated with CD4+ and CD8+ T-cell dynamics. CMV infection associated 
exclusively with an increase in the patterns of intermediate and late differentiated 
CD4+ and CD8+ TemRO and TemRA cells. Associations with EBV were slightly 
more variable, also including early differentiated CD4+ and CD8+ TemRO cells. In 
contrast to both CMV and EBV, HSV-1 and VZV did not associate with CD4+ and 
CD8+ T-cell dynamics.
Within the TCRγδ+ T-cell lineage, CMV infection associated with an increase in the 
pattern of Vδ1+ T cells; premature rupture of membranes was associated with an 
increase in Vδ2+Vγ9+ T cells. 
DISCuSSION 
We here modelled the kinetics of 62 leukocyte subsets, including 31 non-
overlapping subsets, and identified distinct patterns of cell numbers in the first 6 
years of life for innate leukocytes, naive B and T cells, and memory B and T cells. 
Furthermore, we identified multiple determinants related to prenatal maternal 
life style, prenatal maternal immune-mediated diseases, birth characteristics or 
bacterial/viral exposure, that affected the dynamics of each of these leukocyte 
subsets between birth and 6 years of age. 
Unsupervised clustering of all 62 leukocyte subsets, as well as of the set of 31 
phenotypically non-overlapping populations, resulted in 4 clusters with the first 
cluster containing exclusively innate leukocyte subsets. These subsets followed 
highly similar patterns of kinetics with age: they were abundant at birth and 
quickly decreased before stabilizing at 6-14 months of age. Consistent with their 
early predominance, innate leukocyte kinetics was affected by maternal education 
level, which might already influence the fetus prenatally. Maternal education level 
is strongly related to life style with low education being an indicator for a less 
healthy life style, including differences in smoking and alcohol consumption, BMI, 
stress-levels, higher infection load and increased crowding.34 These observations 
might suggests that maternal life style is especially important for shaping of innate 
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leukocyte populations, though the exact mediator of the effect will still have to be 
determined.
The non-classical and intermediate monocytes did not consistently cluster with 
the innate leukocyte subsets due to a later peak in numbers or a slower decline. 
This altered kinetics could be the result of these being derived from classical 
monocytes, and not directly from precursors in bone marrow.35 Furthermore, the 
various subsets of monocytes show distinct expression levels of proteins involved 
in HLA-class II-dependent antigen presentation and CD40-CD40L co-stimulation,35 
and display distinct parasite pattern recognition abilities.35-38 Thus, our data 
support the need to discriminate intermediate and non-classical monocytes from 
the dominant population of classical monocytes in kinetics studies. 
All naive B-cell and T-cell populations clustered together in cluster 2 and their 
numbers increased in the first 14 months followed by a more gradual decline. After 
the first 1-2 years of life, B-lymphocyte production in bone marrow decreases,39,40 
and the thymus starts to involute.41 These processes are likely causes of the 
decline we observed. The nature for decreased bone marrow output remains 
unclear. Recent studies, however, indicate a role for circulating long-lived memory 
B cells in this process.42
Memory B-cell subsets were found in several clusters. Natural effector and CD27-
IgA+ memory B cells clustered together with naive B cells. Both memory B-cell 
populations are suggested to derive, at least in part, from germinal center-
independent responses without T-cell help in the splenic marginal zone and the 
intestinal lamina propria.43-45 The fast rise in cell numbers within the first 6 months 
of life contrasts the kinetics of the other, T-cell dependent, memory B-cell subsets 
in clusters 3 and 4. This supports the concept of these cells being generated in 
first and fast responses, in the absence of the extensive proliferation and selection 
processes of the germinal center.45
IgMonly, CD27-IgG+ and CD27+IgA+ memory B cells clustered in cluster 3, 
representing gradual memory formation. Only the CD27+IgG+ population 
clustered in cluster 4, and developed slightly slower than the other memory B-cell 
populations. In adults, this subset shows a higher level of affinity maturation, more 
extensive replication history, and more frequent development via consecutive 
class-switching, than CD27-IgG+ memory B cells.45,46 It is perceivable that many of 
these CD27+IgG+ cells are generated from CD27-IgG+ memory B cells in secondary 
responses. This could explain the gradual decline in CD27-IgG+ B cell numbers 
after 14 months of age. 
Several external determinants had a significant effect on the B-cell kinetics. First, 
we confirmed our previous observations regarding lower numbers of memory 
B cells in breastfed children.21,23 However, in the current analysis we could not 
reproduce the previously reported association between breastfeeding duration 
and germinal center-dependent memory B-cell numbers at 6 months of age.45 The 
difference is likely due to our current analysis in which duration of breastfeeding 
was not included and the overall pattern between birth and 6 years of age was 
studied. 
IgA+ memory B cells were significantly increased in H. Pylori positive children. The 
colonization of the gastric mucus by H. Pylori has been found to correlate with an 
increase in total blood B-cell counts,47 on top of the local expansion of antibody-
secreting IgA+ cells,48 which are important for the protection against H. Pylori 
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infection.49 Our observed expansion of circulating IgA+ memory B cells included 
both the CD27+IgA+ and mucosa-derived CD27-IgA+ subsets. This would suggest 
that the presence of H. pylori does not only result in a local expansion of plasma 
cells, but also a systemic expansion of memory B cells in otherwise asymptomatic 
carriers. It remains to be determined whether this expansion is beneficial for the 
host as the bacterial protein CagA inhibits B-cell apoptosis and thereby increases 
the risk for mucosa-associated B-cell malignancies.50,51 
Memory T-cell subsets were found in clusters 2, 3 and 4. CD4+ and CD8+ Tcm 
(cluster 2) express lymph node homing markers and are the presumed precursors 
of effector memory T cells.25,52,53 The early peak in Tcm numbers prior to those of 
effector memory T cells in young children would fit with this function. Similarly, 
CD8+ early TemRA cells might be precursors for further differentiated TemRA 
subsets. Vδ1+ T-cell numbers (cluster 2) peaked prior to the Vδ2+ and Vγ9+ 
subsets (cluster 4), thereby confirming the previously observed early shift from 
Vδ1+ to Vδ2+Vγ9+ predominance in children,54,55 Of note, Vδ1+ T cells are abundant 
in adult intestine; their decline in blood might, at least in part, result from altered 
distribution towards mucosal tissue.
Both vaginal delivery and premature rupture of membranes were associated with 
an increase in the pattern of one of the CD4+ TemRO subsets, in line with previous 
literature.56 Stress upon child birth via vaginal delivery has been correlated with 
an increase in CD4+ regulatory T cells.57 As a large fraction of regulatory T cells has 
a memory phenotype, this could explain the observed increase of CD4+ TemRO 
cells in children born by vaginal delivery. Since reduced numbers of regulatory T 
cells in cord blood are associated with the development of atopic dermatitis in the 
first year of life,58 it will be of interest to study whether this effect is modified by 
the mode of delivery.
Both CD4+ and CD8+ memory T-cell dynamics were predominantly affected by 
CMV and/ or EBV seropositivity. This is consistent with previous observations 
in both children and elderly,26,59-63 and in agreement with their function in 
cellular immunity. Moreover, these viruses displayed distinct effects with CMV 
being associated to increased late effector memory T-cell numbers and EBV 
with a slightly more variable effect, including also early effector memory T-cell 
subsets.25,64 Furthermore, we confirmed that HSV-1 did not affect CD4+ and CD8+ 
T-cell populations.26,63 In contrast, HSV-1 seropositivity was associated with a loss 
of naive B cells. This association has, to our knowledge, not been described before. 
EBV infection was associated with a reduction in memory B cells, likely due to the 
selective EBV persistence in these cells.65,66 Our large-scale analysis allowed us to 
separate the herpesvirus-associated effects, with CMV and EBV being associated 
with memory T-cell expansions, and HSV-1 and EBV, with a decrease in naive or 
memory B-cell numbers, respectively. 
Gender had a widespread effect on 13 subsets within multiple leukocyte lineages. 
Interestingly, female gender was associated with an increase in neutrophils, 
T-cell dependent IgA+ and IgG+ memory B-cell populations and CD4+ naive, Tcm 
and early differentiated TemRO cells, while numbers of late differentiated CD4+ 
and CD8+ TemRA cells and TCRγδ+ T cells were reduced. These combined effects 
result in a skewing of humoral and early differentiated CD4+ T-cell responses 
over cellular cytotoxic responses in girls. These effects might be associated with 
differences in sex-hormone levels (testosterone, estradiol) in females versus 
males that are already detectable during early infancy, as well as with genetic 
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differences between females and males.67 In adults, sex-hormones have been 
found to affect immune responses in both quantitative and qualitative aspects.68,69 
These insight can especially be important for dissection of auto-immune diseases, 
which are much more prevalent in females than in males, though predisposition 
for allergic diseases seems to be opposite in infancy.67,70 
methodologiCal Considerations 
The strength of this study is its prospective longitudinal population-based design 
with >1,000 children and the possibility to study 26 external determinants with 
adjustments for major confounders. The linear mixed model approach enabled 
modeling of cross-sectional data, with further improvement of the accuracy by 
incorporating additionally available longitudinal follow-up data. Furthermore, we 
included only children with a two-generation Dutch ancestry, which prevented 
interference of our analyses by strong ethnic and cultural influences. However, 
extrapolation of our findings to different ethnic and cultural populations might be 
limited, and would require additional analysis of ethnically-different population 
cohorts. 
The inclusion of 62 leukocyte populations allowed for the large-scale analysis of 
the effect of external determinants on both total cell lineages as well as on small 
subsets defined by extensive and detailed phenotypic definition. The overlap in 
some populations could have skewed the hierarchical clustering. However, our 
selection of 31 phenotypically non-overlapping populations resulted in clusters 
with similar patterns, indicating the robustness of the 4 major patterns of leukocyte 
dynamics and the observed effects of external determinants. 
Our study was primarily explorative with a focus on the identification of 
determinants related to prenatal maternal life style, maternal immune-mediated 
diseases, birth characteristics or bacterial/viral exposure, that affected leukocyte 
dynamics between birth and 6 years of age. Although we defined whether the 
determinants had a positive or negative association with leukocyte numbers, we 
were unable to identify the exact nature of the effect, i.e. exactly when these 
effects presented and whether these effects will be transient, persistent or 
potentially even increasing over time. Consequently, more research into individual 
determinants will be needed to extend our observations by specifying these effects. 
Finally, special consideration needs to be taken for serology of infectious agents 
that were measured at the age of 6 years. We cannot determine the exact timing 
of primary infections, and this can consequently be in the whole period preceding 
the age of 6 years. Still, most H. Pylori infections already occur in early childhood, 
and IgG seropositivity to herpesviruses only appears several weeks to 3 months 
after infection. Thus, it is likely that these determinants were present during or 
prior to the 6th year of life.  
ConClusions
With our unbiased approach, we were, for the first time, able to classify leukocyte 
populations according to their dynamics between birth and 6 years of age, and 
to assess determinants that are associated with the dynamics of cell lineages or 
specific leukocyte subsets. We confirmed previously described effects of persistent 
CMV and EBV infections on memory T cells and identified new effects, including 
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the effects of HSV-1 on naive B cells. These newly identified determinants can 
provide new targets for studies on the molecular processes that regulate leukocyte 
development and immune responses, and that together underlie formation of long-
lasting immunity without inducing destructive, excessive or insufficient immune 
responses.
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Supplemental Figure 1. Dynamics of innate leukocyte subsets in children between birth and 6 years 
of age.
Absolute numbers and modelled dynamics of granulocytes, monocytes and NK cells (A), CD15+, neutrophilic 
and eosinophilic granulocytes (B), and classical, intermediate and non-classical monocyte subsets (C), from 
birth until 6 years of age. Linear mixed effect models were generated for each population (solid black line) and 
represented with the 90% confidence interval (CI) of the model (dashed black lines). For clarity of the graphs, 
gray lines connect only consecutive time points within one individual; i.e. 0-6m, 6-14m, 14-25m or 25-72m.  
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Supplemental Figure 2. Dynamics of TCRαβ+ T-cell and TCRγδ+ T-cell subsets in children between birth 
and 6 years of age. 
Absolute numbers and modelled dynamics of T cells (A), TCRαβ+ T-cell populations (B), and TCRγδ+ T-cell 
populations (C), from birth until 6 years of age. Linear mixed effect models were generated for each population 
(solid black line) and represented with the 90% confidence interval (CI) of the model (dashed black lines). For 
clarity of the graphs, gray lines connect only consecutive time points within one individual; i.e. 0-6m, 6-14m, 
14-25m or 25-72m.  
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Supplemental Figure 3. Dynamics of CD4+ T-cell subsets in children between birth and 6 years of age.
Absolute numbers and modelled dynamics of total, naive and memory CD4+ T cells (A); CD4+ central memory 
T cells (Tcm), CD45RO+ effector memory (TemRO) and CD45RO- effector memory (TemRA) T-cell subsets (B); 
early, intermediate or late differentiated TemRO subsets (C); or early, intermediate or late differentiated TemRA 
subsets (D), between birth and 6 years of age. Linear mixed effect models were generated for each population 
(solid black line) and represented with the 90% confidence interval (CI) of the model (dashed black lines). For 
clarity of the graphs, gray lines connect only consecutive time points within one individual; i.e. 0-6m, 6-14m, 
14-25m or 25-72m.  
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Supplemental Figure 4. Dynamics of CD8+ T-cell subsets in children between birth and 6 years of age.
Absolute numbers and modelled dynamics of total, naive and memory CD8+ T cells (A); CD8+ central memory 
T cells (Tcm), CD45RO+ effector memory (TemRO) and CD45RO- effector memory (TemRA) T cell subsets (B); 
early, intermediate or late differentiated TemRO subsets (C); or early, intermediate or late differentiated TemRA 
subsets (D), between birth and 6 years of age. Linear mixed effect models were generated for each population 
(solid black line) and represented with the 90% confidence interval (CI) of the model (dashed black lines). For 
clarity of the graphs, gray lines connect only consecutive time points within one individual; i.e. 0-6m, 6-14m, 
14-25m or 25-72m.   
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Supplemental Figure 5. Dynamics of B-cell subsets in children between birth and 6 years of age.
Absolute numbers and modelled dynamics of total B cells (A); naive and total memory B cells (B); total Igκ+ 
and Igλ+ B-cells populations (C); and CD21low B cells (D); CD27- and CD27+ memory B cells (E); total IgM+, 
IgA+ or IgG+ memory B cells (F); IgM+, IgA+ or IgG+ memory B-cell subsets (G) between birth and 6 years of 
age. Linear mixed effect models were generated for each population (solid black line) and represented with the 
90% confidence interval (CI) of the model (dashed black lines). For clarity of the graphs, gray lines connect only 
consecutive time points within one individual; i.e. 0-6m, 6-14m, 14-25m or 25-72m.   
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Supplemental Figure 6. Hierarchical clustering of the dynamics of 31 non-overlapping leukocyte 
subsets in early childhood. 
A) Ward’s hierarchical clustering was performed as in Figure 2, including now only the 31 non-overlapping 
leukocyte subsets. Indicated in gray squares in front of the heat map is the cluster each population was assigned 
to in the analysis of the total 62 leukocyte subsets in Figure 2.  B) Average patterns +/- 1 standard deviation 
of the subsets in each of the 4 major clusters. Indicated in black squares are 3 subsets that were assigned to 
different clusters than in Figure 2. (Figure on next page)
Eosinophils
Neutrophils
NK cells
Classical monocytes
-2
-1
0
1
2
3
4
5
6
-2
-1
0
1
2
3
-5
-4
-3
-2
-1
0
1
2
3
-5
-4
-3
-2
-1
0
1
2
0 6 12 18 24 30 36 42 48 54 60 66 72
1
4
5
6
8
9
10
12
16
20
21
23
24
27
30
33
35
42
44
46
49
CD8+ TemRO interm
CD8+ TemRO early
IgMonly
CD27+IgA+
CD27-IgG+
CD4+ TemRA early
37
39
52
53
55
56
57
59
61
62
CD8+ TemRO late
CD8+ TemRA late
CD4+ TemRO interm
CD8+ TemRA interm
CD4+ TemRA interm
Vδ2+Vγ9+ T cells
CD4+ TemRA late
CD4+ TemRO early
CD4+ TemRO late
CD27+IgG+
Z-
sc
or
e
Z-
sc
or
e
Z-
sc
or
e
Z-
sc
or
e
Age (months)
3
4
2
0 6 12 18 24 30 36 42 48 54 60 66 72
0 6 12 18 24 30 36 42 48 54 60 66 72
0 6 12 18 24 30 36 42 48 54 60 66 72
cluster 1
cluster 3
Non-classical monocytes
CD4+ Tcm
Natural effector B cells
CD27-IgA+
Bnaive
CD8+ TemRA early
Vδ1+ T cells
Intermediate monocytes
CD8+ Tcm
CD4+ Tnaive
CD8+ Tnaive
1
A
B
66
67
Chapter 3
DECREASED MEMORy B CEllS AND INCREASED CD8 
MEMORy T CEllS IN BlOOD OF BREASTFED CHIlDREN: 
THE GENERATION R STuDy 
Running title: Impact of breastfeeding on adaptive immunity 
M.A.E. Jansen,1,2,3 D. van den Heuvel,3 M.C. van Zelm,3 V.W.V. Jaddoe,1,2,4 
A. Hofman,4 J.C. de Jongste,2 H. Hooijkaas,3 H.A. Moll.2 
1 The Generation R Study Group, Erasmus MC, University Medical Center, Rotterdam, NL
2 Dept. of Pediatrics, Erasmus MC-Sophia, Rotterdam, NL 
3 Dept. of Immunology, Erasmus MC, University Medical Center, Rotterdam, NL
4  Dept. of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, NL
PLoS One. 2015; 10(5): e0126019
Chapter 3
68
C
ha
pt
er
 3
ABSTRACT
baCkground. Breastfeeding provides a protective effect against infectious 
diseases in infancy. Still, immunological evidence for enhanced adaptive immunity 
in breastfed children remains inconclusive. 
objeCtive. To determine whether breastfeeding affects B- and T- cell memory in 
the first years of life. 
methods. We performed immunophenotypic analysis on blood samples within 
a population-based prospective cohort study. Participants included children at 6 
months (n=258), 14 months (n=166), 25 months (n=112) and 6 years of age 
(n=332) with both data on breastfeeding and blood lymphocytes. Total B-cell 
and T-cell numbers and their memory subsets were determined with 6-color 
flow cytometry. Mothers completed questionnaires on breastfeeding when their 
children were aged 2, 6, and 12 months. Multiple linear regression models with 
adjustments for potential confounders were performed. 
results. Per month continuation of breastfeeding, a 3% (95% CI -6,-1) decrease 
in CD27+IgM+, a 2% (95 CI % -5,-1) decrease in  CD27+IgA+ and a 2% (95% 
CI -4,-1) decrease in CD27-IgG+ memory B-cell numbers were observed at 6 
months of age. CD8+ T-cell numbers at 6 months of age were 20% (95% CI 
3,37)  higher in breastfed than in non-breastfed infants. This was mainly found for 
central memory CD8+ T cells and associated with exposure to breast milk, rather 
than duration. The same trend was observed at 14 months, but associations 
disappeared at older ages. 
ConClusions. Longer breastfeeding is associated with increased CD8+ T-cell 
memory, but not B-cell memory numbers in the first 6 months of life. This transient 
skewing towards T-cell memory might contribute to the protective effect against 
infectious diseases in infancy.
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INTRODuCTION
Breast milk contains factors that enhance nutrient absorption, stimulate growth 
and enhance the defense against pathogens.1 Consequently, breastfeeding 
provides protection against infectious diseases during infancy.2-4 The protective 
effect persists during childhood,5,6 and modulates vaccination responses.7-9 Thus, 
it is likely that breastfeeding not only provides passive immunization, but also 
enhances adaptive immunity.10 
B and T lymphocytes comprise the cellular components of adaptive immunity, and 
are generated throughout life. B cells contribute to humoral immunity through 
the production of immunoglobulins (Ig), whereas CD8+ cytotoxic T cells provide 
cellular immune responses. CD4+ helper T cells support both humoral and cellular 
immune responses. Each B and T cell generates a unique antigen receptor during 
precursor differentiation in bone marrow or thymus, respectively. Only those 
cells that specifically recognize antigen with their receptor will undergo clonal 
proliferation and are involved in the antigen response. Cells generated from the 
clonal expansion will remain present in the body as long-lived memory cells and 
will initiate a fast and quantitatively stronger response upon secondary antigen 
encounter. In addition to CD27- naive B cells, six memory B-cell subsets can 
be identified.11 Four of these express CD27 and are either positive for IgM, IgM 
and IgD, IgA or IgG. In addition, CD27-IgA+ and CD27-IgG+ memory B cells can 
be identified. Within both the CD4+ and CD8+ T-cell lineages, central memory 
(CD45RO+CCR7+), CD45RO+CCR7- effector memory (TemRO) and CD45RO-
CCR7- (TemRA) can be distinguished from naive T cells (CD45RO-CCR7+).12 
Central memory T cells are most efficient in generating a new immune response 
by proliferating extensively in response to an antigen upon secondary antigen 
encounter.13-15 The diversity and composition of the B-cell and T-cell compartments 
are highly dynamic in the first years of life; blood cell counts are especially high 
up to 2 years of age, following which they slowly decline to reach adult levels 
between 6 and 10 years.16-20 At birth, nearly all B and T cells are naive, and 
memory cells are gradually built up in the first 6 years of life.19 
Several studies have addressed the effects of breastfeeding on adaptive immunity. 
Breastfeeding was found to be associated with decreased frequencies of blood 
CD4+ T cells.21 This was mostly due to lower frequencies of naïve (CD45RA+) T cells 
in breastfed children. Still, these observations were not consistently reproduced 
with some studies showing increased, and some decreased numbers of CD4+ 
T cells.21-24 Furthermore, long term breastfeeding was found to be associated 
with increasing numbers of CD4+ and CD8+ T cells.24 Thus, although previous 
studies have addressed the influence of breastfeeding on blood lymphocyte 
populations,21-24 the results remained inconclusive, mainly due to small samples 
sizes and limitations in the detection of memory cells.21-24 
In the present study we used 6-color flow cytometric analysis of lymphocyte 
subsets in a population-based prospective cohort study to assess the impact of 
breastfeeding on build-up of memory B and T cells in infants and young children.
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MATERIAlS AND METHODS
design and study population
This study was embedded in the Generation R Study, a prospective population-
based cohort study that follows pregnant women and their children from fetal life 
onwards in the Netherlands.25 The study has been approved by the Medical Ethics 
Committee of the Erasmus MC, University Medical Centre Rotterdam. Written 
informed consent was obtained from all parents of participants. We included 1,079 
Dutch pregnant women and their children participating in a detailed subgroup 
study.25 All children were born between February 2002 and August 2006. We 
excluded twins (n=27) in the present analysis to prevent bias due to correlation. 
Of these, data on both breastfeeding and immunophenotyping were available 
from 258 children at 6 months, 166 at 14 months, 112 at 25 months and 332 at 
6 years of age. The main reasons for missing samples were due to non-consent 
of the parents (approximately 55% per visit) and technical or logistical failure 
(approximately 10% per visit). 
breastfeeding
Information regarding breastfeeding was obtained in postnatal questionnaires 
at the ages of 2, 6 and 12 months.25 Mothers were asked whether they had 
ever breastfed their child (yes or no) and, if yes, at what age (months) they 
had stopped.26,27 Breastfeeding duration was then categorized into four groups: 
never, <3 months, between 3 and 6 months and >6 months. An approximation 
of exclusive breastfeeding was performed according to whether the child 
received breastfeeding without any other bottle feeding, milk or solids.27 Partial 
breastfeeding indicates infants receiving both breast-feeding, bottle feeding 
and/or solids in this period. Subsequently, the information on exclusiveness of 
breastfeeding was combined and categorized into the following breastfeeding 
categories: never; partial until 4 months and exclusive until 4 months. 
immunophenotyping of lymphoCyte subsets
Flow cytometry was performed within 24 hours following sampling on fresh whole 
blood at the ages of 6 months (median 6.2; range 5.2; 8.2), 14 months (median 
14.4; range 13.1-17.4), 25 months (median 25.2; range 23.3-29.8) and 6 years 
(median 5.9; range 5.1-7.2). Absolute counts of blood CD3+ T cells, CD16/56+ NK 
cells, and CD19+ B cells were obtained with a diagnostic lyse-no-wash protocol. 
Lymphocytes were gated on the basis of CD45, FSC and SSC characteristics. Gates 
were set based on cells that are known to lack expression of the indicated marker. 
Additionally, 6-color flow cytometry was performed on an LSRII (BD Biosciences) 
to distinguish naive and memory B-cell and T-cell subsets as defined previously 
(Supplemental Table 3).11,12 All flow cytometry acquisition was performed on 
whole blood after red blood cell lysis with ammonium chloride.
Covariates 
The covariates that were assessed in this study were obtained from midwife and 
hospital registries at birth (birth weight, gestational age and gender) or through 
measurements at the research center (child anthropometrics). Additionally, 
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information on smoking and alcohol use during pregnancy and socio-economic 
status was obtained by prenatal questionnaires sent during the first, second 
and third trimesters of pregnancy.28,29 Information on day-care attendance was 
obtained from parent-reported questionnaires at the ages of 6 and 12 months.  
 
statistiCal methods
Because the distribution of lymphocyte numbers in different age groups was 
skewed, these values were normalized by transformation to a natural log-scale. 
Differences in maternal and infant characteristics between breastfed versus never 
breastfed children were tested using independent samples t-tests and Chi-Square 
tests. Differences in baseline characteristics among the groups with different 
duration of breastfeeding were assessed using ANOVA tests and Chi-Square 
tests. Additionally, the associations of breastfeeding, breastfeeding duration 
(measured in groups, and measured continuously per month continuation of 
breastfeeding) and breastfeeding exclusivity with the change in lymphocyte 
numbers were assessed using multiple linear regression models with adjustment 
for potential confounders. For all ages, the category with no breastfeeding was the 
reference. First, associations between breastfeeding and total B, T, CD4 and CD8 
counts were assessed. Subsequently, associations for B, CD4+ and CD8+ T-cell 
subpopulations were studied to assess the effect of breastfeeding on memory 
cells specifically. Multivariable regression models were created with stepwise 
adjustment for potential confounders, which were selected based on previous 
literature. Potential confounders included: maternal age, socio-economic status 
(SES), marital status, maternal BMI, maternal smoking and alcohol consumption 
during pregnancy, maternal reported autoimmune disease (including thyroid 
disease, multiple sclerosis, systemic lupus erythematosus, diabetes mellitus and 
arthritis), elevated anti-tTG level during pregnancy, maternal fever in the last 
trimester of pregnancy, family history of asthma or atopy (hay-fever, allergy, 
eczema), multiple parities, mode of delivery (caesarean section), gender, birth 
weight, gestational age, preterm birth, APGAR score, birth season, weight and 
age at focus visit, fever in the first 6 months (yes/no), frequency of upper and 
lower respiratory tract infections, and day-care attendance in the first year of life. 
Covariates were kept in the final multivariate model if the covariate resulted in an 
alteration in effect estimate of > 10%,30 or if the variables were associated with 
breastfeeding (determinant) and lymphocyte numbers (outcome) in our study. 
Because of the small numbers in the never breastfed group, final adjustment for 
potential confounders was restricted to those who attained the strongest alteration 
(%) in effect estimates. Because of the strong correlation between our outcomes 
(e.g. Pearson’s correlation  between total CD8+ T cells and naive CD8+ T cells r 
=0.82, and between total B cells and IgA r=0.57), and unweighted calculations 
only hold if the tests are independent,31,32 we did not perform adjustments for 
multiple testing. All measures of associations are presented with their 95% 
confidence interval. All statistical analyses were performed using the Statistical 
Package for the Social Sciences version 20.0 for Windows (SPSS Inc, Chicago, IL, 
USA). P values <0.05 were considered to be statistically significant.  
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RESulTS
population CharaCteristiCs
No major differences in characteristics between children included at 6, 14, 25 
months and 6 years of age were observed (Table 1, Supplemental Table 1) Overall, 
more than 86% of mothers started breastfeeding. Mother’s educational level was 
significantly associated with the start of breastfeeding at 6 and 25 months, and 6 
Table 1. Maternal and infant characteristics of the study population at 6 months 
Not 
breastfed (n=35)
Breastfed 
(n=223)
Maternal characteristics (n=258)
Age (Mean + SD; years)                                            32 (3.6) 32 (3.8)
Educational level (n; %)           
Lower 24 (69%) 71 (32%)
Higher 11 (31%) 152 (68%)*
Net household income per 
month (n; %)                       
< € 2400 2 (7%) 23 (11%)
> € 2400 29 (93%) 178 (89%)
Smoking continued during pregnancy (n; %) 4 (14%) 21 (13%)
Alcohol use  continued during pregnancy (n; %) 8 (29%) 55 (35%)
Body Mass Index before pregnancy (Mean + SD; kg/m2) 23 (3) 23 (4)
Fever in third trimester of pregnancy (n; %)                  3 (9) 14 (6%)
Maternal atopy (eczema, allergy HDM, hay-fever)(n; %) 8 (25%) 72 (35%)
Paternal atopy (eczema, allergy HDM, hay-fever) (n; %) 8 (28%) 55 (28%)
Family history of asthma / atopy (n; %)                             13 (37%) 107 (49%)
Any reported autoimmune disease (diabetes mellitus,
SLE, arthritis, MS, thyroid disorder, or celiac disease) (n; %) 0 (0%) 5 (0.02%)
Mode of delivery (n; %)
Vaginal 21 (64%) 129 (61%)
Forceps or vacuum assisted 5 (15%) 44 (20%)
Caesarian section 7 (21%) 40 (19%)
Premature rupture of membranes (n; %) 3 (9%) 6 (3%)
Infant characteristics (n=258)
Males (n; %)                                                                19 (54%) 113 (51%)
Gestational age ( Mean + SD; weeks) 39.4 (2.4) 40.0 (1.7)
Preterm birth (<37 weeks) (n; %)                             2 (6%) 11 (5%)
Birth weight ( Mean + SD; grams)        3439 (632) 3504 (524)
Apgar score at 5 min <7 (n; %)                               0 (0%) 3 (1%)
Birth season (n; %)                
Winter (dec-jan-feb) 5 (14%) 36 (16%)
Spring (mar-apr-may) 10 (29%) 81 (36%)
Summer (jun-jul-aug) 11 (31%) 62 (28%)
Autumn (sept-oct-nov) 9 (26%) 44 (20%)
Siblings >1 (n; %)                        4 (11%) 26 (12%)
Day-care >16 hours /week (n; %)          5 (33%) 77 (46%)
Fever in first 6 months  (n; %)           12 (60%) 121 (62%)
Age at focus visit (Median + range; months)       6.6 (6.2-8.2) 6.2 (5.2-7.9)*
Values are means (SD), absolute numbers (percentages) or #medians (90% range). *Significantly 
different between groups. 
Data were missing on: Household income (n=26) Smoking during pregnancy (n=72), Alcohol during 
pregnancy (n=72)  BMI before pregnancy (n=37), Fever in third trimester (n=9) Mode of delivery (n=12) 
Maternal atopy (n=22) Paternal atopy (n=29), Family history of asthma or atopy (n=3)  Mode of delivery 
(n=12), maternal reported autoimmune disease (n=29),  maternal reported  any other chronic condition 
(n=31), premature rupture of membranes (n=5), Apgar (n=4), Day-care (n=42), weight at focus visit 
(n=1), fever in first 6 months (n=42). Any reported autoimmune disease included thyroid disease (n=4) 
and elevated anti-tTG level during pregnancy (n=1).
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years of age. Moreover, mother’s educational level was significantly associated with 
both the duration of breastfeeding and with B-cell memory subsets at 6 months 
of age [data not shown]. In addition, maternal alcohol use was related to both 
breastfeeding duration and total T, B, CD4+ and CD8+ cell  numbers at 6 months 
[data not shown]. Both maternal educational level and alcohol use influenced the 
regression coefficients by more than 10%. Therefore, all subsequent analysis 
on breastfeeding duration and cell numbers were adjusted for both maternal 
education and maternal alcohol use during pregnancy. 
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Figure 1. Impact of breastfeeding duration on B lymphocyte subsets at 6 months of age.
A) Gating strategy for dissection of CD19+ B cells into 1 naive and 5 memory B-cell subsets by flow cytometry. 
The reference plots depict density plots of total lymphocytes and were used to set the gates accordingly. B) 
Backtransformed B-cell counts (cells/µL) at 6 months of age according to different breastfeeding duration 
categories (reference category is never). Categories of breastfed children contain both partial and exclusively 
breasted children. C) The estimated backtransformed regression line reflects B-cell counts (cells/µL) at 6 months 
of age, per month increase in breastfeeding duration.*, P<0.05.
deCrease in b-Cell memory
Breastfeeding exposure (Figure 1B) and duration (Figure 1C) were not associated 
with total B-cell numbers at 6, 14, 25 months and 6 years of age (Table 2, 
Supplemental Table 2). Furthermore, no associations were observed between 
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breastfeeding exposure and duration and naive B cells, which constitute the 
majority of total B-cell numbers (Table 3, Figure 1B and 1C) However, a longer 
duration of breastfeeding, was associated with changes in the memory B-cell 
compartment. Per month longer breastfeeding, a 3% decrease in absolute 
numbers of CD27+IgM+, and a 2% decrease in both CD27+IgA+ and CD27-
IgG+ memory B cells at 6 months of age were observed (Table 3, Figure 1C). 
CD27+IgG+ and CD27-IgA+ memory B cells at 6 months of age did not change with 
differences in breastfeeding duration. Stronger negative trends were observed for 
the associations between breastfeeding duration and frequencies of CD27+IgM+, 
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CD27+IgA+ and CD27-IgG+ memory B cells within total B cells at 6 months of age, 
resp. -4% (95% CI -7,-1), -4% (95% CI -7, -1), and -3% (95% CI -5,-1) (data not 
shown). At 14 months of age, similar trends for breastfeeding duration and total 
B-cell numbers were observed, although not significant (Table 2). At older ages 
the effects disappeared. (Supplemental Table 2). Thus, a longer breastfeeding 
duration seems to negatively impact B-cell numbers in infants at least until the 
age of 6 months, at older ages these effects disappeared. 
Table 4. unadjusted associations between breastfeeding exclusivity and CD8+ T cell numbers 
at 6 months 
Regression coefficients for logtransformed cell numbers (*10e9/L); 6 months (n=258)
CD8 Total CD8 Tnaive
CD8 
Tcm
CD8 
TemRA
CD8 
TemRO
ExCluSIVENESS
Never (n= 35) REF REF REF REF REF
Partial until 4 months (n=157) 13 (-3,29) 9 (-11,29) 17 (-7,41) -5 (-30,21) 3 (-27,32)
Exclusive until 4 months (n=80) 14 (-3,31) 3 (-19,25) 33 (7,59)* 12 (-16,40) 28 (-3,59)
Unadjusted values are log transformed regression coefficients (95% confidence interval of cell numbers 
(*10e9/L)) derived from linear regression models and reflect the increase or decrease (%) in log 
transformed cell numbers of partial and exclusive breastfed groups relative to the reference group 
(never breastfeeding). Partial breastfeeding indicates infants receiving both breast-feeding, bottle 
feeding and/or solids in this period.*P-value <0.05.
inCrease in t-Cell memory 
Breastfeeding exposure and duration were not associated with total T-cell and 
CD4+ T-cell numbers at 6, 14, 25 months and 6 years of age (Table 2, Figures 2B 
and 2C, and Supplemental Table 2). However, the exposure to breastfeeding was 
associated with CD8+ T cell numbers. CD8+ T-cell numbers were 19% (95% CI 3, 
35) higher in 6-month old infants who were breastfed for less than 3 months and 
remained 20% (95% CI 3, 37) higher in children who were breastfed until 6 months 
(Table 2, Figure 2B), than in children who were never breastfed. Comparable 
effect sizes were observed for exclusiveness of breastfeeding in relation to CD8+ 
T cells (Table 4 and 5). Partial breastfeeding until 4 months was associated with a 
20% increase in total CD8 T cells, and remained 21% higher in infants who were 
exclusively breastfed (Table 5). At 14 and 25 months of age, similar tendencies 
for breastfeeding exposure and CD8+ T cell numbers were observed, however the 
associations were not significant. (Table 2,  Supplemental Table 2). 
Within the CD8+ T-cell compartment at 6 months of age, central memory cell 
numbers (CD45RO+CCR7+) were 30% (95% CI 4, 57) higher in children who were 
breastfed until 3 months than in non-breastfed children (Table 3, Figure 2B). This 
effect was irrespective of duration; central memory cell numbers were still 29% 
(95% CI 1, 57) higher in infants who were breastfed for 6 months or longer than 
in infants who were never breastfed (Table 3, Figure 2B). In line with this, no 
significant associations were found between the duration of breastfeeding and 
CD8+ central memory numbers (Table 3, Figure 2C).
Thus, CD8+ central memory T cells were associated with breastfeeding exposure, 
but not with the duration of breastfeeding. 
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DISCuSSION
Overall we found that breastfeeding was associated with a decrease in B-cell 
memory and an increase in CD8 T-cell memory at 6 months of age. The same 
trend was observed at 14 months of age, and disappeared at older ages. The 
decrease in B-cell memory was associated with the duration of breastfeeding, 
while the increase in total CD8+ T cells and central memory CD8+ T cells did 
not depend on the duration of breastfeeding. This suggests that breastfeeding 
enhances T-cell maturation, but not B-cell maturation.  
Total B-cell numbers nor frequencies were significantly related with breastfeeding. 
This is in line with previous studies.21,23 Only one study reported higher frequencies 
of total B cells in breastfed children at 6 months of age, however sample sizes 
were small (n=7 breastfed infants).22 We found that the duration of breastfeeding 
was associated with decreased numbers of CD27+IgA+, CD27+IgM+ and CD27-
IgG+ memory B cells, which are mostly derived from systemic T-cell dependent 
responses.11 This suggests that continuous breastfeeding inhibits memory B-cell 
development. One of the candidate factors in breast milk that is likely to mediate 
this, is secretory IgA (sIgA).33,34 Continuous breastfeeding will provide a constant 
supply of maternal sIgA onto the epithelial surface of the infant’s gastrointestinal 
tract. This sIgA might prevent exposure of microorganisms to the infant’s humoral 
immune system, and translocation of gut bacteria.34,35 Thus, fewer naive B cells 
might be activated to differentiate into memory B cells (Supplemental Figure 
1). Indeed, in suckling mice it has been suggested that maternal sIgA blocks 
mucosal B cell  responses in the offspring.36,37 Alternatively, the unchanged 
numbers of T-cell independent CD27-IgA+ B cells suggest that breastfeeding does 
not affect local IgA responses. It is therefore possible that maternal IgA helps to 
block translocation of intestinal bacteria, thereby only preventing systemic T-cell 
dependent B-cell memory formation. Other growth factors in breast milk that 
can reduce exposure of microbiota to B cells are epidermal growth factor, IGF-1, 
TGF-β, leptin and prolactin. These factors enhance maturation of the epithelial 
barrier,33,38 and decrease uptake of foreign protein antigens. Factors such as 
lactoferrin, oligosaccharides and lipids may directly prevent attachment of the 
bacterial outer membrane to the mucosal surface.33 Finally, the passive transfer of 
functional Ig-secreting plasma cells in breast milk may prevent bacterial or viral 
transmission.39,40 
Table 5. Adjusted associations between breastfeeding exclusivity and CD8+ T cell numbers at 
6 months
Regression coefficients for logtransformed cell numbers (*10e9/L); 6 months (n=258)
CD8 Total CD8 Tnaive
CD8
 Tcm
CD8 
TemRA
CD8 
TemRO
ExCluSIVENESS
Never (n= 35) REF REF REF REF REF
Partial until 4 months (n=143) 20 (3,38)* 20 (-5,44) 12 (-17,40) 18 (-11,47) 4 (-31,39)
Exclusive until 4 months (n=80) 21 (2,40)* 14 (-14,41) 16 (-15,48) 27 (-5,59) 12 (-28,51)
Values are log transformed regression coefficients (95% confidence interval of cell numbers (*10e9/L)) 
derived from linear regression models and reflect the increase or decrease (%) in log transformed cell 
numbers of partial and exclusive breastfed groups relative to the reference group (never breastfeeding). 
Partial breastfeeding indicates infants receiving both breast-feeding, bottle feeding and/or solids in this 
period.*P-value <0.05. Adjusted for maternal education and maternal alcohol use during pregnancy. 
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Total T-cell numbers nor CD4+ T-cell numbers were associated with breastfeeding 
exposure or breastfeeding duration. However, infants who were breastfed until 3 
months had higher CD8+ T-cell numbers than infants who were never breastfed, 
and this change persisted when breastfeeding was prolonged until 6 months, 
suggesting an ongoing activation of CD8+ T cells by exposure to breast milk, 
but no accumulation over time. These results extend previous observations in 
small studies (n<40) of increased frequencies of CD8+ T cells or decreased CD4/
CD8 ratios.21,22,24 In addition, an increase in CD8+ T cells from 8 to 10 months of 
age was observed before,24 suggesting a longer-lasting effect of breastfeeding. 
However, the children received breastfeeding until 8 months of age.24 In addition, 
the number of children in the breastfeeding group was small (n=35), and no 
detailed analysis of CD8+ subsets was performed. Therefore, future studies will be 
needed to validate these findings.
Within total CD8+ T cells, the central memory subset was most significantly 
increased in breastfed children. This expansion will be the result of stimulation of 
mature T cells. Candidate immune stimulatory factors in breast milk are lactoferrin 
and exosomes. Lactoferrin has direct microbicidal properties, including binding of 
the bacterial cell wall and the concomitant release of lipopolysaccharide (LPS, 
endotoxin). Moreover, lactoferrin is known to enhance T-cell proliferation.21,33 
Exosomes are carrier vesicles of 50-100 nm that can bud from the membrane 
of eukaryotic cells.41 Exosomes formed by B cells or dendritic cells contain MHC 
class I and class II, and have the potential to stimulate T cells.42,43 Human breast 
milk has been found to contain immune modulatory exosomes that express MHC 
molecules, IL-2, IFNγ and TNFα. In line with our findings that breastfeeding did 
not affect memory CD4+ T cells, these vesicles did not appear to stimulate CD4+ T 
cells.44 It is, however, likely that immunostimulatory compounds such as exosomes, 
do have CD8+ T-cell stimulating capacities and contribute to the increase in central 
memory T cells in breastfed infants (Supplemental Figure 1). In addition, it has 
been described that the infants take up live and functional maternal immune cells 
from the breast milk.45-47 This might result in stimulation of CD8+ T cells. Thus, 
it remains unclear whether the increase in central memory CD8+ T cells can be 
attributed to immunostimulatory factors in breast milk, such as lactoferrin and 
exosomes, or reflects a role for maternal immune cells. Nevertheless, central 
memory T cells might mediate reactive immunity,48 because they circulate between 
the spleen, blood and lymph nodes and proliferate extensively in response to a 
second encounter of an antigen.13-15 Therefore, it could be hypothesized that an 
increase in central memory T cells is associated with increased reactive immunity. 
Beneficial effects of breastfeeding on adaptive immune responses have previously 
been demonstrated in vaccination studies.7-9 Breasted children showed increased 
interferon-γ production, and increased frequencies of CD8+ T cells after vaccination 
with measles, mumps and rubella.9 Furthermore,  breastfeeding had beneficial 
effects on virus-specific immune responses to poliovirus, diphtheria toxoid and 
tetanus toxoid,49 whereas the responses to rotavirus are not clearly enhanced.50,51 
These studies included relatively few children, and confounding factors could 
not be taken into account. Thus, our results extend these previous observations 
from vaccination studies. Unfortunately, we were not able to study virus-specific 
memory cells and studies determining associations between central memory cell 
numbers and functional immunity are lacking. Thus, interpretations regarding 
cell-mediated immunity should be made with caution. 
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We did not observe associations between breastfeeding and naive T cells or 
effector memory T cells. In contrast, a previous study reported lower frequencies 
of naive CD4+ T cells,21 but no differences in memory T-cell frequencies. Therefore, 
it was suggested that the adaptive immune system develops slower in breastfed 
infants.21 However, the study reported on a relatively small number of children 
in the breastfeeding group (n=34), and lacked data on absolute B-cell and T-cell 
counts.21 
Our study was conducted in a large population-based prospective birth cohort. 
Previous studies that addressed the effects of breastfeeding on adaptive immunity, 
had smaller sample size and/or lacked follow-up.21-24 Most of these retrospective 
studies were based on recall of infant feeding after several years, making recall 
bias of feeding habits an important concern.52  Because of the prospective design 
of our study, detailed information on the duration of breastfeeding was collected 
at multiple time points shortly after breastfeeding was finished, thereby limiting 
potential recall bias.52 Still, data on breastfeeding was collected retrospectively, 
and due to the use of questionnaires, misclassification may occur.52 Because 
any misclassification would be independent of laboratory determined T-cell and 
B-cell numbers, it is unlikely that these affected the outcome. In addition, our 
study design provided information on a large number of potential confounders. 
We used an unbiased approach, investigating a broad panel of determinants on 
lymphocyte numbers and frequencies. Moreover, we performed measurements of 
lymphocytes at different ages, enabling us to study the effect of breastfeeding 
on adaptive immunity over a longer period of time. Finally, using detailed 6-color 
flow cytometry, we were able to discriminate multiple, functionally distinct B-cell 
and T-cell subsets.11,12,53 Thus, we could evaluate the effects of breastfeeding on 
specific aspects of adaptive immunity. 
At 14 months or age, we observed the same trends of decreasing B-cell 
numbers with longer breastfeeding duration, and higher CD8 T-cell numbers 
with breastfeeding exposure, as we did for 6 months, although effects were not 
significant. The sample size at 14 months was smaller than the sample size at 6 
months. Hence, we cannot exclude that non-significant effects at 14 months are 
due to loss of statistical power, and some effects of breastfeeding remain at this 
age. 
Our measurements were limited to peripheral blood. Thus, it is not possible to 
deduce whether B-cell and T-cell numbers in lymphoid tissue were affected. 
Theoretically, preferential homing to or away from tissue could result in changes 
in blood lymphocyte counts.54 If breastfeeding affects this preferential homing, 
the effects will be lost once breastfeeding is discontinued. Nearly all children were 
no longer receiving breast milk and still showed lower memory B-cell numbers and 
higher CD8+ T-cell numbers. Thus, we conclude that the effects of breastfeeding 
on preferential tissue homing was limited.
In conclusion, this prospective population-based cohort study among a large 
number of healthy children showed that CD27+IgA+, CD27+IgM+ and CD27-
IgG+ memory B-cell numbers decreased with a longer breastfeeding duration. 
CD8+ T cells, and especially CD8+ central memory T-cell numbers, were higher 
in breastfed children up to 6 months of age. This suggests that breastfeeding 
enhances T-cell maturation in the first 6 months of life. On top of the protective 
effects of maternal IgA in breast milk, this might contribute to the protective 
effect against infectious diseases in infancy. 
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Supplemental Table 1. Maternal and infant characteristics of the study population at 14, 25 
months and 6 years
14 months  (n=166) 25 months (n=112) 6 years (n=332)
Not 
breastfed 
(n=16)
Breastfed
(n=150)
Not 
breastfed 
(n=16)
Breastfed
(n=96)
Not 
breastfed
(n=37)
Breastfed
(n=295)
Maternal characteristics
Age (Mean + SD; years) 31 (4.2) 32 (3.9) 31 (4.1) 32 (3.8) 31 (3.6) 32 (3.6)
Educational level (n; %)
lower 7 (44%) 59 (40%) 12 (75%) 31 (33%) 22 (59%) 96 (33%)
Higher 9 (56%) 90 (60%) 4 (25%) 64 (67%)* 15 (41%) 196 (67%)*
Net household income/month (n; %)
< € 2400 0 (0%) 21 (15%) 1 (8%) 13 (15%) 4 (12%) 33 (13%)
> € 2400 13 (100%) 112 (84%) 12 (92%) 73 (85%) 30 (88%) 227 (87%)
Smoking during pregnancy (n; %) 2 (14%) 16 (15%) 1 (7%) 8 (11%) 6 (20%) 32 (15%)
Alcohol use  during pregnancy (n; %) 6 (43%) 41 (38%) 4 (29%) 29 (39%) 11 (37%) 83 (37%)
Body Mass Index before pregnancy (Mean, SD) 25 (5) 24 (5) 25  (5) 23 (4) 24 (5) 24 (4)
Fever in third trimester of pregnancy (n; %) 1(6%) 9 (6%) 2 (13%) 5 (6%) 2 (6%) 19 (7%)
atopy (eczema, allergy HDM, hay-fever) (n; %)
Maternal 3 (21%) 51 (36%) 6 (40%) 41 (46%) 9 (27%) 109 (40%)
Paternal 3 (23%) 41 (29%) 5 (39%) 24 (28%) 13 (39%) 77 (29%)
Family history of asthma / atopy (n; %) 5 (31%) 77 (52%) 9 (56%) 56 (59%) 20 (54%) 156 (54%)
Any reported autoimmune disease (diabetes 
mellitus, SLE, arthritis, MS, thyroid disorder, or 
celiac disease) (n; %)
0 (0%) 3 (2%) 0 (0%) 2 (2%) 2 (5%) 8 (3%)
Mode of delivery (n; %) 
Vaginal  9 (56%) 19 (64%) 7 (47%) 48 (55%) 20 (59%) 182 (65%)
Forceps or vacuum assisted 2 (13%) 30 (21%) 2 (13%) 21 (24%) 5 (15%) 59 (21%)
Caesarian section 5 (31%) 21 (15%) 6 (40%) 19 (22%) 9 (26%) 40 (14%)
Premature rupture of membranes (n; %) 1 (6%) 2 (1%) 1 (6%) 2 (2%) 3 (8%) 4 (2%)
Infant characteristics (n=258)
Males (n; %) 9 (56%) 77 (51%) 7 (44%) 47 (49%) 20 (54%) 144 (49%)
Gestational age ( Mean + SD; weeks) 39.2 (2.2) 40.1 (1.9) 39.7 (1.9) 39.9(1.5) 39.7 (1.7) 40.1 (1.6)
Preterm birth (<37 weeks) (n; %) 1 (6%) 3 (2%) 1 (6%) 4 (4%) 2 (5%) 8 (3%)
Birth weight ( Mean + SD; grams) 3,455 (738) 3,505 (513) 3,516 (614) 3,542 (480) 3,543 (554) 3,531 (508)
Apgar score at 5 min <7 (n; %) 0 (0%) 3 (2%) 0 (0%) 0 (0%) 0 (0%) 3 (1%)
Birth season (n; %)
Winter 2 (13%) 38 (25%) 3 (19%) 28 (29%) 6 (16%) 73 (25%)
Spring 5 (31%) 41 (27%) 3 (19%) 26 (27%) 6 (16%) 93 (31%)
Summer 3 (18%) 32 (21%) 4 (25%) 21 (22%) 11 (30%) 65 (22%)
Autumn 6 (38%) 39 (26) 6 (37%) 21 (22%) 14 (38%) 64 (22%)
Siblings >1 (n; %)  2 (12%) 17 (11%) 1 (6%) 8 (8%) 2 (5%) 26 (9%)
Day-care >16 hours /week (n; %) 3 (33%) 51 (47%) 4 (25%) 33 (34%) 5 (33%) 99 (47%)
Fever in first 6 months  (n; %) 7 (78%) 80 (63%) 3 (60%) 51 (62%) 13 (57%) 175 (67%)
Age at focus visit 
    (Median + range; months/years)
14.4 
(13.2-16.3)
14.4
(13.1-17.4)
25.3 
(23.4-27.5)
25.2 
(23.3-29.8)
6.0 
(5.8-6.6)
5.8 
(5.1-7.2)
Values are means (SD), absolute numbers (percentages) or #medians (90% range). * Significantly different 
between breastfeeding and no breastfeeding groups
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Supplemental Table 3. Antibody panel used for 6-color flow cytometry
labeling Conjugated monoclonal antibodies (clone)
FITC PE PerCP-Cy5.5 PE-Cy7 APC APC-Cy7
1
CD3 CD16.56 CD45 CD4 CD19 CD8
(SK7) (B73.1C5.9) (2D1) (SK3) (SJ25C1) (SK1)
2
IgD CD23 CD19 CD21 IgM CD27
(poly) (EBVCS5) (SJ25C1) (B-ly-4) (G20-127) (M-T271)
3 IgA IgG CD19 CD40 IgM CD27
(poly) (poly) (SJ25C1) (5C3) (G20-127) (M-T271)
4
CD28 CD197 CD3 CD8 CD45RO CD27
(CD28.2) (3D13) (SK7) (SK1) (UCHL-1) (M-T271)
FITC= fluorescein isothiocyanate, PE=phycoerythrin, PerCPCy5.5= peridin chlorophyll protein, 
PE-Cy7= phycoerythrin-cyanin dye, APC=allophycocyanin and APC-Cy7= allophycocyanin-cyanin dye, 
poly = polyclonal antibody
Supplemental Figure 1. Summarizing mechanism of how breastfeeding might affect adaptive memory. 
In absence of breast milk, the infant’s B and T cells respond to microorganisms in the intestine and generate 
long-lived memory cells and IgA (blue) that circulate through the body (left). Breast milk contains immune 
modulating components (right). Of these, maternal sIgA (green) is able to catch microorganisms and prevent 
recognition of these by B-cells. This might inhibit B-cell responses and B-cell memory formation. Other 
immunostimulatory components, such as exosomes, might stimulate naive T cells and increase T-cell memory 
formation. Abbreviations: Bn, naïve B cell; Bm, memory B cell; DC, dendritic cell; pc,plasma cell; Tn, naive T 
cell; Tm, memory T cell. 
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ABSTRACT
objeCtive. To identify whether there are ethnic differences in CMV, EBV and HSV-1 
seroprevalence rates in children at 6 years of age, and when present, to evaluate 
how these differences can be explained by socio-demographic and environmental 
factors.
methods. This study was embedded within a multi-ethnic population-based 
prospective cohort study. Serum IgG levels against CMV, EBV and HSV-1 were 
measured by ELISA in 4,464 children (median age 6.0 years). Information on 
demographics and characteristics were assessed by questionnaires. Herpesvirus 
seroprevalences between Surinamese-Creole, Surinamese-Hindustani, Turkish, 
Moroccan, Cape Verdean and Antillean and Native Dutch children were compared. 
results. Non-western ethnicity was an independent risk factor for CMV (aOR, 
2.16; 95% CI 1.81;2.57), EBV (aOR 1.76; 95% CI 1.48;2.09) and HSV-1 
seropositivity (1.52; 1.39;1.66). Among the ethnic groups, CMV seroprevalences 
ranged between 29-65%, EBV between 43-69% and HSV-1 between 13-39%. 
Socio-economic position, crowding and lifestyle factors explained up to 48% of 
the ethnic differences in HSV-1 seroprevalences, and up to 39% of the ethnic 
differences in EBV seroprevalences. These factors did not explain ethnic differences 
in CMV seroprevalences.  
ConClusion. Socio-economic position and factors related to lifestyle only explain 
a part of the large ethnic differences in EBV and HSV-1 seroprevalences, whereas 
they do not explain ethnic differences in CMV seroprevalences in childhood.  
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INTRODuCTION
Cytomegalovirus (CMV), Epstein Barr virus (EBV), and herpes simplex virus 1 
(HSV-1) are ubiquitous herpesviruses, and often acquired in childhood. They 
are usually transmitted by contact with infected saliva (all three viruses), 
breastfeeding, placental transfer (CMV), {Longnecker, 2007 #3882;Boppana, 
2007 #3880}or through contact with infectious skin lesions or secretions (HSV-
1).1,2 The viruses establish a lifelong latency after primary infection, and can 
periodically reactivate with shedding of the virus. Most primary infections are 
mild or asymptomatic in childhood, but they can cause serious complications 
in fetuses, immunocompromised individuals, or in elderly.3-9 The incidence and 
severity of these herpesvirus associated diseases vary geographically, and many 
studies link age at primary infection to the pathogenesis of herpesvirus associated 
diseases.10-14 
CMV seroprevalences vary between 40-60% in children aged 4-12 years,8,15,16 
with exclusion of African countries where almost all children have already been 
seroconverted by 3 years of age. Approximately 50% of children in the US and 
Europe are seropositive for EBV in the first years of life, but seroprevalences 
vary from 20-80% depending on age, race/ethnicity, geographic location and 
socio-economic development of the country.9,12,17,18 HSV-1 is widespread during 
the first few years of life in developing countries, whereas in some European 
countries primary infection occurs relatively at older age.19-22 Besides geographical 
differences, also ethnic differences have been described in population subgroups.23 
Ethnic and geographical differences in CMV, EBV and HSV-1 seroprevalences 
might be explained by differences in behavior that facilitate transmission, such as 
breastfeeding, daycare, family size and socio-economic position.17,22,24,25 Because 
socio-economic position and ethnicity are strongly related, it remains unclear 
to what extent socio-economic factors explain ethnic differences in herpesvirus 
seroprevalences.26 In addition, knowledge on other lifestyle related determinants 
is mainly based on prevalence studies from the late 90’s,27-30 but social conditions 
and lifestyle have changed over time.31,32 Furthermore, the relative importance of 
each risk factor needs to be assessed,26 and many studies lack the assessment of 
multiple risk factors. Previously, it has been suggested that early life exposures, 
in particular breastfeeding, are more important for CMV infection than adulthood 
exposures.33 On the other hand, the ALADDIN birth cohort study found no strong 
influence of these early life risk factors.34 Understanding transmission dynamics 
of herpesvirus infections within populations, and understanding how socio-
economic and ethnic groups are differentially exposed to these infections, can 
improve existing preventive policies and interventions, including on the long run, 
vaccination programs.35 
Therefore, the first aim is to assess whether there are ethnic differences in CMV, 
EBV and HSV-1 infection in children at 6 years of age. The second aim is to 
evaluate how ethnic differences in CMV, EBV and HSV-1 infections, when present, 
can be explained by socio-demographic and environmental factors. 
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METHODS
study design
This study was embedded within the Generation R Study, a prospective population 
based cohort study from fetal life onwards.36,37 All children were born between 
2002 and 2006 in Rotterdam, the second largest city in the Netherlands. The 
study area covers more than half of the cities inhabitants, reflecting Rotterdam’s 
multi-ethnic population.36 The largest ethnic groups are of Dutch, Surinamese, 
Turkish, Moroccan, Dutch Antilles and Cape Verdean origin.36 In total, n=8,305 
children participated in the postnatal phase of the study, of whom 81% (n=6,690) 
visited the research centre (median age 6.0 years).37 During this visit, blood 
samples were collected from 4,593 children. In total, n=4,464 children provided 
serological data on EBV, CMV, HSV-1 status (Supplemental Figure 1). The study 
was approved by the Medical Ethical Committee of Erasmus MC, University Medical 
Centre Rotterdam. Parents of the children gave written informed consent. 
herpesvirus serology
Venous blood plasma samples were analysed using enzyme immunoassays for IgG 
antibodies against CMV, EBV (capsid antigen), HSV-1 (glycoprotein C1; all from 
EUROIMMUN®, Lübeck, Germany). Results were evaluated semiquantitatively 
relative to a manufacturer-provided reference threshold sample. Per manufacturer’s 
instructions, an optical density in the patient sample >10% above the provided 
threshold sample was defined as positive. 
ethniC baCkground 
Ethnicity of the child was determined by country of birth of the parents. The 
child was of non-native Dutch origin if one of the parents was born in another 
country than the Netherlands.38 If both parents were born abroad, the country of 
birth of the mother prevailed. To study whether ethnic background was related 
to herpesvirus infections, we constructed a dichotomous variable ‘Western/non-
western’ ethnicity. Next, to study to what extent socio-economic and lifestyle 
factors explained associations between ethnicity and herpesvirus infections, and 
to study the effect of cultural background of the mother (most often primary 
caregivers),39 a distinction was made between mothers of Dutch, Turkish, 
Moroccan, Cape Verdean, Antillean, Surinamese Creole and Surinamese Hindustani 
ethnic background. Maternal ethnic background was based on country of birth 
of mother’s parents and was assessed by questionnaires at enrollment. Mothers 
were considered non-native Dutch if one of her parents was born abroad.40 If both 
parents were born abroad, country of birth of the mother’s mother prevailed. 
Generational status of non-native Dutch mothers was based on their own country 
of birth. Foreign-born mothers were classified as ‘first generation’ and mothers 
born in the Netherlands were classified as ‘second generation’.39 
other determinants
Other potential determinants of herpesvirus infections were selected based on 
existing literature.2,12,24,32,33,41,42 These are: socio-economic position, family size/
parity, maternal lifestyle, breastfeeding, daycare and gender. Data on gender, 
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gestational age, birth weight, parity and mode of delivery were obtained from 
obstetric records from hospitals and mid-wife practices. Data on socio-demographic 
and lifestyle factors were obtained by a combination of pre- and postnatal 
questionnaires completed by both parents. Prenatal questionnaires included 
information on maternal lifestyle and socio-economic position. Information on 
socio-economic position was also determined by questionnaires obtained at 6 
years of age. Information on breastfeeding and daycare was obtained by postnatal 
questionnaires. All questionnaires were available in three languages (Dutch, 
English and Turkish) and further support for verbal translation of questionnaires 
was available in Arabic, Portuguese and French. 
explanatory variables
Most effects of ethnicity on herpes virus infections are probably indirect ones, 
acting through more proximal determinants of CMV, EBV, and HSV-1. We 
considered the following factors to be potential explanatory variables: socio-
economic position, breastfeeding, parity as indicator for siblings/family size, 
and day-care attendance.2,12,24,32,33,41,42 Information on household income43 and 
educational level,44 both indicators of socio-economic position, were obtained 
using prenatal questionnaires. The Dutch Standard Classification of Education 
was used to categorize 4 subsequent levels of education: 1=high, 2= mid-high, 
3=mid-low, and 4=low.44 For additional analyses, income was subdivided into 
three categories: 1. Below modal <2,000 euro’s per month, 2. Between 2,000 and 
3,200 euro’s per month, 3. > 3,200 euro’s per month.45,46 Child’s age and gender 
were treated as potential confounders in the association between ethnicity and 
herpesvirus seroprevalences. 
statistiCal analysis
First, independent student’s T-tests, and χ2 tests were used to test whether 
characteristics were different between children who were seropositive for CMV, 
EBV and HSV-1, and who were not. To investigate which determinants were 
associated with CMV, EBV and HSV-1 seropositivity (y/n), logistic regression 
analyses were performed with herpesvirus seropositivity at the age of 6 years 
as dependent variables (CMV y/n, EBV y/n, and HSV-1 y/n). To study to which 
extent associations between ethnicity and CMV, EBV, and HSV-1 seropositivity 
were explained by factors associated with socio-economic position, crowding, 
breastfeeding behaviour and maternal lifestyle, we used Baron and Kenny’s causal 
step approach.47 Only those factors that were unequally distributed across the 
ethnicity groups (determinant) (Table 6; online) and were significant (p<0.05) 
associated with CMV, EBV and HSV-1 seropositivity (outcomes) (independent of 
ethnicity, gender and age); (Table 7; online) were added separately to the model.47 
To assess their mediating effects, the corresponding percentages of attenuation 
of effect estimates were calculated by comparing differences of model 1 with the 
adjusted ones (100 x (OR model 1 – OR model 2 with explanatory factor)/ (OR 
model 1)). Finally, a full model containing ethnicity and all the explanatory factors 
assessed the joint effects of explanatory factors. Interaction terms between ethnic 
background and the explanatory variables were tested for significance. If the 
test was significant (p<0.05), we also stratified the analysis by the variables. 
To reduce attrition bias, multiple imputation of the covariables was performed 
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(n=5 imputations).48 Regression coefficients were pooled by taking the average 
of the coefficients of the 5 imputed datasets. The pooled results of the 5 imputed 
datasets were reported in this paper as Odds Ratios (ORs) and 95% confidence 
intervals (CI’s). A 95% CI was calculated around the percentage attenuation 
using a bootstrap method with 1,000 resamplings per imputed dataset in the 
statistical program R.49 All other statistical analyses were performed in SPSS 20.0 
for Windows (SPSS Inc., Chicago, Il). 
RESulTS
Maternal and child characteristics related to CMV, EBV and HSV-1 are shown 
in (Table 1). Within the total group of 4464 children (median age 6.0 years), 
n=1,692 (38%) were infected with CMV, n=2,279 (51%) were infected with EBV, 
and n=877 (20%) were infected with HSV-1. Thirty percent (n=1,319) were 
seronegative for CMV, EBV and HSV-1, 39% (n=1,735) were infected with one 
of these viruses, and 32% (n=1,410) were infected with two or more viruses. Of 
children with available data on herpesvirus serology, a total of 2,368 children were 
Native Dutch, 181 were Cape Verdean, 247 Moroccan, 109 Dutch-Antillean, 131 
Suriname-Creole, and 136 children were of Surinamese-Hindustani origin (Figure 
1).
determinants of Cmv, ebv and hsv-1 seropositivity
CMV seropositive children were more likely of non-Western ethnicity (aOR 2.16; 
95% CI 1.81-2.57), to be girls (aOR 1.18, 95% CI 1.02, 1.36), and to be breastfed 
for 6 months or longer (aOR 1.96; 95% CI 1.25-3.07) than CMV seronegative 
children. Multiparity was inversely associated with CMV seropositivity (aOR 0.76; 
95% CI 0.65-0.90). 
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Figure 1. Seroprevalence of herpesvirus infections in childhood according to maternal ethnic 
background. Values are seroprevalences of CMV, EBV, and HSV-1 infections  (%) per ethnicity category. CMV, 
EBV, and HSV-1 seroprevalences of Cape Verdean, Moroccan, Dutch Antillean, Turkish, Surinamese-Creole, and 
Surinamese-Hindustani children are compared to Dutch children. Footnotes:  ¶ p-value <0.05, #P-value <0.01, 
*P-value <0.001 based on  χ2 test. 
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Similar to CMV, non-Western ethnicity was an independent risk factor for EBV (aOR 
1.76; 95% CI  1.48-2.09) and HSV-1 (aOR 1.52; 95% CI 1.39-1.66). In contrast, 
EBV and HSV-1 seropositive children more often had 2 or more siblings (aOR EBV 
parity >2 1.35; 95% CI 1.05-1.740, aOR HSV-1 parity >2 1.31; 95% CI 1.14-1.50), 
than EBV and HSV-1 seronegative children (in contrast with the observations for 
CMV). Daycare and socio-economic position were only associated with HSV-1 
seropositivity (aOR daycare 0.89, 95% CI 0.81-0.97). Mothers of HSV-1 seropositive 
children were lower educated (aOR 1.55, 95% CI 1.35, 1.79) and their family 
household income was lower (aOR 1.11 , 95% CI 1.01-1.23), than mothers of 
HSV-1 seronegative children (Table 5; online). Additional analyses between the 
seroprevalence of herpes virus infections and net household income more in 
detail strengthened the inverse associations between socio-economic position and 
herpesvirus seroprevalences (Table 8; online).
ethniC baCkground and Cmv seropositivity
Children of Cape Verdean, Moroccan, Turkish, Surinamese-Creole and Surinamese 
Hindustani mothers were more often seropositive for CMV, than children of native 
Dutch mothers. CMV seroprevalences in the non-native Dutch groups ranged 
between 44-65%, compared to 29% in the native Dutch group (Figure 1). To 
explain the observed ethnic differences in CMV seroprevalences, the following 
explanatory variables were selected: maternal educational level, parity, daycare 
and breastfeeding duration,47 (Table 6 and 7; online). However, after including all 
the explanatory factors in the model, differences in CMV seroprevalences compared 
to Dutch children increased with 55% (95% CI 24 to 124) for Surinamese-
Hindustani children, 36% (95% CI 19 to 60) for Moroccan children, 34% (95% 
CI 14 to 66) for Surinamese-Creole children, 33% (95% CI 13 to 59) for Turkish 
children, and 23% (95% CI 5 to 47) for Cape Verdean children (Table 2).
ethniC baCkground and ebv seropositivity
Children in non-native Dutch groups were more often EBV seropositive than native 
Dutch children. EBV seroprevalences in the non-native Dutch minority groups 
ranged between 59-69%, compared to 43% in the native Dutch group (Figure 
1). Maternal educational level, net household income and parity were selected to 
explain ethnic differences in EBV seroprevalences,47 (Table 6 and 7; online). Socio-
economic position was the most important contributor to the association between 
ethnicity and EBV seroprevalence. For example, net household income explained 
22% (95% CI -41 to -6) of the differences in EBV seroprevalences between Cape 
Verdean and native Dutch children, followed by maternal educational level, which 
explained 18% (95% CI -31 to -7) (Table 3). Overall, 39% (95% CI -66 to -19) 
of the difference in EBV seroprevalences prevalence between Cape Verdean and 
Dutch children was explained by differences in socio-economic position and family 
size. These factors explained 36% (95% CI -55 to -19) of the differences in EBV 
seroprevalences between Moroccan and Dutch children, 33% (95% CI -48 to -17) 
of the differences in EBV seroprevalences between Turkish and Dutch children, 
and 25% (95% CI -60 to -3) of the differences in EBV seroprevalences between 
Antillean and Dutch children (Table 3). 
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ethniC baCkground and hsv-1 seropositivity
All ethnic minority groups, except for Surinamese-Creole, were more often HSV-
1 seropositive than native Dutch children. HSV-1 seroprevalences in the non-
native Dutch groups ranged between 22-39%, compared to 13% in the native 
Dutch group (Figure 1). To explain ethnic differences in HSV-1 seroprevalences, 
maternal educational level, net household income and breastfeeding duration were 
selected as explanatory variables,47 (Table 6 and 7; online). Maternal educational 
level and net household income were the most important factors to explain ethnic 
differences in HSV-1 seroprevalence. For example, 27% (95% CI -38 to -16) of 
this differences in HSV-1 seroprevalences between Turkish and Dutch children 
was explained by maternal educational level (Table 4). Socio-economic position 
and breastfeeding together explained 24% (95% CI -40 to -7) of the difference in 
HSV-1 seroprevalence between Turkish and Dutch children; they explained 48% 
(95% CI -150 to -18) of the differences in HSV-1 seroprevalences between Cape 
Verdean and Dutch children;  30% (95% CI -68 to -10) of the differences in HSV-
1 prevalence between Surinamese-Hindustani and Dutch children and 22% (95% 
CI -36 to -5) of the differences in HSV-1 seroprevalence between Moroccan and 
Dutch children. Maternal educational level was the most important explanatory 
factor in the association between ethnicity and HSV-1 seroprevalence (Table 4). 
Next, we observed that  children who were seropositive for a single virus, were 
more likely to be infected with multiple herpesviruses. For example, the odds for 
CMV seropositivity was 1.69 times greater, and the odds for HSV-1 seropositivity 
was 2.17 times greater in EBV infected children than in EBV seronegative children. 
Also, the odds for both CMV and HSV-1 seropositivity was almost 3 times greater 
in EBV seropositive children than in EBV seronegative children (Table 9; online). 
Also, CMV, EBV and HSV-1 seropositive children tended to have more frequently 
‘first’ generation mothers, than seronegative children, although differences were 
not significant (Figure 2). Differences in characteristics between seronegative 
children and children with multiple herpes virus infections are described in Table 
10; online. Mothers of seronegative children were more often higher educated, 
had a higher net household income, than mothers of children who had 1 or 2 
herpes virus infections. Seronegative children were more often of Western origin, 
and had fewer siblings, than children who had 1 or 2 herpes virus infections (Table 
10; online).
DISCuSSION
In this large and multi-ethnic population-based cohort, we found 1) large ethnic 
differences in seroprevalences of EBV (range 43-69%), CMV (range 29-65%) and 
HSV-1 (range 13-39%) among 6 year old children 2) the highest seroprevalence in 
non-Dutch children. Socio-economic factors and factors related to crowding early 
in life only partly explained ethnic differences in EBV and HSV-1 seroprevalence in 
childhood, but did not explain ethnic differences in CMV seroprevalence. 
Our study design provided a unique opportunity to study determinants of these 
infections, to investigate variation in seroprevalence by ethnic group, and to study 
to which extent socio-economic and lifestyle factors explained these differences. 
Our results confirm and extend previous studies by observing that socio-economic 
position partly explains ethnic variation in EBV and HSV-1 seroprevalences, but not 
in CMV seroprevalences.12,35,42 Although these three viruses are all members of the 
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herpesvirus family, and thus share significant biological properties, transmission 
dynamics between these viruses seem to be different. Our results suggest that 
ethnic differences in CMV seroprevalences in childhood are mainly determined by 
factors that facilitate vertical transmission (e.g. pregnant women that transmit 
CMV to their child), which is in line with the idea that the most important source 
for CMV infection in childhood is breastmilk.50-52 In contrast, ethnic differences in 
EBV and HSV-1 seroprevalences are partly determined by factors that facilitate 
horizontal transmission, such as family size and daycare, which are strongly 
related to socio-economic position. In fact, we were able to explain up to 39% of 
the ethnic differences in EBV seroprevalences, of which socio-economic position 
was the most important contributor, which is in line with a recent study.53 However, 
in contrast with our study, the authors suggested that ethnic differences could not 
be explained by crowding. However, it could be speculated that socio-economic 
position reflects more proximal determinants (e.g. factors that facilitate horizontal 
transmission, such as family size, bed sharing and childcare arrangements). 
Indeed, the results from our multivariable model confirm that family size is 
important in estimating the risk of EBV infection.18 In fact, we observed a dose-
response relationship between parity and the risk of EBV and HSV-1 seropositivity. 
In contrast with the results on EBV and HSV-1, ethnic differences in CMV 
seroprevalences could not be explained by socio-economic position, nor by other 
‘explanatory variables’ such as breastfeeding, daycare and parity. In fact, these 
factors rather strengthened than weakened the association between ethnicity 
and CMV. We expected breastfeeding to partly mediate this association, because 
breastfeeding can transmit CMV, and breastfeeding behavior is influenced by 
ethnic background.54 Nevertheless, vertical transmission from mother to child is 
probably more important in explaining ethnic differences in CMV seroprevalences 
than factors that facilitate horizontal transmission. Given the economic burden 
of CMV associated diseases, it has been suggested that vaccination in the 
general population would be the most straightforward way to control for all CMV 
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Figure 2. Percentages of first generation mothers according to CMV, EBV or HSV-1 seropositivity in 
childhood. 
Values are percentages of ‘first’ generation mothers according to CMV, EBV or HSV-1 seroprevalences in childhood. 
Generational status of non-native Dutch mothers was based on their country of birth. Foreign-born mothers were 
classified as ‘first generation’ and mothers born in the Netherlands were classified as ‘second generation’.
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associated diseases.3 Some recommend to include 12-year old children, whereas 
others suggested to include vaccination of toddlers.33 55 However, thus far, safe 
and effective vaccines have not been developed. Nevertheless, on the basis of our 
results, ethnic and socio-economic differences should be taken into account when 
vaccination is contemplated.
HSV-1 prevalence was highest in Turkish and Moroccan children, which is in line 
with a  previous Dutch study in adolescents.42 Our results confirm that differences 
in HSV-1 seroprevalences between European countries could be partly explained 
by socio-economic factors.22 It has been shown that lower socio-economic position 
indeed increases the risk for HSV-1.42 All factors together, including socio-economic 
position, breastfeeding and crowding, explained up to 48% of ethnic differences in 
HSV-1 seroprevalence, of which socio-economic position was the most important 
contributor, suggesting an important role for factors that facilitate horizontal 
transmission. 
methodologiCal Considerations
An important strength of this study is that we had a large multi-ethnic cohort 
study population drawn from the general population of Rotterdam. Because 
immigration is common in Western countries, our findings may be more broadly 
applicable. In addition, our study design enabled us to assess multiple risk factors, 
and to study the relative importance of each using multivariate models. Moreover, 
an explanation of ethnic differences in herpesvirus infections using a mediator 
approach has never been performed before. Besides socio-economic position, 
numerous other factors vary between countries, and adjustment for these factors 
might decrease ethnic/racial or geographical variation.12 Because our study was 
performed within a population based study of a region within a single country, we 
were able to adjust for all of these variables. A limitation of this study is that we did 
not have data on maternal CMV, EBV, HSV-1 seroprevalences, preventing analysis 
of mother-to-child transmission. A second limitation was lack of data on EBV, CMV 
and HSV-1 seroprevalences in fathers and siblings, precluding examination of 
their roles in horizontal transmission. 
ConClusion
In this multiethnic population-based cohort, we found large ethnic differences in 
seroprevalences of CMV, EBV and HSV-1 among 6 year old children, with higher 
seroprevalences in non-Dutch children. Socio-economic factors and factors related 
to crowding early in life partly explained ethnic differences in EBV and HSV-1 
seroprevalence, but did not explain ethnic differences in CMV seroprevalence. 
When immunization against these viruses is considered, ethnic and socio-economic 
differences should be taken into account. 
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Table 5 (online). Determinants of herpesvirus seropositivity in children at 6 years of age 
n=4,464 Cytomegalovirus Epstein-Barr Virus Herpes simplex virus 1
Determinants  (aOR 95% CI) (aOR 95% CI)  (aOR 95% CI)
Gender   
        Male 
        Female 
1.0
1.18 (1.02, 1.36)*
1.0
0.99 (0.87, 1.15)
1.0
1.05 (0.97, 1.13)
Ethnicity 
        Western
        Non western
1.0
2.16 (1.81, 2.57)***
1.0
1.76 (1.48, 2.09)***
1.0
1.52 (1.39, 1.66)*
Income
        Low (<2200)
        High (>2200)
1.18 (0.98, 1.42)
1.0
1.09 (0.91, 1.30)
1.0
1.11 (1.01, 1.23)*
1.0
Maternal educational level
        Low 
        Mid-low
        Mid-high 
        High 
0.95 (0.73, 1.23)
0.82 (0.66, 1.01)
0.96 (0.77, 1.19)
1.0
1.09 (0.85, 1.41)
0.93 (0.76, 1.15)
0.94 (0.77, 1.15)
1.0
1.55 (1.35, 1.79)***
1.19 (1.05, 1.35)**
1.16 (1.03, 1.31)*
1.0
Daycare 1.20 (1.00, 1.43) 1.06 (0.86, 1.31) 0.89 (0.81, 0.97)*
Breastfeeding duration
        Never
        <3 months
        3-6 months
        >6 months
1.0
1.53 (1.04, 2.23)*
1.77 (1.21, 2.60)**
1.96 (1.25, 3.07)**
1.0
0.98 (0.73, 1.33)
1.20 (0.85, 1.69)
1.08 (0.78, 1.85)
1.0
1.02 (0.89, 1.16)
1.08 (0.93, 1.26)
1.06 (0.92, 1.22)
Parity
        0 
        1
        2
        >3
1.0
0.76 (0.65, 0.90)**
0.90 (0.69, 1.18)
0.85 (0.54, 1.33)
1.0
1.11 (0.95, 1.30)
1.35 (1.05, 1.74)*
1.58 (1.01, 2.48)*
1.0
1.18 (1.08, 1.29)***
1.31 (1.14, 1.50)***
1.60 (1.29, 1.99)***
Abbreviations: aOR, adjusted Odds Ratio; CI, confidence interval. Values reflect aOR’s (95% CI). Table 
is based on imputed data set. *P<0.05, ** P<0.01, *** P<0.001. Models were adjusted for age, 
gender, socio-economic position (ethnicity, income, maternal educational level), crowding (daycare, 
breastfeeding, parity) and maternal lifestyle (maternal age, smoking and alcohol use during pregnancy, 
maternal BMI).
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Table 7 (online). Associations between potential mediators and herpes virus seropositivity
Cytomegalovirus Epstein-Barr virus Herpes Simplex virus 1
OR 
(95% CI)
P-
value
OR 
(95% CI)
P-
value
OR 
(95% CI)
P-
value
Potential mediators
Parity 0.89 (0.82,0.98) 0.012 1.08 (0.99,1.17) 0.096 1.07 (0.96,1.18) 0.22
Maternal educational level 
Low 0.67 (0.53,0.85) 0.001 1.34 (1.07,1.69) 0.011 1.88 (1.41,2.51) <0.001
Mid-low 0.66 (0.54,0.82) <0.001 0.99 (0.81,1.21) 0.93 1.37 (1.03,1.83) 0.03
Mid-high 0.89 (0.72,1.11) 0.31 0.92 (0.75,1.13) 0.43 1.14 (0.80,1.63) 0.46
High Ref Ref Ref
Net household income 
≤ 2200 euro 0.87 (0.72, 1.06) 0.16 1.20 (1.00, 1.44) 0.057 1.29 (1.02,1.64) 0.036
> 2200 euro Ref Ref Ref
Daycare 
No Ref Ref Ref
Yes 1.38 (1.09, 1.76) 0.009 0.97 (0.76,1.23) 0.77 0.86 (0.68, 1.09) 0.20
Breastfeeding duration
never Ref Ref Ref
<3 months 1.34 (0.94,1.90) 0.10 0.89 (0.66,1.20) 0.44 0.74 (0.51,1.08) 0.12
3-6 months 1.48 (1.07,2.06) 0.019 1.01 (0.72,1.42) 0.95 0.67 (0.43,1.03) 0.067
>6 months 1.63 (1.13,2.36) 0.012 0.83 (0.60,1.14) 0.23 0.67 (0.44,1.02) 0.061
OR=odds ratio, CI=confidence interval. Values are OR’s (95% CI)
Table is based on imputed dataset (potential confounders and mediators are multiple imputed, 
determinant observed).
Values are derived from logistic regression models and represent effect estimates (95% confidence 
intervals), adjusted for gender, age and ethnic background.
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Table 10 (online). Maternal and infant characteristics of the study population (n=4,464) 
EBV, CMV or HSV-1
0 infections 
(n=1,319)
1 Infection 
(n=1,735)
>2 infections 
(n=1,410)
Maternal characteristics 
Age (Mean + SD; years) 31.7 (4.7) 30.8 (5.0)*** 29.7 (5.4)***
Educational level (n; %)
        Low
        Mid-Low
        Mid-High
        High 
180 (14.4%)
376 (30.0%)
329 (26.3%)
368 (29.3%)
322 (20.3%)***
476 (30.0%)
336 (21.2%)
452 (28.5%)
366 (30.1%)***
382 (31.5%)
229 (18.9%)
237 (19.5%)
Net household income per month (n; %)
        < € 2,000
        € 2,000-3,200
        > € 3,200
177 (16%)
291 (22%)
668 (59%)
325 (23%)
370 (26%)
716 (51%)
368 (35%)***
254 (24%)
443 (42%)
Smoking continued during pregnancy (n;%) 138 (13%) 232 (17%)** 166 (15%)
Alcohol use continued during pregnancy (n;%) 487 (46%) 595 (43.4) 395 (35.7%)***
BMI before pregnancy (Mean + SD; kg/m2) 23.4 (3.9) 23.6 (1.7) 23.9 (4.3)**
Maternal atopy (n; %) 396 (33.8%) 548 (36.9%) 354 (30.2%)
Family history of asthma / atopy (n; %) 605 (48.7%) 809 (51.1%) 541 (43.7%)*
Parity 
        0 
        1
        2
        >3
717 (57%)
404 (32%)
118 (9%)
23 (2%)
917 (55%)*
533 (32%)
162 (10%)
61 (3%)
736 (54%)***
401 (29%)
169 (12%)
62 (5%)
Mode of delivery (n; %)  
        Vaginal   
        Forceps or vacuum assisted
        Caesarian section 
825 (73.4%)
166 (14.8%)
133 (11.8%)
1071 (72%)
203 (13.6%)
214 (14.4%)
914 (74.6%)
163 (13.3%)
148 (12.1%)
Premature rupture of membranes (n; %) 51 (4.1%) 72 (4.4%) 58 (4.3%)
Infant characteristics (n=258)
Males (n; %) 683 (51.8%) 922 (53.1%) 699 (49.6%)
Western ethnicity (n;%) 1047 (80%) 1162 (69%)*** 655 (49%)***
Gestational age (Mean + SD; weeks)  39.8 (1.9) 39.8 (1.7) 39.8 (1.8)
Preterm birth (<37 weeks) (n; %) 76 (6.0%) 104 (6.0%) 79 (5.6%)
Birth weight ( Mean + SD; grams) 3442 (599) 3413 (557) 3386 (552)**
Low birth weight (<2500 gr) 75 (5.7%) 98 (5.7%) 67 (4.8%)
Day-care in first year (n; %) 567 (85%) 699 (89%)* 447 (88%)
Breastfeeding  (n; %)
        Never
        < 3 months
        3-6 months
        >6 months
98 (10.2%)
340 (35.5%)
195 (20.4%)
324 (33.9%)
114 (10.0%)
364 (32.0%)
237 (20.8%)
423 (37.2%)
52 (6.3%)*
286 (34.8%)
186 (22.7%)
297 (36.2%)
Infections first year (n; %)
        RTI
             LRTI
             URTI
        GI                  
538 (57.2%)
125 (13.8%)
490 (49.8%)
329 (55.7%)
652 (59.4%)
140 (13.5%)
607 (52.6%)
378 (58.0%)
495 (63.3%)*
107 (15.0%)
471 (56.1%)**
296 (64.1%)**
Atopy first year
        Eczema 
        Wheezing (> 1 epsiode)
264 (27.4%)
338 (42.8%)
312 (28.2%)
412 (45.5%)
215 (27.2%)
315 (49.5%)*
Nasopharyngeal bacterial carriership 6 years (n; %)
        No pathogen
        S Aureus
        S. Pneumoniae
        H. Influenza
        M. Catarrhalis
606 (47.3%)
338 (26.4%)
255 (19.9%)
125 (9.8%)
117 (9.1%)
794 (46.8%)
459 (27.0%)
296 (17.4%)
197 (11.6%)
156 (9.2%)
606 (44.2%)
408 (29.8%)
246 (17.9%)
152 (11.1%)
156 (11.4%)
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Table 10. (continued)
EBV, CMV or HSV-1
0 infections 
(n=1,319)
1 Infection 
(n=1,735)
>2 infections 
(n=1,410)
Antibiotic use (n; %)
        year 1
        year 2
        year 3
        year 4
        year 6
        ever (at age 6 years)
386 (47.6%)
413 (41.6%)
313 (32.4%)
260 (27.6%)
227 (18.9%)
830 (85.0%)
504 (54.1%)**
520 (44.9%)
396 (36.4%)
331 (30.1%)
339 (23.0%)*
1059 (89.4%)**
340 (52.7%)
374 (47.3%)*
281 (37.5%)*
247 (32.2%)*
266 (23.9%)**
774 (90.0%)**
Age at focus visit 
(Median + range; years) 6.0 (5.0-8.8) 6.0 (5.0-9.0)***6.1 (4.9-9.1)***
BMI for age (mean; sd; SDS) 0.20 (0.85) 0.25 (0.92) 0.39 (0.95)***
Values are means (SD), absolute numbers (percentages) or #medians (90% range). Based on observed 
dataset. Significantly different from 0 infections *(p<0.05), ** (p<0.01) *** (p<0.001). Maternal 
atopy: eczema, allergy HDM, hay-fever. Any reported autoimmune disease: diabetes mellitus, SLE, 
arthritis, MS, thyroid disorder, or celiac disease
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CHIlDREN DO NOT IMPAIR NAIVE T-CEll POPulATIONS 
OR VACCINATION RESPONSES: THE GENERATION R STuDy
Running title: CMV and EBV T-cell expansion in children
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ABSTRACT
baCkground. Cytomegalovirus (CMV) and Epstein Barr virus (EBV) induce effector 
memory T-cell expansion, which are variable and potentially depend on the age 
at primary exposure and co-infections. We evaluated the T-cell compartment and 
herpesvirus infections in 6-year-old children.
methods. T-cell subsets and IgG seropositivity for CMV, EBV, herpes simplex 
virus-1 (HSV-1) and varicella zoster virus (VZV) were studied in 1,079 6-year-
old children. A random subgroup of 225 children was evaluated for CMV and EBV 
seropositivity before 2y of age and vaccination responses against measles and 
tetanus.
results. CMV and EBV infections were associated with significant expansions 
of CD27- and CD27+ effector memory T cells, respectively. These expansions 
were enhanced in CMV+EBV+ children and were independent of VZV or HSV-1 
co-infection. Naive and central memory T-cell numbers were not affected, nor 
were anti-tetanus and anti-measles IgG levels. Children infected before 2y of age 
showed smaller effector memory T-cell expansions than children infected between 
2-6y. 
ConClusions. CMV- and EBV-related T-cell expansions do not impair naive T-cell 
numbers nor maintenance of protective responses against non-related pathogens. 
Duration of infection was not directly related to larger expansions of effector 
memory T cells in children, suggesting that other mechanisms affect these 
expansions at later age. 
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INTRODuCTION
Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) are ubiquitous in the human 
population and persist with presumed viral latency.1,2 Infection occurs mainly in 
childhood, reaching ~50% seropositivity around the age of 6y and 80-90% in 
adults within the Western world.3,4 CMV and EBV are associated with changes in 
immunological memory. Infected adults display persistent expansions of virus-
specific effector memory T cells in both the CD8+ and the CD4+ lineages.5,6 CMV-
specific CD8+ T cells are predominantly CCR7-CD45RO+CD27+/- in young adults, 
while more clonal CCR7-CD45RA+CD27- populations are found in elderly.5,7-14 
EBV-specific T cells are mainly CCR7-CD45RO+CD27+.5,8,15,16 The majorities 
of these populations have an extended lifespan, but a poor response to T-cell 
mitogens.7-9,16-18
Co-infection with CMV and EBV can have both synergistic and antagonistic effects: 
CMV co-infection can restore defective vaccination responses in EBV-infected 
children, while EBV co-infection can boost CMV-induced NK-cell differentiation, 
and together they affect the chance for developing allergic complications.19-21 In 
contrast, infections with herpes simplex virus 1 (HSV-1) do not result in persistent 
effector T-cell expansions.15 Less is known for co-infection with varicella zoster 
virus (VZV), because this already reaches 90-100% seropositivity in young 
adulthood in the Western world. 
Accumulations of CMV- and EBV-induced effector memory T-cells have been 
suggested to overcrowd T cells with other specificities,5,22 and to negatively impact 
immune responses to other infections and/or vaccinations.9,17,23-25 Moreover, 
CMV and EBV persistence are associated with cardiovascular disease, infectious 
complications and with increased mortality rates, especially in immunosuppressed 
individuals or the very elderly.23,26-31 Still, these effects are not consistently 
observed,32-35 and despite high CMV and EBV seropositivity rates in elderly, only 
a minority develops clinical complications. An explanation could be the variation 
in T-cell responses: virus-specific T-cell numbers vary from barely detectable to 
>30% of total memory T-cells in peripheral blood. This diversity might be affected 
by the infectious dose,36 and with long-term infection, and thus especially develop 
in individuals who had been infected early in life. However, in contrast to infection 
after puberty, primary infections with CMV or EBV in early childhood are mostly 
asymptomatic and might even be protective against the development of Celiac 
disease and allergies.37,38 
To study whether the developing immune system in childhood provides more 
effective control of persistent viruses,39 we studied 1,079 6-year old children in 
the Generation R cohort. The combined analysis of CMV, EBV, HSV-1 and VZV 
infection in this large cohort allowed us to study virus-specific and modifying 
effects on the T-cell compartment and their relation with vaccination responses to 
tetanus and measles. 
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MATERIAlS AND METHODS
study subjeCts
This study was conducted in the context of the Generation R Study, a prospective 
population-based cohort study from fetal life until young adulthood.40 We included 
1,079 6-year-old children (range 5.0-7.9y) from whom CMV, EBV, HSV-1 and VZV 
IgG serology, and detailed immunophenotyping of blood T cells was performed. 
From a random selection of 225 of these children, additional virus serology and 
immunophenotyping was performed on blood samples obtained in the second year 
of life (age range 13.1-29.9 months). Written informed consent was obtained from 
all parents of participating children. Ethical approval for the study was obtained 
from the Medical Ethical Committee of the Erasmus MC.
serology
Blood plasma samples were subjected to enzyme-linked immunoassays for IgG 
antibodies against CMV, EBV capsid antigen (EBV-VCA), HSV-1 glycoprotein C1, 
VZV, Tetanus toxoid or Measles antigen (EUROIMMUN®, Lübeck, Germany). 
Results were evaluated relative to a manufacturer-provided reference threshold 
sample. Seropositivity, and assumed virus persistence, was defined by a sample/
threshold ratio above 0.6 (CMV), 0.8 (EBV-VCA) 1.6 (HSV-1) and 1.0 (VZV). Anti-
measles and anti-tetanus IgG levels were analyzed in international units/ml (IU/
ml) as a continuous variable and with plasma levels above 275 IU/ml (measles) or 
0.5 IU/ml (tetanus) being defined as protective vaccination responses. 
immunophenotyping
Absolute numbers of CD3+ T cells were obtained with a routine diagnostic lyse-
no-wash protocol. Detailed analysis of T-cell subsets was performed with 6-color 
flowcytometry (Supplemental Table 1 and Supplemental Figure 1).22,41 
Antigen-specific T-cells were detected in thawed post-Ficoll PBMC of 15 CMV+ 
and 14 EBV+ children who carried the HLA-A*0201 allele, defined by SNPtags 
rs2844821(G) and rs762324(C) in previously generated SNP arrays.40,42 Virus-
specific CD8+ T cells were detected with HLA-A*0201 tetramers loaded with CMV 
peptides NLVPMVATV (from pp65; APC-labeled) or VLEETSVML (from IE-1; PE-
labeled) proteins and EBV peptides GLCTLVAML (from BMLF-1; APC-labeled) 
or YVLDHLIVV (BRLF-1; PE-labeled). Flowcytometric data were acquired on a 
FACSCalibur or LSRII (BD Biosciences) and analyzed using FACSDiva software 
(BD Biosciences; version 6.2) and Infinicyte (Cytognos; version 1.7) analysis 
software.43 
statistiCal analyses
Differences in infection prevalence were assessed using Chi-square tests. 
Differences in lymphocyte numbers (or frequencies) between uninfected controls 
and virus-infected groups were assessed with a Kruskal-Wallis test, followed 
by post-hoc Dunn’s tests. Differences in longitudinal frequencies of lymphocyte 
populations were assessed using paired t-tests. P-values <0.05 were considered 
statistically significant.
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RESulTS
herpesvirus seropositivity
Among the 1,079 children included in the study, 36.2% was IgG-seropositive 
for CMV, 47.1% for EBV, 14.0% for HSV-1 and 92.1% for VZV. Because mainly 
CMV and EBV are reported to result in chronic T-cell expansions, we divided the 
1,079 children into 4 groups: CMV-EBV- (uninfected; n=399); CMV+EBV- (CMV+; 
n=172); CMV-EBV+ (EBV+; n=289); CMV+EBV+ (n=219) (Table 1). 
Co-infection with VZV was >90% in all groups. HSV-1 infection was significantly 
more frequent in EBV+ (p=0.02) or CMV+EBV+ (p<0.001) children (Table 
1). Therefore, especially HSV-1 infection needs to be considered for possible 
confounding effects in our analyses on EBV. 
Cmv- and ebv-speCifiC effeCtor memory t-Cells 
To analyze whether 6-year-old children carried virus-specific T-cell expansions, we 
phenotyped virus-specific CD8+ T cells in 15 CMV+ and 14 EBV+ children using 
CD27 and CD45RA  and HLA-A*0201 tetramers loaded with CMV-specific peptides 
of pp65 and IE-1 and EBV-specific peptides of BMLF-1 and BRLF-1 (Figure 1). 
Virus-specific CD8+ T cells were detected in blood at frequencies of 0.01-0.52% 
(pp65-NLV) and 0.01-2.32% (IE-1-VLE) for CMV peptides and 0.02-0.64% (BMLF-
1-GLC) and 0.02-2.6% (BRLF-1-YVL) for EBV peptides. The CMV- and EBV-specific 
CD8+ T-cells were phenotypically diverse and predominantly consisted of CD45RA-
CD27+/- and CD45RA+CD27- memory T-cells (Figure 1). Thus, 6-year old children 
already display expansions of effector memory T cells directed against CMV and 
EBV antigens. 
Cmv and ebv assoCiated memory t-Cell expansions
To study the effects of CMV and EBV on the T-cell compartment, we 
immunophenotyped CD8+ and CD8- (CD4+) T cells in 18-20 randomly-selected 
children being either uninfected, CMV+, EBV+ or CMV+EBV+. T-cell data from 
each group of children were merged and subjected to automatic population 
separation (APS) with Infinicyte software,43 based on the expression of CD3, 
CD8, CCR7, CD45RO, CD27 and CD28. Within both CD8+ and CD4+ T cells, four 
populations were distinguished in 2D plots of principle component (PC)1 vs PC2 
(Figure 2). CMV was associated with a relative increase of two CD8+ populations: 
population 2 (CCR7-CD45RO-; 9.2% uninfected  vs 15.1% CMV+) and population 
Table 1. HSV-1 or VZV co-infection in correlation to CMV- and EBV-IgG seropositivity at 6 years 
of age.
 n %
HSV+ 
n (% of group)
VZV+
n (% of group)
HSV+VZV+
n (% of group)
Uninfected 399 37.0 39 (9.8%)refa 367 (92%)refa 35 (8.8%)refa
CMV+ 172 15.9 18 (10.5%) 165 (95.9%) 18 (10.5%)
EBV+ 289 26.8 46 (15.9%)* 260 (90%) 42 (14.5%)*
CMV+EBV+ 219 20.3 48 (21.9%)**** 202 (92.2%) 40 (18.3%)***
total 1,079 100 151 (14%) 994 (92.1%) 135 (12.5%)
a Significance of co-infection in the CMV+, EBV+ or CMV+EBV+ group is tested relative to the CMV-EBV- 
uninfected controls, using the Chi-square test; *, p<0.05; ***, p<0.001; ****, p<0.0001. 
Chapter 5
118
C
ha
pt
er
 5
3 (CCR7-CD45RO+; 2.8% uninfected vs 5.9% CMV+). EBV-infected children 
showed an increase in CCR7-CD45RO+ populations, both CD27- (population 3; 
2.8% uninfected vs 4.1% EBV+) and CD27+ (population 4; and 10.5% uninfected 
vs 14.1% EBV+, respectively). CMV- and EBV-infections were also associated with 
CD4+ T-cell memory expansions: CCR7-CD45RO+ (population 3; 14.2% uninfected; 
20.6% CMV+; 16.6% EBV+) and CCR7-CD45RO- (population 4; 6.7% uninfected; 
10.9% CMV+; 8.6% EBV+) (Figure 2B/D). Thus, CMV and EBV infection in young 
children are associated with relative expansions of memory T cells.
normal numbers of naive and Central memory t Cells in Cmv- or ebv-
infeCted Children 
To quantify whether the relative memory T cell expansions in CMV- and/or EBV-
carriers also affected absolute T-cell numbers, we next evaluated the CD4+ and 
CD8+ T-cell lineages in 1,079 6-year-old children. CCR7+CD45RO-CD27+CD28+ 
naive T cells were distinguished from CCR7+CD45RO+CD27+CD28+ central 
memory T cells (Tcm), CCR7-CD45RO+ effector memory (TemRO) and CCR7-
CD45RO- effector memory (TemRA) (Supplemental Figure 1A).22,41 TemRO and 
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Figure 1. Frequencies and phenotypes of CMV- and EBV-specifi c CD8+ T cells in 6-year-old children. 
CD8+ T cells recognizing CMV- (A-B) or EBV-specifi c peptides (C-B) were detected with multicolor fl owcytometry 
and further analyzed for CD27 and CD45RA expression. Flowcytometry plots consist of merged data fi les of 14 
representative HLA-A*0201+ CMV+ (A-B) or EBV+ (C-D) children. The bottom graphs depict for each individual 
the relative distributions of tetramer-positive cells as fold increase compared to the relative distribution of total 
CD8+ T-cells.
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Figure 2. Relative change in the T-cell phenotype in CMV- or EBV-infected children.
Unbiased fl owcytometric analyses of CD8+ T cells (A) and CD8- T cells (B) in uninfected (uninf), CMV+, EBV+ 
and CMV+EBV+ children. Data from 18-20 children in each group were merged into one fi le, and subjected to 
automatic population separation (APS) based on the expression of CD3, CD8, CCR7, CD45RO, CD27 and CD28. 
2D projections of principle component (PC)1 versus PC2 revealed four populations. The relative contributions 
of CCR7, CD45RO, CD27 and CD28 to PC1 or PC2 are indicated. C and D) CD45RO vs CCR7 expression of the 
populations defi ned by APS. Populations 3 and 4 in panel C were both CCR7-CD45RO+, but differed in CD27 and 
CD28 expression (small inset). 
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TemRA CD8+ T cells were significantly increased in children with CMV or EBV 
infection compared to uninfected controls (Figure 3B). For CMV, these specifically 
concerned a 4.4 fold increase of CD27-CD28- late differentiated TemRA cells and 
1.3-3.3 fold increase of CD27-/+CD28- intermediate to late-differentiated TemRO 
cells over uninfected controls (Figure 3C-D). EBV-infected children showed a 1.2-
1.3 fold increase in CD27-/+CD28- intermediate to late-differentiated TemRA cells 
over uninfected controls and a 1.4-1.8 fold increase in all TemRO subsets (Figure 
3C-D). Naive CD8+ T cells and CD8+ Tcm cells were present in normal numbers. 
Thus, the expansions of effector memory cells resulted in a significant 1.1 fold 
increase in the total number of CD8+ T cells (Figure 3A). Combined CMV and 
EBV infections resulted in a further increase in total CD8+ T-cell numbers (Figure 
3A), with seemingly additive effects of the two viruses in double-infected children 
versus the single-infected children (Figure 3). Thus, in these 6-year-old children, 
infections with CMV and EBV were both associated with T-cell memory expansions. 
The phenotypes of the expanded populations differed for each of the viruses, did 
not affect each other in CMV+EBV+ double infection, and did not result in loss of 
naive CD8+ T cells. 
Total CD4+ T-cell numbers were not affected by CMV and/or EBV infection 
(Supplemental Figure 1B). Still, EBV-infected children had 1.5 fold more CD27-
CD28- late-differentiated TemRO cells than uninfected controls. Furthermore, 
CMV-infected children showed a 1.3-2 fold increase in CD27- intermediate and 
late-differentiated TemRO cells, and a 1.9 fold increase in CD27-CD28- late-
differentiated TemRA cells over uninfected controls (Supplemental Figure 1B). 
Similar to CD8+ T cells, CMV and EBV infection independently resulted in effector 
memory CD4+ T-cell expansions, which did not affect naive T-cell numbers.
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Figure 3. Absolute numbers of CD8+ T-cell subsets in CMV- or EBV-infected children. 
A) Absolute numbers of total CD8+ T-cells in children uninfected with CMV or EBV (uninf), infected with only 
CMV, only EBV or CMV and EBV. B) Similar as in A, for 4 main CD8+ T-cell subsets: CCR7+CD45RO-CD27+CD28+ 
Naive, CCR7+CD45RO+CD27+CD28+ Central memory (Tcm), CCR7-CD45RO+ Effector memory (TemRO) and CCR7-
CD45RO- Effector memory (TemRA) cells 41. C-D) Similar as in A, for CD27+CD28+ early, CD27+CD28- intermediate 
and CD27-CD28- late TemRO (C) and TemRA (D) populations 22. Bars depict stacked median values per T-cell 
population. The number of individuals per category is indicated underneath each plot. Significance was tested 
first by a Kruskal-Wallis test per T-cell population relative to the uninfected controls, and in case of significance 
(p<0.05) followed by a Dunn’s test of individual patient groups. Significance for the Dunn’s test is indicated in the 
plots: *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. 
CMV and EBV T-cell expansion in children
121
C
ha
pt
er
 5
effeCt of hsv-1 and vZv on t-Cell subset numbers
Through combined analysis of children with single CMV, or single EBV, and double 
CMV/EBV infection, we could distinguish distinct effects of these viruses on the 
T-cell compartment in young children. Still, the observed effects could be influenced 
by infection with other viruses, such as HSV-1 or VZV, especially considering the 
increased HSV-1 positivity in EBV+ children (Table 1). Therefore, we separated 
the groups of uninfected controls, CMV+, EBV+ and CMV+EBV+ children further 
into VZV-HSV-1-, VZV+HSV-1 and VZV+HSV-1+ subgroups. Because VZV 
prevalence was >90% in our cohort, the effect of HSV-1, without VZV, could 
not be determined. Though the TemRO and TemRA populations were significantly 
different between all virus-infected groups (Kruskal Wallis; p<0.0001), these 
effects were only caused by CMV- or EBV-associated expansions. The presence of 
VZV and HSV-1 within the CMV+ or CMV+EBV+ group was only associated with 
a slight, but not significant increase of TemRA cells (Figure 4). Thus, co-infection 
with VZV and HSV-1 did not significantly affect CMV- or EBV-associated effector 
memory T-cell expansion. 
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Figure 4. Effect of HSV-1 and VZV on blood CD8+ TemRO and TemRA cell numbers.
Uninfected, CMV+, EBV+ and CMV+EBV+ children were further subdivided in children without HSV-1 and VZV 
(white), co-infected with only VZV (light gray) or with both HSV-1 and VZV (dark gray). Absolute numbers of CD8+ 
TemRO (A) and TemRA (B) cells in all population groups depicted as 10-90% box-whisker-plots. The number of 
individuals per category is indicated underneath each plot. Significance was tested first by a Kruskal-Wallis test 
per T-cell population, and in case of significance (p<0.05) followed by a Dunn’s test of individual patient groups, 
comparing HSV-1 and/or VZV subgroups within each category of uninfected, CMV, EBV or CMV+EBV+ children.
normal vaCCination responses in Cmv- or ebv-infeCted Children
The effector memory T-cell expansions in CMV- or EBV-infected children did not 
result in a reduction of naive and Tcm numbers (Figures 2 and 3). To study if 
immunological memory to other pathogens was normally present in these 6-year-
old children, we tested their responses to previous vaccinations with tetanus at 2, 
3, 4, 11 months and 4 years, and measles at 14 months according to the Dutch 
national vaccination protocol.44 We defined vaccination responses in a randomly 
selected subgroup of 225 6-year-old children that showed similar seroprevalence 
for CMV and EBV  (Supplemental Table 2),  and similar effector memory T-cell 
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expansions (data not shown) as the total cohort of 1,079 children. Furthermore, 
the seroprevalence of co-infection with HSV-1 and VZV was not significantly 
different between the CMV+ or EBV+ groups in this selected cohort (Supplemental 
Table 3). In total, 81.2% of the children had IgG antibodies against measles, 
and 63.2% against tetanus. These frequencies were not significantly different in 
children with CMV and/or EBV infection (Figure 5). Furthermore, median titers of 
anti-measles and anti-tetanus IgG did not differ between the four groups. Thus, 
EBV and CMV seropositivity did not impair immunity to measles and tetanus 
vaccination in 6-year-old children. 
0.5
275
Uninfected     CMV+     EBV+ CMV+EBV+
  n=90  n=39  n=52   n=42
BA
Uninfected     CMV+     EBV+ CMV+EBV+
  n=90  n=39  n=52   n=42
82.2%   76.9%    82.7%      81.0% 66.7%    61.5%    65.4%     54.8%
p=0.32 p=0.56
an
ti-
m
ea
sl
es
 (I
U
/m
l)
0
1000
2000
3000
4000
5000
6000
7000
an
ti-
te
ta
nu
s 
(IU
/m
l)
0
1
2
3
4
5
6
Figure 5. Vaccination responses in 6-year-old CMV or EBV infected children.
Anti-measles (A) and anti-tetanus (B) IgG levels in uninfected, CMV+, EBV+ or CMV+EBV+ children. Specific 
IgG levels were not significantly different between the virus positive groups as compared with uninfected controls 
as determined with the Kruskal-Wallis test; p-values are indicated at the top right of the plot. Percentages at the 
top represent the number of children with a protective anti-measles IgG response >275 international units/ml 
(IU/ml) (A) or anti-tetanus IgG response >0.5 IU/ml (B). Percentages were not significantly different as tested 
by Chi-square test. 
no assoCiation between t-Cell expansions and duration of Cmv or ebv 
infeCtion
Our results indicate that the EBV- and CMV-specific T-cell expansions do not 
affect naive T-cell numbers or vaccination responses to tetanus and measles in 
6-year old children. To study whether infection early in childhood has different 
immunological consequences than infection later in childhood, we determined 
CMV and EBV seropositivity around 2 years of age in a subgroup of 225 children. 
We observed that of the CMV+EBV+ children, 80% already carried anti-CMV IgG 
before 2 years of age, and 46.8% anti-EBV IgG.
We subdivided the EBV+ and CMV+ children into early-infected (before 2y) and 
late-infected subgroups (2-6y), and compared their T-cell compartments at 6 
years of age. Early nor late infection affected naive and Tcm cell numbers (not 
shown), whereas CD4+ and CD8+ effector memory T cells were significantly 
increased (Figure 6 and Supplemental Figure 1C). CMV+EBV+ early-infected 
children had significantly smaller CD8+ TemRO and TemRA T-cell populations 
than late-infected children, with numbers in early-infected children being similar 
to uninfected controls (Figure 6A). Moreover, retrospective longitudinal analysis 
of early-infected children indicated that CD8+ effector memory T-cell numbers 
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were stable between the age of 2y and 6y (Figure 6B). CD4+ effector memory 
T-cell numbers did not significantly differ between early-infected and late-infected 
children. Still, some subsets in late-infected children were significantly higher than 
in uninfected controls, whereas these were not increased in early-infected children 
(Supplemental Figure 1C). Furthermore, CD4+ effector memory T-cell numbers 
increased between the ages of 2y to 6y in early-infected children (Supplemental 
Figure 1D). Together, these results suggest that CD8+ effector memory T-cell 
numbers are not directly related to the time post infection. Rather, the early 
infections were associated with smaller expansions of effector memory T cells at 
6 years.
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Figure 6. limited effector memory T-cell expansions in children infected with EBV and CMV <2y. 
6-Year old CMV+EBV+ children were subgrouped based on infection <2y of age (early; light gray; n=11) and >2y 
of age (late; dark gray; n=10), and compared to CMV-EBV- uninfected controls (white; n=397). A-B) Absolute 
number of CD8+ TemRO (A) and TemRA (B) cell subsets. Plots depict 10-90% box-whisker plots. Significance was 
tested first by a Kruskal-Wallis test per T-cell population, and in case of significance (p<0.05) followed by a Dunn’s 
test of individual patient groups. Significance for the Dunn’s test is indicated in the plots: *, p<0.05; **, p<0.01; 
***, p<0.001; ****, p<0.0001. C-D) Longitudinal follow-up of frequencies of CD8+ TemRO (C) and TemRA (D) 
subsets at the age of 2y and 6y in early infected children. No significant differences between 2y and 6y could be 
observed by paired T-test (p>0.12).
DISCuSSION
We studied the effects of single or combined infection with CMV, EBV, HSV-1 and/
or VZV on naive and memory T cells in a large cohort of more than 1,000 6-year-
old children. CMV and EBV infections each resulted in distinct effector memory 
T-cell expansions, which were additive in case of co-infection. HSV-1 and VZV 
infections did not significantly affect the T-cell compartment, but might slightly 
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enhance CMV- and EBV-associated T-cell expansions. In contrast to adults, CD8+ 
Tem-cell expansions (either TemRO or TemRA) in CMV- or EBV-infected children 
did neither result in overcrowding of naive and Tcm compartments, nor in loss 
of vaccination responses to tetanus or measles. Notably, children infected <2y 
showed fewer Tem cells at 6-years than children infected between 2-6y. Thus, 
depending on the age at the time of infection, CMV and EBV infections seem to be 
controlled differently. 
We, here, detected sizeable CMV- and EBV-specific CD8+ memory T-cell expansions 
in 6-year-old children. Unfortunately, the real extent of virus-specific T-cell 
expansions is difficult to assess due to the large number of viral epitopes and 
the diverse HLA backgrounds of the children in our study. However, since 1) the 
phenotype of the antigen-specific T cells is largely similar to the phenotype of the 
expanded effector memory T-cell populations, both relatively and absolute, within 
the total CD8+ T-cell pool in our cohort of children, and 2) the antigen-specific 
phenotypes are in accordance with previous literature on CMV and EBV infections 
in adults,45 we are convinced that phenotyping the total CD8+ T-cell compartment 
generates an reliable representation of virus-associated changes of the immune 
compartment. 
Our observation that CMV and EBV were associated with an increase of 
distinct CD8+ Tem subsets is consistent with previous literature in adults and 
children.5,7-12,15,46,47 Importantly, our large cohort allowed us to further analyze 
the possible antagonistic, synergistic or independent impact of CMV and EBV on 
the immune compartment. Importantly, in the group of CMV and EBV co-infected 
children, an additive effect was seen for the Tem expansions compared to that seen 
in single-infected patients. Furthermore, the size of the CMV-associated TemRA 
late population was not (negatively) affected by the size of the EBV-associated 
TemRO populations in individual patients (data not shown). Thus, the distinct 
effects of CMV and EBV on CD8+ Tem expansions, appear to be independent of 
each other.
In addition to CD8+ Tem expansions, we found that CD4+ Tem-cell numbers were 
increased in both CMV and EBV infections, which is similar to observations in 
adults.6 Although these expansions were smaller and did not result in a significant 
increase in total CD4+ T-cell numbers, they were distinct between both viruses. 
Furthermore, the phenotypes of the CD4+ Tem expansions were remarkably 
similar to their CD8+ counterparts and were additive in CMV and EBV double 
positive children. Despite these seemingly minor expansions, CD4+ T cells have 
an important role in controlling primary CMV infection.48 Apparently, the formation 
of sizeable Tem populations is necessary to successfully suppress the virus. 
Importantly, these expansions did not result in overcrowding of more immature 
T-cell subsets, something that for CMV infection in elderly has been associated 
with poor CD4+ memory T-cell responses to influenza proteins.24 
Our large cohort allowed us to study the effects of HSV-1 and VZV in EBV and 
CMV double negative children, as well as any modifying effects on CMV and/or 
EBV infections. Because virtually all adults are infected with VZV, little is known 
on the effects on T-cell memory15 and we could for the first time conclude that 
VZV does not modify T-cell memory alone or in combination with CMV and/or EBV. 
Co-infection with HSV-1 was more frequent in EBV+ and CMV+EBV+ children and 
might therefore be an important contributor to the immune modulation that is 
currently assumed to be EBV-associated. Still, HSV-1 did not affect Tem in EBV+ 
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children, suggesting that these expansions are EBV-specific and not due to HSV-
1. The difference in T-cell modulation between CMV and EBV on the one hand and 
VZV and HSV-1 on the other hand is most likely due to tropism and anatomical 
localization of the viruses. In fact, it is well-possible that HSV-1 and VZV induce 
T-cell expansions, but these cells are thought to reside mostly in the human skin 
or locally around virus-infected cells.49
Despite the expansions of CD8+, and CD4+, Tem in children infected with CMV and/
or EBV, these did not result in decreased naive or Tcm cell numbers. In fact, infected 
children had significantly more total CD8+ T cells. Especially in immunosuppressed 
individuals, but also in CMV-infected elderly, effector memory T-cell expansions 
with a subsequent loss of naive T cells and loss of vaccination responses have 
been described to be hallmarks of CMV-associated immunosenescence.9,17,24,25 
However, literature is inconsistent,32-35 and the loss of vaccination responsiveness 
in children, is not consistently observed.19 In our cohort, IgG titers to previous 
measles and tetanus vaccinations were similar between uninfected and infected 
children. Combined, our data suggest that 6-year-old CMV- and/or EBV-infected 
children do not lose their immune responsiveness due to virus-related effects. 
An important explanation for the discrepancy in the literature on the loss of 
naive T cells could be differences in analysis strategies. In fact, due to the Tem 
expansions, the relative proportions of naive and Tcm are decreased in infected 
children in our study. Moreover, the expansion of total CD8+ T-cell numbers causes 
a shift in the CD4:CD8 T-cell ratio. These relative shifts are, however, the results of 
data analysis, rather than real defects, because the absolute naive CD8+ and total 
CD4+ T-cell numbers were normal. This is why we have for long time advocated for 
consistent analysis of absolute cell numbers with age-matched controls.50
Although 90% of elderly are infected with CMV and EBV, only a minority of these 
individuals shows loss of naive T-cell numbers, impaired vaccination responses 
and clinical complications. The reason why only a minority develops complications 
is still unclear. Our study at the age of 6y indicates that early infection before the 
age of 2y results in smaller Tem expansions than infection between 2-6y. Since 
the size of the expanded virus-specific Tem pool has been directly correlated to the 
extent of CMV-induced endothelial damage, the children that have been infected 
before 2y might have a reduced risk for developing cardiovascular complications.31 
CMV-related clinical complications might occur only in individuals infected later in 
life and who show the strongest CMV-associated T-cell expansions. An important 
factor influencing the variability in the response might be the infectious dose.36 It 
would therefore be interesting to correlate the age at infection and the subsequent 
size of the Tem-cell expansions with the infectious dose  and the development of 
clinical complications in children and adults, in a separate cohort or in longitudinal 
follow-up of the uninfected children in our cohort. 
In conclusion, we here provide evidence that in young children, CMV and 
EBV infections lead to sizeable Tem expansions, but not to the associated 
immunosenescence. In fact, the Tem expansion result in increased total T-cell 
numbers, while naive and Tcm remain normally present, as are responses to 
previous vaccinations. Moreover, 6-year old children who were infected prior to 
2 year of age maintained a stable control of these persistent viruses with only 
limited Tem expansions. These new insights into the immuno-modulatory effects 
of herpesviruses in young children are important to understand herpesvirus-
associated immunosenescence in elderly.
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Supplemental Table 1. Antibody details
Antibody clone manufacturer
CD45-PerCP 2D1 BD Biosciences
CD3-FITC SK7 BD Biosciences
CD3-PerCP SK7 BD Biosciences
CD4-PE-Cy7 SK3 BD Biosciences
CD8-APC-H7 SK1 BD Biosciences
CD8-PE-Cy7 SK1 BD Biosciences
CD45RO-APC UCHL-1 BD Biosciences
CD28-FITC CD28.2 BD Biosciences
CD27-APC-H7 M-T271 BD Biosciences
CD197(CCR7)-PE 3D13 e-Bioscience
Supplemental Table 2. CMV- and EBV- IgG seropositivities in the total and selected cohorts 
Total cohort
n(%)
Selected cohort
n(%)
Uninfected 399 (37.0) 90 (40.0)
CMV+ 172 (15.9) 41 (18.2)
EBV+ 289 (26.8) 52 (23.1)
CMV+EBV+ 219 (20.3) 42 (18.7)
total 1,079 225
No significant differences were observed in IgG 
seropositivity between the two cohorts using the 
Chi-square test.
Supplemental Table 3. HSV-1 or VZV co-infection in relation to CMV- and EBV-carriership.
 n % HSV+n(% of group)
VZV+
n(% of group)
HSV+VZV+
n(% of group)
Uninfected 90 40.0 9 (10%)refa 83 (92.2%)refa 8 (8.9%)refa
CMV+ 41 18.2 5 (12.2%) 41 (100%) 5 (12.2%)
EBV+ 52 23.1 10 (19.2%) 48 (92.3%) 9 (17.3%)
CMV+EBV+ 42 18.7 6 (14.3%) 39 (92.9%) 6 (14.3%)
total 225 100.0 30 (13.3%) 211 (93.8%) 28 (12.4%)
a No significant differences were observed of co-infection in the CMV+, EBV+ or CMV+EBV+ groups 
relative to the CMV-EBV- uninfected controls using the Chi-square test.
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Supplemental Figure 1. CD4+ T cell subset analyses
A) Gating strategy for delineating T-cell subsets. Total CD3+ T cells were subdivided into CD8+ (blue) and 
CD8- (CD4+; green) T cells. Both CD4+ and CD8+ T cells were further subdivided into CCR7+CD45RO- Naive, 
CCR7+CD45RO+ central memory (Tcm), CCR7-CD45RO+ effector memory (TemRO) and CCR7-CD45RO- effector 
memory (TemRA) cells [41]. TemRO and TemRA subsets were further subdivided into CD27+CD28+ early, 
CD27+CD28- (CD8+) or CD27-CD28+ (CD4+) intermediate and CD27-CD28- late populations [22]. B) Absolute 
numbers of total CD4+ T-cells and CD4+ T-cell subsets in children uninfected with CMV or EBV (uninf), infected 
with only CMV (CMV), only EBV (EBV) or both CMV and EBV (CMV EBV). Bars depict stacked median values per 
T-cell population. The number of individuals per category is indicated underneath each plot. C) Absolute numbers 
of CD8+ TemRO (left) and TemRA (right) cell subsets in 6-year-old children who were either CMV-EBV-, became 
CMV+EBV+ before the age of 2y (early) or CMV+EBV+ between 2 and 6y of age (late). Plots depict 10-90% box-
whisker plots. B-C) Significance was tested first by a Kruskal-Wallis test per lymphocyte population, and in case 
of significance (p<0.05) followed by a Dunn’s test of individual patient groups. Significance for the Dunn’s test 
is indicated in the plots: *, p<0.05; **, p<0.01; ***, p<0.001. D) Longitudinal follow-up of frequencies of CD8- 
(CD4+) TemRO (left) and TemRA (right) subsets at the age of 2y and 6y in 9 early infected children. Significance 
between 2y and 6y was tested by paired T-tests: *, p<0.05. 
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ABSTRACT
The Epstein Barr virus (EBV) can persists both in IgM+ and in Ig class-switched 
memory B cells. However, it remains unclear whether EBV infection results in 
depletion of these target cells. We here studied the presence of EBV genomes in 
6 memory B-cells subset in adults, and we investigated how EBV infection during 
the first year of life affects the numbers of these memory B cells in young children 
at the ages of 14 months and 6 years. EBV genomes were equally numerous in 
CD27+IgG+, CD27+IgA+ and CD27-IgA+ memory B cells, and to a lesser extent in 
IgM-only, natural effector and CD27-IgG+ B cells. The blood counts of all memory 
B-cell subsets were highly dynamic in children in the first two years of life with 
peak levels around 14 months of age. IgM-only, CD27+IgG+, CD27+IgA+ and 
CD27-IgA+ memory B-cell counts at 14 months of age were significantly lower 
in EBV seropositive children than in uninfected controls. However, at 6 years, 
these counts were normalized, as were plasma IgG levels to previous primary 
measles and booster tetanus vaccinations. Thus, EBV persists mainly in Ig class-
switched memory B-cells, even when derived from T-cell independent responses 
(CD27-IgA+), and results in transient depletion of these cells in young children. 
Combined, our studies demonstrate the  impact of EBV infection on immunological 
memory in young children, as well as the plasticity of the immune system to 
overcome this. 
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INTRODuCTION 
The Epstein Barr virus (EBV) is a gamma-herpesvirus that is ubiquitous in the 
human population. Primary infection occurs predominantly in childhood, after 
which EBV establishes life-long persistence by inducing viral latency in B cells.1,2 
EBV targets B cells through interactions with complement receptor 2 (CR2; CD21), 
MHC-II co-receptor surface molecules, or the Beta-1 integrin.3-5 Even though all B 
cells express these molecules, EBV persists preferentially in memory B cells.1,6 It 
is thought that this is the result of EBV infection in activated B cells that undergo 
an immune response after which the virus persists in the long-lived memory B-cell 
compartment.1,7-9 Recent studies, however, indicate that both activated naive and 
memory B cells can be infected,10 and that EBV can establish persistence in the 
absence of fully functional germinal center activity.11
Primary EBV infection induces a strong expansion of memory B cells that 
normalizes within 1 week after the appearance of clinical complications.12 It is 
likely that infected cells are killed by the virus or anti-viral immune responses. 
However, there is limited information on how EBV infection and persistence affect 
the memory B-cell compartment.9,12 Importantly, about 40% of EBV infections 
occur in the first 5 years of life,13,14 during which the memory B-cell compartment 
is gradually build up.15 Human memory B cells are phenotypically diverse. The 
majority originates from T-cell dependent germinal center responses: CD27+IgD-
IgM+ ‘IgM-only’, CD27-IgG+, CD27+IgG+ and CD27+IgA+ memory B cells.16 In 
addition, T-cell independent responses in the splenic marginal zone and the 
intestinal lamina propria can generate CD27+IgD+IgM+ ‘natural effector’ and CD27-
IgA+ memory B cells, respectively.16-18 
We here studied EBV persistence in all 6 memory B-cell subsets and investigated 
how EBV infection during the first year of life affects the memory B-cell counts in 
young children at the ages of 14 months and 6 years. 
METHODS 
deteCtion of ebv genomes in isolated memory b-Cell subsets in ebv+ adults
Buffy coat material of 5 EBV-positive adults was obtained from Sanquin 
(Amsterdam, NL) and mononuclear cells were isolated by Ficoll-density gradient 
separation. Genomic DNA of 3.0 x106 mononuclear cells was isolated (Sigma-
Aldrich) to determine the presence of EBV genomes with a quantitative PCR 
directed against specific for BALF5 (EBV DNA polymerase).6,19
The remaining post-Ficoll mononuclear cells were presorted using human CD19+ 
MicroBeads (Miltenyi Biotech) on an autoMACS system and stored in liquid 
nitrogen. From EBV-positive donors, the CD19+ B cells were thawed and B-cell 
subsets were purified after labeling with CD38-PE-Cy7 (clone HB7), CD24-APC-H7 
(ML5), CD19-PerCP-Cy5.5 (SJ25C1), CD27-APC (L128), IgD-PO (IA6-2), IgM-PB 
(G20-127), IgG-PE (G18-145; all from BD Biosciences), and IgA-FITC (IS11-8E10; 
Miltenyi Biotech). Cell sorting was performed on a FACS Aria I (BD Biosciences) 
using standardized measurement settings.20 Genomic DNA was isolated, and EBV 
genome copies per 1x106 isolated cells were determined as described above. 
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the generation r population Cohort
Analysis of EBV infection in young children was conducted in the context of the 
Generation R study, which is a prospective population-based cohort study from 
fetal life until young adulthood.21,22  In this study, a subgroup of 1,182 Dutch 
children were included, who were all born between August 2003 and August 2006. 
Ethical approval for the study was obtained from the Medical Ethical Committee of 
the Erasmus MC, University Medical Center Rotterdam. Written informed consent 
was obtained from all parents of participating children.
flowCytometriC immunophenotyping
Peripheral blood was obtained at the mean ages of 0 (cord blood; n=220), 6 (n=376), 
14 (n=241), 25 (n=257) or 72 (n=916) months for detailed immunophenotyping. 
With 1-5 measurements per child this resulted in a total of 2,010 data points. 
Absolute numbers of CD19+ B cells were obtained with a routine diagnostic lyse-
no-wash protocol and measured on a FACSCalibur (BD Biosciences). Six memory 
B-cell populations were defined,16 using the following antibodies: CD19-PerCP 
(clone SJ25C1), CD27-APC-H7 (clone M-T27/L128), IgM-APC (polyclonal; all 
from BD Biosciences), IgD-FITC (polyclonal), IgG-PE (polyclonal; both Southern 
Biotech), and IgA-FITC (polyclonal; Kallestad). Flowcytometry was performed on 
a BD LSRII (BD Biosciences) using standardized measurement settings.20
ebv and measles serology
IgG antibody levels against the EBV viral capsid antigen (EBV-VCA) were 
determined in plasma samples from age 14 months and age 6 years of a subset of 
219 children with enzyme-linked immunoassays (EUROIMMUN®). EBV positivity 
was determined based on a ratio of 0.8 of the sample over a manufacturer-
provided reference threshold sample. In the same 219 children, anti-measles 
and anti-tetanus IgG levels were determined at 6 years of age (EUROIMMUN®). 
The presence of more than 275 international units per ml (IU/ml) for measles or 
0.5IU/ml for tetanus were defined as protective vaccination responses. 
statistiCal analysis
Statistical comparison of EBV- and EBV+ groups were performed using the Mann-
Whitney U test, paired T-test or Fisher’s exact test as indicated in figure legends. 
P-values <0.05 were considered statistically significant.
To model the memory B-cell dynamics between birth and the age of 6 years, 
linear mixed effect analyses were performed on the relationship between the age 
of the children and the size of individual memory B-cell populations. By including 
random-effects in the model, this approach enabled modeling of cross-sectional 
data, with further improvement of the accuracy by incorporating longitudinal 
follow-up data from individual children. To capture the trend in the data more 
precisely, we included a natural spline with different knots (0-3 knots) into the 
models. Basically, the number of knots is inversely related to the smoothness 
of the curve. Positions of the knots in the 1-knot model was defined as the 50th 
percentile (25.5 months), the 2-knots model at 33rd and 66th percentiles (14.1 
and 70 months); the knots in the 3-knot model were defined manually at 6, 14 
EBV-associated depletion of memory B cells
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and 24 months, focusing around the time points of data inclusion. Model selection 
was performed by likelihood ratio test. Statistical analyses were performed in R 
(version R-3.2.1).23
RESulTS 
ebv persists in iga+ and igg+ Class-switChed memory b Cells in adults
To test whether EBV preferentially persists in certain B-cell subsets, we purified 8 
previously defined populations from human blood.16 Naive B cells were separated 
into CD38+CD24+ transitional and CD38dimCD24dimCD27-IgD+IgM+ naive mature 
B cells. In addition 6 CD38dimCD24dim memory B-cell subsets were studied: 
CD27+IgM+IgD+ ‘natural effector’, CD27+IgM+IgD- ‘IgM-only’, CD27+IgA+, CD27-
IgA+, CD27+IgG+ and CD27-IgG+ memory B cells (Figure 1A). The numbers of EBV 
genomes per million cells were determined in all subsets from 5 EBV+ adults and 
represented relative to the number of EBV genome copies in CD27+IgG+ memory B 
cells (Figure 1B). EBV genomes were readily detectable in CD27+ Ig-class switched 
memory B cells, but hardly detected in transitional, naive mature and IgM-only 
B cells (containing <8% of the number of copies detected in CD27+IgG+ memory 
B cells).1,6,11 While low numbers of CD27+IgM+IgD+ and CD27-IgG+ memory 
B cells carried EBV (25% and 39% compared to CD27+IgG+ memory B cells, 
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Figure 1. 
EBV persistence in 
isolated memory B-cell 
subsets in adults.
A) Definition of transitional 
B cells, naive mature 
B cells and IgM+, IgG+ 
or IgA+ memory B-cell 
subsets. B) Relative EBV 
load in the populations 
defined as in A in 
peripheral blood of 5 EBV+ 
adults. Data is depicted as 
mean (+ SEM) EBV load 
relative to EBV copies/106 
cells in CD27+IgG+ 
memory B cells. Number 
of donors tested in each 
individual populations is 
indicated under the plot. 
Significance was tested 
between all subsets and 
CD27+IgG+ memory B 
cells with  paired T-tests. 
*, p<0.05; **, p<0.01; 
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respectively), EBV was as frequent in CD27-IgA+ memory B cells as in the CD27+ 
Ig-class switched memory B cells. Thus, EBV can persist in all 6 memory B-cell 
populations, but is most abundant in the T-cell dependent CD27+IgG+, CD27+IgA+ 
subsets and the T-cell independent CD27-IgA+ subset.
dynamiCs of memory b Cells in the first two years of life
In previous transversal studies, it has been found that memory B cells are 
gradually build-up in the first years of life.15,24-27 To study the longitudinal dynamics 
of memory B cells in the first years of life, we performed repeated flowcytometric 
immunophenotyping measurements between birth and 6 years of age in 1,182 
children in the context of the Generation R study. We performed linear mixed 
effect modeling of memory B-cell populations to define the immune dynamics 
while taking into account the information from longitudinal measurements within 
individuals (Figure 2). All memory B-cell populations showed the largest dynamics 
during the first two years of life. Blood B-cell counts strongly increased within the 
first 14 months of age, followed by a gradual decline and finally a stabilization of 
cell counts between 4-6 years. Thus, the build-up of the various memory B-cell 
subsets occurs most strongly in the first year of life. 
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Figure 2. Dynamics of memory B-cell populations from birth until 6 years of age. 
Included were 1,182 individuals with 1-5 measurements per individual, resulting in a total of 2,010 data points. 
Individual data is depicted in gray dots; directly consequetive timepoints within one individual are connected 
by gray lines (0-6m, 6-14m, 14-25m, 25-72m). Longitudinal linear mixed effect models describe the overall 
dynamics between birth and 6 years of age. Solid black lines represent the modelled data, dashed lines are 90% 
confidence intervals.
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transient deCline in memory b Cells of ebv positive Children
To study whether EBV infection in the first year of life affects the dynamic 
development of memory B cells, we studied the naive and memory B-cell counts 
in blood of 149 14-month-old children, consisting of 13 EBV carriers and 136 
EBV-negative children, as assessed by anti-EBV-VCA IgG serology. While total, as 
well as naive, natural effector and CD27-IgG+ B cells were similar between EBV+ 
and EBV- children, four memory B-cell populations were significantly reduced 
in EBV-infected children: CD27+IgD-IgM+ ‘IgM-only’, CD27-IgA+, CD27+IgA+ and 
CD27+IgG+ (40.6-60.6% reduction in median values of EBV+ vs EBV- children) 
(Figure 3A). 
The long-term effects of this decline were studied by follow-up analysis of the 
blood B cells of the same children at 6 years of age. At this age, 81 children were 
still EBV negative and 53 became seropositive between 14 months and 6 years 
of age. Regardless of early (<14 months) or late (>14 months) EBV infection, 
nearly all memory B-cell counts were comparable to those in uninfected controls 
(Figure 3B). Only the numbers of IgM-only memory B cells were significantly 
lower in late EBV+ than in EBV- children (31% decrease) (Figure 3B). Thus, the 
decline in memory B cells at 14 months seems to be transient and the numbers 
are normalized at 6 years of age.
effeCts of b-Cell depletion on vaCCination responses
To study whether the low memory B-cell counts at 14 months of age were associated 
with abnormal antibody responses, we measured IgG levels in plasma samples of 
6-year-old children to previous primary vaccination against measles and booster 
vaccination against tetanus. Both vaccinations are performed in the context of the 
Dutch national vaccination protocol.28 Primary measles vaccination is performed 
at the age of 14 months when EBV+ children show a decline in memory B cells. 
Tetanus vaccination is performed at the ages of 2, 3, 4 and 11 months during the 
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Figure 3. Effects of EBV persistence on circulating B cells in children.
A) Absolute numbers of total B cells and naive, IgM+ memory, IgA+ memory or IgG+ memory B-cell subsets in 
EBV- (n=131) and EBV+ (n=13) children at the age of 14 months. B) Absolute numbers of total B cells and naive, 
IgM+ memory, IgA+ memory or IgG+ memory B-cell subsets at the age of 6 years in EBV- children (n=81), children 
infected with EBV between 1-6 years of age (late EBV+; n=52) and children infected with EBV within the first 14 
months of age (early EBV+; n=13). Bars depict median and interquartile range. Significance was tested by Mann-
Whitney U test relative to EBV- individuals. *, p<0.05; **, p<0.01; ***, p<0.001. 
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first year of life, followed by a booster at 4 years (Figure 4A). Thus, in plasma 
of children at 6 years of age, we could evaluate build-up and/or maintenance 
of protective primary responses against measles, as well as memory responses 
against tetanus. Both the anti-measles (Figure 4B)  and the anti-tetanus (Figure 
4C) IgG levels at 6 years of age were similar between early EBV+, late EBV+ and 
EBV- children. Furthermore, the percentage of children with a protective response 
was similar between early EBV+, late EBV+ and EBV- children, with >80% 
(measles) and >67% (tetanus) of children having a protective titer at 6 years. 
Thus, both primary responses against measles and memory responses against 
tetanus were not affected by EBV infection and/or memory B-cell depletion in the 
first year of life. 
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Figure 4. Vaccination responses in EBV-
infected children. 
A) Schematic representation of the measles and 
tetanus vaccination protocol in the Netherlands 
28. Tetanus vaccinations were performed at 
the age of 2,3,4,11 months and 4 years, and 
measles vaccination at 14 months of age. 
EBV+ children carried low numbers of memory 
B cells at 14 months of age, and IgG titers to 
previous vaccinations were determined at 6 
years of age. B,C) Anti-measles IgG titers (B) 
and anti-tetanus IgG titers (C) in international 
units per ml (IU/ml) at 6-years of age in EBV- 
(n=73), late EBV+ (n=47) or early EBV+ 
children (n=12). The threshold for a protective 
vaccination response (anti-measles, 275 IU/
ml; anti-tetanus, 0.5 IU/ml) is indicated by the 
dashed line. The frequencies of individuals with 
vaccination responses above this threshold are 
indicated at the top of the plots. Significance 
was tested by Mann-Whitney U test or Fisher’s 
exact test relative to EBV- individuals. No 
significant differences were observed; all p 
values >0.46.
DISCuSSION 
We here studied the persistence of EBV in memory B-cell populations and its 
effect on blood memory B-cell counts. EBV was able to persist in all class-switched 
memory B-cell populations. Memory B-cell populations were highly dynamic in size 
in the first 2 years of life, peaking around 14 months of age. Early EBV infection 
associated with a transient decline of memory B-cell numbers at 14 months of age, 
which normalized before 6 years and which did not affect vaccination responses 
against measles and tetanus.
In line with previous observations,1,6,11 we hardly detected any EBV genomes 
in naive B cells, and only to a limited extent in IgM-only memory B cells and 
natural effector B cells.1,6,11 Interestingly, EBV genome copies were equally 
numerous in CD27-IgA+ memory B cells as in the classical CD27+ IgA+ and IgG+ 
subsets. CD27-IgA+ memory B cells appear to originate through germinal center-
independent maturation pathways in local tissue, as they have been observed 
in patients with a lack of germinal centers due to a mutation in the CD40L gene 
and show strong similarities with IgA+ memory B cells in the intestinal lamina 
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propria.16 The observation that these mucosa-derived CD27-IgA+ memory B cells 
contained the highest number of EBV copies, therefore, fits with the oral pathway 
of EBV infection. Previously, EBV was also detected in natural effector B cells that 
originate from T-cell independent responses in the splenic marginal zone.11,18,29,30 
Our observations therefore strengthen the concept that EBV is able to infect cells 
outside of the germinal center, not only in the spleen, but also in mucosal tissue. 
We here observed decreased numbers of memory B cells in blood of 14-month-old 
EBV-infected children. These children were unlikely to be in the phase of acute 
infection, as they had a positive IgG serology against the viral capsid antigen 
(VCA) of EBV. Since these antibodies typically appear a week after acute infection, 
and remain positive for life,31 these children most likely were infected during their 
first year of life. Even though the impact of EBV on T-cell populations has been 
extensively described,13,32 effects of EBV on the B-cell compartment are less well 
described. Primary EBV infection was shown to result in a large relative expansion 
of EBV+ B cells, which subsequently contracted resulting in low frequencies of 
virus-carrying cells 1 week after appearance of clinical symptoms.12 This depletion 
of virus-expressing cells is most likely the result of virus-induced or immune-
mediated cell death. Our observations extend these observation with long-term 
effects on memory-B-cell numbers in young children. Importantly, we did not 
observe effects on memory B cell numbers in older children who were infected 
>14 month of age. During the first 5 years of life, memory B cells show dynamic 
changes in cell number with peaks around 14 month of age. It is therefore 
conceivable that EBV infection has the greatest effect at this age. 
Despite a reduction in memory B-cell numbers at 14 months of age, early EBV-
infected children had normal memory B-cells counts at 6 years of age, and 
carried normal IgG titers to previous measles and tetanus vaccinations. Since 
antigen-specific memory B-cell numbers correlate well with anti-measles IgG 
titers in the first years after vaccination,33,34 it appears that these were normally 
formed in our EBV+ children at 14 months. Moreover, anti-tetanus IgG titers 
were normal in 6-year-old EBV-infected children. These children had received a 
booster vaccination at 4 years after initial vaccinations during the first year of 
life. This booster is expected to trigger long-lived memory B cells. Thus, despite 
a depletion in memory B cell, the remaining cells were sufficient to mount an 
antigen-specific response with protective IgG levels. Thus, the B-cell response 
shows large plasticity in immunological memory in these young children. Still, the 
outcomes we measured are of low-resolution. We cannot exclude that the antigen-
specific memory B cells have a more restricted Ig gene repertoire following EBV-
associated memory B cell depletion. 
It is unlikely that natural exposure to measles or tetanus had a large effect on our 
observations, because of the >86% vaccination coverage in the Netherlands.35 
The last reported national measles outbreak was in 1999/2000, at least two years 
before the children in our study were born.36 The vast moajority of infected children 
were not previously vaccinated, and a large-scale outbreak could be prevented 
due to the high overall vaccination coverage in the Netherlands.35 Tetanus infection 
is rare in the Netherlands, with 5 or less reported cases of tetanus infection per 
year.37 It will, therefore, be unlikely that natural exposure increased the anti-
measles or anti-tetanus IgG titers and thereby interfered with our analyses.
Altogether, our data indicates that EBV is able to persist in all class-switched 
memory B-cell populations in blood, including CD27-IgA+ and CD27-IgG+ memory 
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B cells, and that although early EBV infection associated with a significantly 
smaller memory B-cell expansion in the first year of life, long-term effect on the 
composition of the blood memory B-cell compartment or its function in vaccination 
responses seem to be limited. 
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ABSTRACT
objeCtives. With the introduction of combined antiretroviral treatment (cART), 
HIV-infected children can reach adulthood with minimal clinical complications. 
However, long-term HIV and cART in adults is associated with immunosenescence 
and end-organ damage. Long-term consequences of HIV and cART in children are 
currently unknown.
design and method. We studied 69 HIV-infected children and adolescents under 
cART (0-23y) for the occurrence of subclinical immunological aberrations in blood 
B and T cells, using detailed flow cytometric immunophenotyping and molecular 
analyses. 
results. Children with undetectable plasma HIV viral loads for >1 year showed 
near-normal to normal CD4+ T-cell numbers and near-normal numbers of most 
class-switched memory B cells. Furthermore, expansions of aberrant CD21low B 
cells  contracted in patients with virus suppression. In contrast, CD8+ effector 
T cells were increased, and CD4+ memory T cells, Vγ9+Vδ2+ T cells and CD27-
IgA+ memory B cells were decreased and did not normalize under ART. Moreover, 
Vγ9+Vδ2+ T cells showed defects in their T-cell receptor repertoire selection. 
ConClusion. Our results show the effectiveness of current cART to enable the build-
up of phenotypically diverse B-cell and T-cell memory in HIV-infected children. 
However, several subclinical immune abnormalities were detected, which were 
partially caused by defective immune maturation. These persistent abnormalities 
were most severe in adolescents and therefore warrant long-term follow-up of 
HIV-infected children. Early identification of such immune defects might provide 
targets for monitoring future treatment optimization.
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INTRODuCTION
Current combined antiretroviral therapy (cART) protocols have been successful 
in the treatment of human immunodefiency virus (HIV)-infected children, who 
can now reach adulthood with minimal clinical complications.1 cART effectively 
induces viral suppression and in most patients plasma HIV RNA levels are below 
the detection limit within 1 year after start of treatment.2 Furthermore, treatment 
restores total CD4+ T cell numbers to levels within the normal range,3 suggesting 
that the treatment is effectively inhibiting viral replication and inducing immune 
recovery.4,5 Signs of immune activation in HIV-infected adults and children, i.e. the 
CD8+ T-cell expansions and hypergammaglobulinemia, resolve after the initiation 
of cART.1 Thus, cART changes HIV-infection from a lethal disease into a chronic, 
treatable disease. 
However, long-term HIV infection has in adults been associated with clinical 
complications, such as cardiovascular complications, neurological diseases and 
malignancies.6-8 Both HIV-associated immune aberrations and immunosenescence, 
as well as long-term cART are important contributors to the development of these 
diseases.6-8 Immune aberrations in HIV-infected adults include an expansion 
of CD8+ T cells with an effector memory phenotype: CD45RA-CCR7-. These 
HIV-specific cells display reduced cytolytic potential and are more prone to 
apoptosis,9-11 mechanisms that could contribute to impaired clearing of HIV.12,13 
Furthermore, the  Vδ2-expressing subset of TCRγδ+ T cells is contracted both in 
mucosal tissues and in blood. This defect is associated with increased microbial 
translocation in the intestine.14-16 Finally, HIV-infection affects B-cell responses 
leading to hypergammaglobulinemia,17,18 an expansion of the aberrant, anergic 
CD21low B-cell population,19-22 and a reduction of CD27+ class-switched memory B 
cells,18,23 of which especially the latter persists despite ART.18,24-26
Long-term effects of HIV infection and cART in children currently remain unclear. 
The first few years of life are crucial for the proper human immune maturation, 
and thereby to prepare them for adulthood.27 Even though cART successfully 
suppressed HIV, it is unclear whether the dynamic adaptive immune maturation 
is normal in HIV-infected children. Early detection of immune aberrations could 
be predictive of future complications. Some persistent aberrancies in T-cell and 
B-cell memory have been described in HIV-infected children,28-30 and their nature 
seems to depend on the child’s age at the start of ART.30-37 Still, an in-depth study 
into immune aberrations that might have long-term pathogenic effects has, to our 
knowledge, not been performed.
We, therefore, studied the blood B- and T-cell compartments in a cohort of 69 
perinatally HIV-infected children and adolescents (0-23 years). The vast majority 
of these individuals responded well to ART with HIV levels below the detection 
limit and total CD4+ T-cell numbers within the normal range. However, several 
persistent subclinical immune abnormalities could be identified in both B and T 
cells that warrant long-term follow-up of these perinatally HIV-infected children 
and might be predictive for future complications. 
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METHODS
study subjeCts
Blood was obtained from 69 HIV-positive children between 0 and 23 years of age 
during routine outpatient clinic visits (Supplemental Table 1).1,5,38 HIV-infected 
individuals were stringently treated and monitored every 3-6 months at Erasmus 
MC-Sophia Children’s hospital and part of The Dutch vertically HIV-infected pediatric 
population cohort as registered by the Dutch HIV Monitoring Foundation.1,5,39 
Except for 1 child that did not give consent, all children of the cohort that were 
below 23 year of age and visited the outpatient clinic between December 2009 
and December 2012 were included in the study. 148 age- and sex-matched HIV-
negative healthy individuals were recruited in the same hospital.1,5,38 Included 
were children undergoing orthopedic, ophthalmic, urologic or other non-infectious 
surgical procedures in otherwise healthy condition. Excluded were children having 
fever, burns or using antibiotics at the moment of sampling, and children having a 
known immunodeficiency, cardiovascular disease, coagulopathy, renal or hepatic 
impairment, and children undergoing organ transplantation. Patients and controls 
were included following informed consent from the parents according to the 
guidelines of the Medical Ethics Committee of Erasmus MC.
flow CytometriC immunophenotyping and isolation of b- and t-Cell subsets 
from peripheral blood
Absolute counts of blood CD4+ and CD8+ T cells were obtained with a diagnostic lyse-
no-wash protocol. Detailed flow cytometric immunophenotyping was performed 
on fresh blood samples after red blood cell lysis with ammonium chloride. CD4+ 
T cells, CD8+ T cells, TCRγδ+ T cells and B cells were characterized using the 
antibodies described in Supplemental Table 2. Flowcytometric analyses were 
performed on an LSRII or CantoII (both from BD Biosciences) using standardized 
measurement settings.40
Post-Ficoll PBMCs were stored in liquid nitrogen and later thawed for sorting of 
CD24dimCD38dimCD27-CD21low (CD21low) B cells and three CD24dimCD38dimCD21+ 
subsets: CD27-IgD+ naive mature, CD27+IgD+ natural effector and CD27+IgD- 
memory B cells on a FACS Aria I (BD Biosciences).
sequenCe analysis of rearranged TCR and IGH transCripts
The presence of the invariant-T nucleotide within the Vδ2-Jδ1 junctional region 41 
was determined in rearranged transcripts amplified from PBMC cDNA, using the 
BIOMED-2 Vδ2 forward and Jδ1 reverse primers.42 Rearranged Vγ9-Jγ1.2 transcripts 
were amplified with the BIOMED-2 Vγ9 forward primer and the fluorescently 
labeled BIOMED-1 Jγ1.2 reverse primer.42,43 Amplified products were subjected to 
GeneScan analyses using an ABI PRISM 3130XL fluorescent sequencer (Applied 
Biosystems) to determine the frequencies of canonical rearrangements.41,44 
IgM and IgG transcripts were amplified and cloned from cDNA of sorted B-cell 
subsets, using IGHV3 and IGHV4/6 leader forward primers and IGHM and IGHG 
reverse primers.45,46 Sequences were generated on an ABI PRISM 3130XL and 
analyzed with the IMGT (http://imgt.org/), and BASELINe (http://selection.med.
yale.edu/baseline/) software.47,48
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b-Cell repliCation history using the kreC assay
DNA was isolated from sorted B-cell subsets with the GenElute Mammalian 
Total DNA Miniprep Kit (Sigma-Aldrich) to determine the replication history with 
the Kappa-deleting Recombination Excision Circles (KREC) assay as described 
previously on a StepOnePlus Real-Time PCR system (Applied Biosystems).49
statistiCal analyses
Statistical analyses were performed using the Mann-Whitney U test, unpaired 
T-test, Fisher exact test or Chi-square test. P-values <0.05 were considered 
statistically significant. 
RESulTS
patient CharaCteristiCs
In this study, we included 69 children and adolescents who were infected with HIV 
in early childhood  (Supplemental Table 1). Of these, 4 patients had plasma HIV 
viral loads (VL) >15,000 copies/ml at the moment of sampling (HIVhigh). Of the 
remaining 65 patients (HIVlow), 26 had detectable VL <900 copies/ml at the time 
of first sampling or detectable VL at least once in the preceding year (suboptimal 
viral suppression; HIVdetect) and 39 patients had undetectable VL for >1y (stable 
viral suppression; HIVund) (Supplemental Table 1). 
All HIVlow patients received ART treatment for an average of 7.3y (HIVund) and 
5.1y (HIVdetect). Two of the four HIVhigh patients received ART for 9.9 and 12.3y; 
the other two patients were clinically well and treatment was postponed according 
to guidelines at that time. Disease severity scores at diagnosis, according to 
Center for Disease Control and Prevention (CDC) guidelines,50 varied between N1 
and C3. The nadir CD4+ T-cell counts were not significantly different between the 
three patient groups, as was the age at which the patients reached their nadir 
CD4. During the study follow-up, patients were clinically well; only 8 children 
needed a short-term hospitalization within the cumulative cohort follow-up. Total 
CD4+ T-cell numbers at the moment of inclusion were normal in 81.5% of HIVlow 
patients (87.2% HIVund; 73.1% HIVdetect) and in 50% of HIVhigh patients (1 
treated, 1 untreated).27 Serum IgA, IgG and/or IgM levels above the normal range 
were detected in only 17.9% of HIVund patients, but were significantly more 
frequent in HIVdetect (53.8%) and HIVhigh (75%) patients.51 Vaccinations against 
Hepatitis A and B induced a protective response (>100 International units/L 
(IU/L)) in 29/29 vaccinated HIVlow children and 1/2 vaccinated HIVhigh patients. 
Within the HIVlow group, increasing age of the patients correlated to significantly 
lower nadir CD4 counts, which were furthermore reached at significantly later 
age. Also treatment was initiated later in older patients and children of 16-23y 
more frequently showed reduced CD4+ T-cell counts at the moment of sampling, 
suggesting persistent CD4+ T-cell defects. Clinical severity score, high serum Ig 
and plasma HIV RNA levels were, however, independent of the age of the child at 
inclusion or treatment duration. 
Altogether, cART appeared effective in most patients as evidenced by the limited 
clinical complications, the normal response to vaccinations and the increase in 
CD4+ T-cell counts. 
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low Cd4+ memory t-Cell numbers in Cart-responsive adolesCents
CD4+ T-cell numbers were within the normal range in most children <16y, but 
were reduced in many older children and adolescents (Supplemental Table 1). 
When divided over 5 age-groups (<2y, 2-4y, 5-9y, 10-15y, 16-23y), CD4+ T-cell 
numbers in HIVlow patients were comparable to age-matched controls, except for 
a signifi cant reduction in adolescents of 16-23y (Figure 1A). 
To address whether CD4+ T-cell numbers were related to plasma HIV RNA levels, 
children of 5-20y were separated into HIVund, HIVdetect and HIVhigh (Supplemental 
Table 1). CD4+ T-cell numbers were only slightly, but not signifi cantly, reduced in 
HIVund patients, and more severely reduced in HIVdetect and HIVhigh patients 
(Figure 1A). 
To study the nature of the CD4+ T-cell reduction, we dissected total CD4+ T cells into 
CD45RO-CCR7+CD27+CD28+ naive, CD45RO+CCR7+CD27+CD28+ central memory 
(Tcm), CD45RO+CCR7- effector memory (TemRO) and CD45RO-CCR7- effector 
memory (TemRA) (Figure 1B). These four subsets were all signifi cantly reduced 
in 16-23y HIVlow patients (Figure 1C). In younger children, these subsets were 
normally present, except for signifi cantly increased TemRA in 2-4y and decreased 
TemRO in 5-9y. Within TemRO, the early differentiated CD27+CD28+ subset was 
not only signifi cantly reduced in the 16-23y, but all age groups >5y (Supplemental 
Figure 1A). The reductions in Tcm and TemRO numbers were similar in HIVund or 
HIVdetect patients, but slightly stronger in patients with high viral load (Figure 
1C and Supplemental Figure 1A). Thus, viral suppression seems to restore the 
CD4+ T-cell compartment to a large extent in HIVlow patients, but especially 
adolescents showed reduced Tcm and TemRO numbers that are typically seen in 
viremic patients. 
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Cd8+ effeCtor memory t-Cell expansions in young Children
Of the 65 HIVlow patients, only 4 showed the increase in total CD8+ T-cell numbers 
that is typically associated with HIV infection. Still, direct comparison of patients 
groups with age-matched controls showed signifi cantly increased numbers of 
CD8+ T cells in children of 2-4 and 5-9y. (Figure 2A). Subset analysis revealed 
that this increase was mainly due to signifi cantly high numbers of TemRA and to 
a lesser extent of TemRO (Figure 2B-C). Within these effector subsets, especially 
CD27-CD28- late effectors were signifi cantly increased in HIV-infected children 
(Supplemental Figure 1B-C). In line with this, more CD8+ T cells expressed CD57 
and HLA-DR (not shown).52-54 The expansions of total and TemRO CD8+ effector T 
Figure 1. The CD4+ T-cell compartment in HIV-infected children and adolescents. 
A) CD4+ T-cell counts in controls and HIVlow patients under ART (left) and in uninfected controls (ctrl), HIVund, 
HIVdetect or HIVhigh patients of 5-23y old (right). The number of individuals per group are indicated in 
parentheses. Plots depict 25-75th percentiles (box) and 10-90th percentile (whiskers). B) Defi nition of naive 
(Tnaive), central memory (Tcm), CD45RO+ effector memory (TemRO) and CD45RO- effector memory (TemRA) 
subsets within CD3+CD8- T cells. C) Absolute numbers of CD4+ Tnaive, Tcm, TemRO and TemRA subsets presented 
similarly as in panel A. Statistical signifi cance was determined using the Mann-Whitney U test; *, p<0.05; **, 
p<0.01; ***, p<0.001; ****, p<0.0001.
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Figure 2. The CD8+ T-cell compartment in HIV-infected children and adolescents. 
A) CD8+ T-cell counts in controls and HIVlow patients under ART (left) and in uninfected controls (ctrl), HIVund, 
HIVdetect or HIVhigh patients of 5-23y old (right). The number of individuals per group are indicated in 
parentheses. Plots depict 25-75th percentiles (box) and 10-90th percentile (whiskers). B) Defi nition of naive 
(Tnaive), central memory (Tcm), CD45RO+ effector memory (TemRO) and CD45RO- effector memory (TemRA) 
subsets within CD3+CD8+ T cells. C) Absolute numbers of CD8+ Tnaive, Tcm, TemRO and TemRA subsets presented 
similarly as in panel A. Statistical signifi cance was determined using the Mann-Whitney U test; *, p<0.05; **, 
p<0.01; ***, p<0.001; ****, p<0.0001
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cells significantly related to the presence of virus, whereas TemRA T-cell expansions 
were found in all three VL-groups (Figure 2C and Supplemental Figure 1B-C). 
Thus, good control of viremia seems to inhibit the CD8+ effector memory T-cell 
expansions, but abnormalities can still be found, especially in young children. 
Cellular and moleCular tCrγδ+ t-Cell repertoire Changed in hiv patients 
TCRγδ+ T-cell numbers were low to normal in our patients with the typically 
increased ratio of Vδ1+ over Vδ2+ T cells (Figure 3A).15,16 In young children, this 
was mainly due to significantly increased numbers of Vδ1+ T cells, whereas older 
children and adolescents had significantly reduced Vδ2+ T-cell numbers compared 
to controls (Figure 3B-C). Moreover, Vγ9+ T-cell numbers were slightly reduced in 
children of 5-9y and 16-23y, suggestive of a reduced number of Vγ9+Vδ2+ T cells, 
the dominant population in healthy adults (Supplemental Figure 2A-B).44 
To study the nature of the Vγ9+Vδ2+ T-cell defects, we analyzed two typical selection 
determinants in these cells: 1) selection for the invariant-T nucleotide in the Vδ2-
Jδ1 junctional regions, normally occurring within the first year of life and present 
in 90% of healthy adults, and 2) the canonical Vγ9-Jγ1.2 rearrangement, formed 
through homology-mediated repair and yielding a canonical Complementarity 
Determining Region 3 (CDR3) of 14 amino acids.41,44 In 15 patients, we did not find 
the invariant-T (Figure 3D). These mainly concerned young children <2y, but their 
frequency was also significantly reduced in the patients of 2-23y. Furthermore, 
patients showed a trend towards reduced usage of the canonical Vγ9-Jγ1.2 
rearrangements, even despite effective virus suppression in HIVund patients 
(Supplementary figure 2C). Thus, in adolescents Vγ9+Vδ2+ T-cells were impaired 
in numbers and in their TCR maturation and repertoire selection, irrespective of 
ART.
reduCtions in iga+ b-Cell memory despite art
Total B-cell numbers, including the transitional and naive mature B-cell subsets, 
were normal in HIV patients of all age-groups (Figure 4A and data not shown). 
Within the memory B-cell compartment, all subsets were decreased in number, 
except for a slight increase in IgM-only B cells (Figure 4BC). Partial normalization 
of CD27-IgG+, CD27+IgG+ and CD27+IgA+ memory B-cell numbers was related to 
viral suppression, whereas the IgM+ populations were equally affected in HIVund, 
HIVdetect and HIVhigh patients. The strongest effect was observed in the CD27-
IgA+ subset that is thought to originate from T-cell independent responses in the 
gut.46 This population was consistently reduced in all age categories and to the 
same extent in HIVhigh, as well as HIVdetect or HIVund children (Figure 4C). 
Thus, even though ART seems to partially restore class-switched memory B-cell 
defects, increased IgM-only and decreased CD27-IgA+ memory B-cell numbers 
persist during ART in HIV-infected children. 
Cd21low b Cells are assoCiated with high hiv loads
HIV-infected adults show expansions of atypical CD21low B cells with molecular 
signs of antigen-maturation and reactivity to HIV.55 They are functionally impaired 
due to reduced replication history and somatic hypermutation (SHM) levels, 
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 7Figure 3. Cellular and 
molecular defects in TCRγδ+  T 
cells of HIV-infected children 
and adolescents 
A) TCRγδ+ T-cell counts in 
controls and HIVlow patients 
under ART (left) and in uninfected 
controls (ctrl), HIVund, HIVdetect 
or HIVhigh patients of 5-23y old 
(right). The number of individuals 
per group are indicated in 
parentheses. Plots depict 25-
75th percentiles (box) and 10-
90th percentile (whiskers). B) 
Definition of Vδ1- and Vδ2-
expressing T-cell subsets. C) 
Absolute numbers of Vδ1- and 
Vδ2-expressing T-cell subsets 
presented as in panel A. D) 
Molecular analysis of TCRDV2-
TCRDJ1 rearrangements for 
detection of the invariant-T 
nucleotide in the first codon of 
the complementary determining 
region (CDR)3. A/C) Plots depict 
25-75th percentile (box) and 
10-90th percentile (whiskers). 
Statistical significance was 
determined, using the Mann-
Whitney U test; *, p<0.05; 
**, p<0.01; ***, p<0.001; 
****, p<0.0001. D) Statistical 
significance was determined, 
using the Chi-square test.
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and reduced responsiveness to stimulation.55 Our HIVhigh children also carried 
signifi cant expansions of CD38dimCD27-CD21low B cells (Figure 5AB). Importantly, 
numbers of these CD21low B cells were near-normal in HIVlow patients in all age 
groups (Figure 5A-C). To study whether CD21low B-cell numbers were directly 
related to HIV viral loads, we performed longitudinal analysis (1.7-2.9 year) of 14 
patients (Figure 5D and Supplemental Figure 3). In all four patients with high viral 
loads, we observed increased CD21low B-cell numbers. In 2 patients, the CD21low 
B-cell numbers increased within 0.5 year following the rise of plasma HIV RNA 
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Figure 4. The memory B-cell compartment in HIV-infected children and adolescents. 
A) CD19+ B-cell counts in controls and HIVlow patients under ART (left) and in uninfected controls (ctrl), 
HIVund, HIVdetect or HIVhigh patients of 5-23y old (right). The number of individuals per group are indicated in 
parentheses. Plots depict 25-75th percentiles (box) and 10-90th percentile (whiskers). B) Defi nition of 6 memory 
B-cell subsets: CD27+IgD-IgM+ (IgM-only), CD27+IgD+IgM+ (natural effector), CD27–IgA+, CD27+IgA+, CD27–IgG+ 
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as in panel A. Statistical signifi cance was determined, using the Mann-Whitney U test; *, p<0.05; **, p<0.01; 
***, p<0.001; ****, p<0.0001.
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levels. Patients with consistently low plasma HIV RNA levels carried a persistently 
small CD21low population of <20% of total B cells. Finally, patients who successfully 
started ART showed a concomitant decrease in CD21low B-cell numbers within 0.5 
year of decreased plasma HIV RNA levels (Figure 5D and Supplemental Figure 3). 
Thus, CD21low B-cell numbers seem directly related to active HIV infection and can 
be normalized by ART in children. 
Cd21low b-Cells in hiv patients are a mixture of naive and antigen-
experienCed b Cells
To study the nature of these CD21low B cells, we purified these, as well as the CD21-
expressing CD27-IgD+ naive B cells, CD27+IgD+ natural effector and CD27+IgD- 
memory B cells from 5 HIV-infected children over 13y for comparative analysis of 
replication history and SHM levels (Figure 5E). Similar to previous observations in 
adults,55 CD21low B cells had a replication history of ~6 cell divisions, which was 
comparable with natural effector B cells, but clearly less than CD27+IgD- memory B 
cells (Figure 5F). The CD21low population consisted mainly of IgM+ (with or without 
IgD) and IgG+ B cells (data not shown). To distinguish between these subsets 
for SHM analysis, we sequenced IGHV genes from separately amplified IGHM 
and IGHG transcripts. IgG transcripts of CD21low B cells were nearly all mutated, 
although the SHM loads were slightly lower than in IgG transcripts from classical 
CD27+IgD- memory B cells (Figure 5G). Still, the transcripts of CD21lowIgG+ and 
CD27+IgD- cells showed similar selection for replacement mutations in CDRs 
(Figure 5H). Furthermore, both subsets showed similar IgG subclass distributions 
with the IgM-proximal IgG1 and IgG3 mostly used (Figure 5I). In contrast, about 
half of the IgM transcripts in CD21low B cells were unmutated. The range of SHM 
levels and selection for replacement mutations of the mutated clones were more 
similar to natural effector B cells, but clearly lower than CD27+IgD- memory B cells 
(Figure 5G-H). Thus, our molecular analyses indicate that the CD21low population 
in HIV patients is actually a mixture of naive and memory B cells, and that the 
molecular signs of antigen maturation in the IgG+ subset are more similar to 
classical CD27+IgG+ memory B cells than might have been previously appreciated. 
DISCuSSION
We here performed an in-depth study on the effect of perinatal HIV infection 
and cART treatment on the immune compartment of children and adolescents. 
Our results show the effectiveness of current cART to enable the build-up of 
phenotypically diverse B- and T-cell memory in HIV-infected children. This included, 
Figure 5. kinetics and molecular diversity of CD21low B cells of HIV-infected children. 
A) Definition of CD19+CD38dimCD21lowCD27- “CD21low B cells”. B) CD21low B-cell counts in controls and HIVlow 
patients under ART (left) and in uninfected controls (ctrl), HIVund, HIVdetect or HIVhigh patients of 5-23y old 
(right). The number of individuals per group are indicated in parentheses. Plots depict 25-75th percentiles (box) 
and 10-90th percentile (whiskers). C) CD21low B-cell frequencies within total CD19+ B cells presented similarly 
as panel B. D) Longitudinal follow up of HIV plasma loads and CD21low B-cell frequencies in one representative 
patients with high-VL (left column), low-VL (middle) and decreasing VL (right). E) Sorting strategy and definition 
of CD21low, naive mature, natural effector and CD27+IgD- memory B cells. F) Replication history of purified B-cell 
subsets of 3 HIV-infected children (patients 28 29 and 34) as determined with the KREC assay.49 G) Mutation 
frequencies in IGHV regions of IgM and IgG transcripts in 5 HIV-infected children (patients 52, 56, 59, 67 and 68). 
The number of transcripts analyzed in each category is indicated in parentheses. H) BASELINe analysis of IgM and 
IgG transcripts to determine the selection strength for replacement mutations.47,48 I) IgG subclass distributions 
of sequenced IgG transcripts from CD21low and CD27+IgD- B cells. The number of sequences included is depicted 
in the center of the chart. Statistical significance was determined using the Mann-Whitney U test (B/C/G) or Chi-
Square test (I); *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.
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at least in part, the normalization of CD4+ T-cell numbers in the youngest children, 
normalization of class-switched memory B-cell numbers, and the reduction of 
CD21low B-cell expansions. However, persistent expansions of CD8+ effector T-cells, 
and the reductions in Vγ9+Vδ2+ T-cells and CD27-IgA+ memory B cells were not 
restored by cART.  
Nearly all children in our cohort responded well to ART; they hardly had 
clinical complaints, mounted protective vaccination responses, showed low to 
undetectable HIV counts in plasma, and carried near-normal blood CD4+ T-cell 
counts.4,5 Adolescents more often showed a persistent reduction in their CD4+ T-cell 
numbers. Various reasons might underlie this age-associated effect, including a 
lack of medication adherence, waning of the T-cell compartment over time due 
to prolonged HIV infection,56 or the change in treatment protocols over the last 
10 years (Supplemental Table 1).57 The later start of ART treatment in children 
>10y of age was associated with significantly lower nadir CD4+ T-cell counts 
than in children <10y, suggesting a more disrupted immune compartment in the 
adolescents. The near-normal CD4+ T-cell compartment in the young children 
might therefore highlight a strong improvement in ART regimens in recent years 
and might further emphasize the importance of an early start of ART treatment. 
Still, future longitudinal studies will be needed to address whether the waning of 
CD4+ T cells over time is stably inhibited in these young children.
While the depletion of CD4+ T cells in adolescent patients concerned all naive, 
memory and effector subsets, Tcm and early TemRO cells were most severely 
affected. Even in adolescents with undetectable HIV for >1y CD4+ Tcm and 
TemRO cells were lower than in uninfected controls, indicating that, once lost, 
these populations might be impossible to fully restore by ART. Loss of Tcm cells 
was reported to correlate with rapid disease progression,58 whereas a small HIV 
reservoir in Tcm cells and stable Tcm functionality were observed in long-term non-
progressors and natural HIV-controllers.59,60 The higher numbers of Tcm cells in 
young HIVlow patients in our study might, therefore, again indicate an important 
immunological improvement due to ART, suggesting that early diagnosis and 
treatment might be important to prevent the initial loss of these populations.
All patients >2y had increased numbers of effector memory CD8+ T cells, which 
might reflect ongoing response caused by residual HIV replication or  might 
potentially be an early sign of immunesenescence. It will be important to 
longitudinally follow-up these CD8+ TemRA expansions, to address whether they 
indeed correlate to chronic immune activation or possibly indicate early signs of 
immunosenescence. 
The HIV-infected children in our cohort had increased numbers of Vδ1+ T cells 
and decreased Vδ2+ T cells, extending previous TCRγδ+ T-cell aberrations found 
in blood and the intestinal mucosa of HIV-infected adults.15,16,61 The increase in 
Vδ1+ T cells did not result from clonal expansion (data not shown), but could still 
be the result of chronic stimulation.15 The low Vδ2+ T cell numbers were mainly 
due to a reduction in the Vγ9+Vδ2+ subset. On top of the depletion that has 
previously been described in adults,62 we here showed that in children Vγ9+Vδ2+ 
T cells showed defective repertoire selection. Because the defects in Vγ9+Vδ2+ T 
cells were not restored by ART, their levels could be good biomarkers to monitor 
future treatment optimization. Still, longitudinal follow-up of our patients will be 
important to define potential clinical complications that are associated with defects 
in Vγ9+Vδ2+ T cells.
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In our cohort, we observed severely reduced numbers of blood CD27-IgA+ memory 
B cells, which are derived from T-cell independent responses in the intestinal 
lamina propria.46 Because these responses do not critically depend on CD4+ 
T-cell help, this defect is most likely independent of any impaired CD4+ T-cell 
responses, but likely depend on other, possibly HIV-targeted, mechanisms.63,64 In 
line with the increased monocyte activation and intestinal microbial translocation 
observed by others,37 the persistent loss of CD27-IgA+ B cells might result from 
persistent intestinal complications and ongoing HIV replication. However, we 
cannot exclude a possible effect of the oral intake of antivirals, which might affect 
B-cell responses in the intestine. Studies in HIV-negative individuals receiving 
post-exposure prophylaxis treatment might help to unravel the effect of treatment 
on the intestinal immune responses.
CD27-IgG+, CD27+IgG+ and CD27+IgA+ memory B-cell numbers were near-
normal in children under ART. Ig serum levels and memory responses to common 
vaccination antigens, such as measles, pneumococci, influenza and tetanus antigens 
are reported to be reduced in HIV-infected patients, and it is debated whether ART 
is able to restore these.65-68 The normalization of these T-cell dependent memory 
B-cell subsets in our patients, coinciding with a normalization of CD4+ memory T 
cells and protective hepatitis A/B vaccination responses suggests maintenance or 
recovery of T-cell dependent humoral responses in our cohort. 
We found that CD21low B-cell expansions correlated with plasma HIV RNA levels. 
We, moreover, showed that this subset was composed of both naive and memory 
IgM+ B cells and IgG+ B cells. This could explain the low replication history of the 
total subset. The CD21lowIgG+ subset contained SHM and IgG1 and IgG3 usage that 
was  more similar to CD27-IgG+ than to CD27+IgG+ memory B cells.46,69 Considering 
that CD21low B cells display poor response to antigen and contain high frequencies 
of HIV-reactive B cells,55 downregulation of CD21 could be a mechanism for HIV 
to impair the host’s protective Ig responses, which, we here showed for the first 
time, could affect both naive and memory B-cell responsiveness. The direct and 
stable contraction in CD21low B-cell numbers following declines in plasma HIV RNA 
levels after cART treatment, therefore, indicates an important beneficial effect of 
cART treatment and makes it a good candidate marker for successful cART.
Altogether, our study showed the effectiveness of current ART to enable the 
build-up of phenotypically diverse B- and T-cell memory in HIV-infected children, 
especially in the younger children in our study, who receive the most recent 
treatment protocols and in whom treatment was started significantly earlier than 
in adolescents. However, even with undetectable viral loads, subclinical defects in 
CD4+ TemRO and Tcm, CD8+ TemRA, Vδ2+ T cells and CD27-IgA+ memory B cells 
persisted, which were partially caused by defective immune maturation. Careful 
prospective monitoring of these persistent defects will be important for the early 
detection of clinical complications, ongoing virus replication or immunosenescence 
that might arise from these defects when these children grow older.37,56
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Supplemental Table 1B. Characteristics of HIV patient groups
HIVlow
HIVund HIVdetect HIVhigh
n 39 26 4
Plasma HIV RNA copies/ml at inclusion 
          (average (range)) a
0 (0-0)
63.2 
(0-900)
111,275 
(16,600-328,000)
Age at inclusion in years 
          (average (range))
10.4 
(1.0-18.9)
10.9 
(0.4-20.6)
15.6 
(12.2-19.0)
ART treatment 
          (n (%))
39 
(100)
26 
(100)
2 
(50)
CDC score 
          (at diagnosis) b
N1-C3 N1-C3 N1-A1
Age at start ART in years 
          (average (range))
2.6 
(0-11.1)
6.2 
(0-17.0)
4.4 
(1.1-7.8)
ART duration in years 
          (average (range))
7.3 
(0.8-13.3)
5.1 
(0.2-12.8)
11.1 
(9.9-12.3)
Nadir CD4 in % of age-matched reference value 
          (average (range)) c
67.4 
(6.9-301.5)
53.1 
(0-160)
43.5 
(21-64.3)
Age at nadir CD4 in years 
          (average (range))
6.1 
(0.3-19.4)
6.9 
(0.2-17.0)
9.9 
(1.6-16.8)
Reduced CD4+ T-cell numbers at inclusion 
          (n (%)) c
5 
(12.8)
7 
(26.9)
2 
(50)
Hyperglobulinemia 
          (n (%)) d
7 
(17.9)
14 
(53.8)
3 
(75)
Protective Hepatitis A/ B response 
          (nprotected/ntested (%))
16/16 
(100)
13/13 
(100)
1/2 
(50)
a Undetectable virus load was depicted as 0
b CDC= Center for Disease Control and Prevention; N/A/B/C, increasing clinical severity; 1/2/3, 
increasing CD4 depletion 50
c CD4+ T-cell numbers below age-matched reference values 27,50 
d Ig serum levels above age-matched reference values 51
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Supplemental Table 2. Antibodies used for flow cytometry
 Antibody Fluorochrome Clone Manufacturer
T cells
CD3 PerCP-Cy5.5 SK7 BD Biosciences
CD4 PB RPA-T4 BD Biosciences
CD8 APC-H7 SK1 BD Biosciences
CCR7 PE 3D13 eBiosciences
CD45RO FITC UCHL1 Zebra/Dako
CD27 APC L128 BD Biosciences
CD28 PE-Cy7 CD28.2 eBiosciences
TCRαβ APC IP26 eBiosciences
TCRγδ PE-Cy7 11F2 BD Biosciences
Vδ1 FITC TS8.2 Thermo Scientific
Vδ2 FITC B6.1 BD Biosciences
Vδ2 PE B6 BD Biosciences
Vγ9 PE B3.1 BD Biosciences
CD57 FITC HNK-1 BD Biosciences
HLADR PE-Cy7 L243 BD Biosciences
CD45 PO HI30 Invitogen
B cells
CD19 PerCP-Cy5.5 SJ25C1 BD Biosciences
CD21 PE-Cy7 B-ly4 BD Biosciences
CD24 PB SN3 Exbio
CD27 APC L128 BD Biosciences
CD38 APC-H7 HB7 BD Biosciences
IgA FITC IS11-8E10 Miltenyi Biotech
IgA PE IS11-8E10 Miltenyi Biotech
IgA FITC polyclonal Kallestad
IgD bio IA6-2 BD Biosciences
IgD FITC polyclonal SBA
IgG PE G18-145 BD Biosciences
IgG PE polyclonal SBA
IgM PB G20-127 BD Biosciences
IgM PE polyclonal SBA
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Supplemental Figure 2. Cellular 
and molecular defects in 
Vγ9+Vδ2+ T cells of HIV-infected 
children and adolescents 
A) Gating strategy for Vγ9+Vδ2+ 
T cells. B) Left plot depicts the 
absolute numbers of Vγ9+Vδ2+ T 
cells in controls and HIVlow patients 
under ART. Right plot depicts the 
subset of 5-23y-old children in 
either uninfected controls (ctrl), 
HIVund, HIVdetect or HIVhigh 
patients. The number of individuals 
in each category is represented in 
parentheses underneath the plots. 
Plots depict 25-75th percentile 
(box) and 10-90th percentile 
(whiskers) of data. Statistical 
significance was determined, 
using the Mann-Whitney U test; *, 
p<0.05. C) Frequency of Vγ9-Jγ1.2 
rearrangement of 14 amino acids 
in size, representing the canonical 
rearrangement. Patients are 
represented as in panel B. Statistical 
significance was determined, using 
the unpaired T-test; *, p<0.05. 
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Supplemental Figure 3: longitudinal follow-up of CD21low B-cell frequencies and HIV Vl in HIV+ 
children. 
Longitudinal follow up of plasma HIV RNA levels and CD21low B-cell frequencies in 4 patients with high-VL (left 
column), 5 patients with low-VL (middle) and 5 patients with decreasing VL (right). The 3 top panels are the same 
as shown in Figure 5D in the main paper.
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During the first few years of life, newborns mount immune responses to diverse 
pathogenic threats and generate immunological memory post infection. This will 
prevent clinical illness during subsequent encounters with the same pathogen and 
thereby provide functional immunity. Maturation of the largely immature neonatal 
immune system is necessary to provide a young child with an immune system 
that supports long-term survival without the development of clinical complications 
due to either insufficient responses (immunodeficiency or immunosenescence) or 
unwanted responses (autoimmunity or allergies). In adults and elderly, persistent 
viral infections have been shown to skew T-cell memory. This mostly concerns the 
cytomegalovirus (CMV), Epstein Barr virus (EBV) and human immunodeficiency 
virus (HIV).1-3 Little is known about the factors that affect leukocyte subset 
numbers and formation of immunological memory in young children. 
In this thesis, we aimed to identify the effects of various external determinants 
during pregnancy, around child birth and during the first years of life on the 
leukocyte populations in young children. In Chapter 2, we studied leukocyte 
population dynamics between birth and 6 years of age in relation to a large 
number of external determinants. The association between breastfeeding and 
reduced B-cell memory was further studied in more detail in Chapter 3. Various 
aspects of persistent viral infections were studied: i.e. factors that affect the 
prevalence of herpesvirus infections (Chapter 4), the CMV- and EBV-associated 
changes in T-cell memory (Chapter 5), the EBV-associated reduction of memory 
B cells (Chapter 6), and the effect of perinatal HIV infection on the B-cell and 
T-cell compartments of HIV-infected children receiving combined antiretroviral 
(cART) treatment (Chapter 7). Together, the studies in this thesis illustrate the 
dynamics of childhood immune maturation and the plasticity of the childhood 
immune system to cope with persistent viral infections. 
BREASTFEEDING PROVIDES STEPwISE MATuRATION OF CEllulAR 
AND HuMORAl IMMuNITy
In Chapter 2 we observed a selective negative effect of breastfeeding on the pattern 
of CD27-IgA+ memory B-cell dynamics, but not the germinal center-dependent 
memory B-cell populations, between birth and the age of 6 years. Breastfeeding 
is known to provide passive protection to the newborn during the first few months 
of life, in the form of maternal immunoglobulins or anti-pathogenic molecules, 
growth factors, lactoferrin and exosomes.4-6 Maternal IgA is important to reduce 
bacterial adhesion to epithelial cells and intestinal translocation in the neonate and 
thereby to prevent bacterial exposure to the newborn’s humoral immune system.4 
The CD27-IgA+ memory B-cell population is generated from local intestinal IgA 
responses,7 which is the direct target organ of breastfeeding. This would suggest 
that breastfeeding reduces especially the formation of local humoral responses, 
whereas systemic germinal center-dependent responses are less or not affected. 
However, in Chapter 3, we observed that breastfeeding duration was associated 
with smaller T-cell dependent memory B-cell populations, an effect that resolved 
after discontinuation of breastfeeding. Growth factor proteins (e.g. epidermal 
growth factor and insulin-like growth factor) and hormones (e.g. erythropoietin) 
in breast milk were observed to reduce the intestinal permeability and subsequent 
microbial translocation.6,8-10 This would be in line with our observation of a 
reducing effect of breastfeeding on systemic memory B-cell populations during 
breastfeeding duration. The longitudinal approach in Chapter 2 focused on 
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the impact of breastfeeding on the overall pattern between birth and 6 years 
of age without including information on breastfeeding duration, which might in 
part explain why we did not observe the reduced numbers of systemic T-cell 
dependent memory B-cell populations in breastfed children in this study. Though 
speculative, breastfeeding might transiently delay the induction of systemic B-cell 
responses during the period of breastfeeding, whereas the effect of breastfeeding 
on the intestinal microbiota and subsequent intestinal CD27-IgA+ memory B-cell 
responses might be more long-lasting and therefore detectable on the overall 
pattern of CD27-IgA+ memory B-cell development. Detailed follow-up analyses of 
CD27-IgA+ memory B cells in association with breastfeeding or formula feeding 
will be important to understand the long-term consequences of breastfeeding on 
this population. 
In contrast to inhibiting effects on B-cell memory, we observed expansions of 
central memory T (Tcm) cells in the presence of breastfeeding on. Expansion of 
the Tcm subset depended on breastfeeding exposure, but not on breastfeeding 
duration. This might suggest that it primes the newborn’s T-cell compartment, 
and would be in line with the more effective vaccination responses observed in 
breastfed children.11 Currently no direct CD8+ T-cell stimulating component has 
been identified in breastfeeding. Potential factors in breast milk that might stimulate 
CD8+ T-cell maturation include vitamins, cytokines, exosomes, and potentially 
viral or bacterial structures.4-6 Cytokines, such as interleukin (IL)-15, can have 
CD8+ T-cell stimulatory potential,12 and IL-15 in breast milk has been associated 
to protection from mother-to-child HIV-transmission.13 Exosomes in breast 
milk contain major histocompatibility complex (MHC)-class I and MHC-class II 
proteins, as well as various co-stimulatory molecules, and functional micro-RNAs, 
all of which might provide them with immunomodulatory potential.14-16 Exosomes 
might be involved in presentation of maternal viral or bacterial antigens, and 
thereby stimulate T-cell maturation, either directly, or by bringing together CD4+ 
and CD8+ T cells.15 This is in line with the described increase in CD4+ regulatory 
T-cell differentiation under the control of exosomes in breast milk.14 Based on 
the complex membrane protein composition of exosome pools and the extensive 
content of these vesicles, I am convinced that more regulatory properties are 
likely to be identified in the future, which might provide an explanation for the 
CD8+ T-cell stimulation that we observed in breastfed children. 
One might speculate that breastfeeding reduces the need for humoral immune 
responses, while T-cell responses are primed, thereby boosting cellular immunity. 
It will be important to study the receptor diversity and reactivity of this expanded 
CD8+ Tcm pool, to define whether they are the result of antigen-independent or 
antigen-driven differentiation and proliferation, the first of which might provide a 
broadly reactive Tcm pool, whereas the latter would likely skew the repertoire of 
these cells. Future research into the immune stimulatory properties of exosomes, 
cytokines, and other components of breast milk, will be important to provide 
insights into the broad or targeted effect of breastfeeding-associated CD8+ T-cell 
expansions. 
PERSISTENT VIRAl INFECTIONS INDuCE DISTINCT CD8+ 
EFFECTOR MEMORy T-CEll ExPANSIONS IN yOuNG CHIlDREN
We observed that in 6-year-old children, CMV and EBV (Chapter 5), and HIV 
(Chapter 7), induces distinct CD8+ effector memory T-cell expansions: EBV was 
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predominantly associated with expansions of early CD45RO+ effector memory; 
HIV predominantly with intermediate to late CD45RO+ or CD45RA+ effector 
memory; and CMV predominantly with late CD45RA+ effector memory (Figure 1). 
Why infections with these viruses result in CD8+ T-cell expansions with distinct 
immunophenotypes is currently still under debate. 
An important aspect will be the distinct functional properties of early differentiated 
T cells (high proliferative potential, but low cytotoxicity) and terminally 
differentiated T cells (low proliferative potential, but high cytotoxicity) in relation 
to the optimal anti-viral response required to clear each distinct virus.12,17-19 Poly-
functionality, measured as simultaneous production of IL-2, TNFα and IFNγ, is 
assumed to be essential for long term viral control.20-22 However, these poly-
functional T cells might have a more intermediate differentiation phenotype, in 
both CMV and HIV infection,23,24 whereas the predominantly late-differentiated 
CMV-specific cells might be enriched for low avidity cells that are less responsive 
to antigenic stimulation.25 Apparently, these functional properties alone do not 
explain the phenotypic differences in anti-viral responses.
CMV-specific T cells in children (Chapter 5) were mostly CD45RA- rather than 
CD45RA+. This was in line with previous data on children,25 but contrasted 
observation in adults of expansions of CMV-specific CD45RA+ effector memory 
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Figure 1. CD8+ effector memory T-cell expansions in children infected with CMV, EBV or HIV. Absolute 
numbers of early, intermediate are late differentiated CD45RO+ (TemRO; left) or CD45RO- (CD45RA+ TemRA; right) 
CD8+ effector memory T-cell populations in 5-9 year old children of the Generation R birth cohort (Uninfected, 
CMV+ and/or EBV+) and the HIV-cohort (HIV+). Included HIV-infected children showed undetectable viral 
load for more than 1 year, or detectable viral load in the preceding year, but below 900 copies/ml at the time 
of inclusion. Data in HIV infected children was not corrected for co-infection with CMV or EBV. Bars depict 
stacked median values per T-cell population. The number of individuals per category is indicated underneath 
each plot. Significance in CMV- and EBV-infected children was tested first by a Kruskal-Wallis test per lymphocyte 
population, and in case of significance (p<0.05) followed by a Dunn’s test of individual patient groups relative 
to the uninfected controls. Significance between uninfected controls and HIV-infected children was subsequently 
tested by Mann Whitney U test. Significance for the Dunn’s test or Mann Whitney U test is indicated in the plots: 
*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. 
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T cells. This might mean that terminally differentiated CMV-specific CD45RA+ 
effector memory T cells accumulate with increasing age as a result from repetitive 
antigenic stimulation.18,21,26 As these terminally-differentiated CD45RA+ effector 
memory T cells show signs of replicative senescence,27,28 this might result in 
the eventual loss of this response. In line with this hypothesis, especially T-cell 
clones with high HIV-antigen binding sensitivity that was associated with high 
initial anti-viral functionality and anti-viral protection, showed CD57 expression 
and frequent loss of dominant clones.21 This might also explain the need for large 
accumulations of terminally differentiated T cells to maintain viral control in CMV-
infected elderly.25 It will be of interest to longitudinally follow-up the phenotype of 
CMV-specific cells in the children studied in Chapter 5, as this will show whether 
the phenotype is stable or changes over time into a terminally-differentiated 
phenotype. Furthermore, the effect of high antigenic stimulation on the phenotype 
of these T cells might be tested by comparing early treated HIV-infected children 
that show virus-control prior to the onset of high viremia, with children treated 
after the development of high HIV viremia. 
Multiple findings in literature contrast the hypothesis of replicative senescence 
upon repetitive stimulation. The terminally differentiated CMV-specific T cells 
that predominate in elderly retain the potential to function upon re-stimulation.29 
Furthermore, poly-functional T cells accumulate in CMV-infected elderly,22 and a low 
HIV viral setpoint and high CD4+ T-cell count correlated with the presence of T cells 
with a terminally-differentiated phenotype, instead of the intermediate phenotype 
related to poly-functionality.23,24,30,31 Furthermore, initiation of cART treatment, 
and subsequent reduction in HIV loads in serum, in HIV infected patients, might 
not change the phenotype of the initially developed CD8+ T-cell populations. This 
latter observation might suggest that the initial anti-viral response defines the 
long-term phenotypic (and potentially functional) characteristics of anti-viral CD8+ 
T-cell populations.
In Chapter 5, we observed higher CMV than EBV prevalence in 2-year-olds, 
suggesting younger infection with CMV than EBV. Furthermore, we observed 
in Chapter 4 that CMV infection might depend more on vertical transmission, 
such as via breastfeeding, whereas EBV and HSV-1 depended more on horizontal 
transmission as they were associated with having siblings or attending daycare. 
As childhood immune maturation is associated with strong changes in the 
inflammatory milieu,32-34 the inflammatory milieu at the time of infection might be 
an additional factor adding to the complexity of determining the T-cell phenotype. 
Antigen-independent cytokine stimulation (e.g. by IL-15) has been described to 
induce a terminally-differentiated phenotype in otherwise functional CMV- and 
EBV-specific T cells in elderly.12,17,24,25,35,36 Their increased resistance to apoptosis 
might subsequently contribute to their accumulation. A similar increase in survival 
and effector functions has also been described upon IL-15 treatment of HIV-
specific effector memory T cells, although this did not directly induce their terminal 
differentiation.37 In the studies presented in this thesis, we were, unfortunately, 
unable to correlate the age of infection with the phenotype of the virus-specific 
CD8+ T cells and the inflammatory state of the immune system. Correlating this 
information will be essential to further test the importance of the inflammatory 
milieu on the priming of anti-viral responses. 
The potentially distinct routes of infection for CMV (vertical transmission, such as 
via breastfeeding), compared to EBV and HSV-1 (more horizontal transmission, 
via contact between children) (Chapter 4), might be another important factor 
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influencing the primary anti-viral response as it can affect virus load or virus-
stability. Cytokines and growth factors in breast milk have been suggested to 
perform protective functions either by enhancing activation of CD8+ T cells in 
breast milk, via the reduction of intestinal permeability, or via the activation 
of the infant’s intestinal epithelial intestinal tissue to prime the infant against 
intestinal infection.13,38 Although this was only shown for HIV infection, a similar 
situation might apply for infectious CMV in breast milk.12 While inducing a more 
terminally differentiated phenotype of CD8+ effector memory T cells, 12,24 it might 
induce early and strong control of infection, and could explain the relatively small 
CD8+ T-cell expansions that we observed in Chapter 5. This hypothesis could be 
tested by comparing the phenotype and size of virus-specific or virus-associate 
CD8+ T-cell populations in children fed with breast milk versus formula milk. 
Additional insights into the effect of maternal cytokines on direct immune priming 
in the breastfed infant, instead of on the virus within the breast milk, could be 
obtained by studying EBV- and HSV-1-infected children. These two viruses are 
less frequently acquired via breastfeeding (Chapter 4). Differences between EBV- 
or HSV-1-infected children fed with breast milk or formula milk would therefore 
indicate a direct effect of breastfeeding on the infant’s immune system. 
INHIBITION OF IMMuNE RESPONSES By PERSISTENT VIRAl 
INFECTIONS IN yOuNG CHIlDREN
Besides the strong induction of anti-viral CD8+ effector memory T-cell expansions, 
we also observed two negative associations of these viruses with B-cell and T-cell 
numbers. First, EBV infection was found to associate with a transient reduction 
in memory B-cell numbers, likely resulting from direct infection and persistence 
of the virus in these cells (Chapters 2 and 6). Second, HSV-1 infection did not 
induce CD8+ T-cell expansions, but instead was associated with reduced naive 
B-cell numbers (Chapter 2). Naive B cells themselves are not permissive for HSV-
1 infection, suggesting indirect effects. The reduction in naive B cells might involve 
increased differentiation into memory or effector cells, which would suggest the 
involvement of more humoral responses against HSV-1 instead of cytotoxic T-cell 
responses. However, we did not observe an increase in memory B cells in our 
analyses and were unable to study plasma cell responses. It will be important 
to define whether the effects are persistent or transient in nature. The effect of 
EBV seemed mainly due to a reduced expansion of memory B cells within the first 
year of life. Although these cell numbers have normalized after their initial decline 
at 14 months (Chapter 6), it remains unclear whether these are as diverse as 
in uninfected children, or children infected after 14 months of age. Specifically 
the clonal diversity and replication history could reveal insights into whether 
memory B-cell numbers normalized through replenishment from naive cells or 
through enhanced compensatory proliferation of the few remaining memory cells. 
When the normalization of cell numbers would be due to increased bone marrow 
output, it could potentially restore this diversity, whereas we might speculate that 
normalization by increased homeostatic proliferation of circulating memory B cells 
could induce permanent reduced diversity of the memory B-cell compartment, 
and potentially reduced humoral immunity, in these EBV-infected children. 
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PERSISTENT SuBClINICAl IMMuNE DEFECTS IN HIV-INFECTED 
CHIlDREN
In Chapter 7, we found that current cART protocols restored (or prevented the 
loss of) many aspects of memory B and T cells in perinatally HIV-infected children 
and adolescents. However, we also identified a selected set of persistent defects 
that were not prevented nor restored under cART treatment. These especially 
concerned: expansions of CD8+ effector memory T cells, and reductions in CD4+ 
central memory and CD45RO+ effector memory T cells, Vδ2+Vγ9+ T cells and CD27-
IgA+ memory B cells. Even though these defects were currently still subclinical, 
complete normalization of these populations might be essential for an efficient 
immune system and for long-term protection of HIV-infected individuals.39-42 
Current cART protocols provide HIV-infected children with a relatively good 
prognosis, but the challenge will be to have these children to age with minimal 
clinical complications. A detailed understanding of the immunological conditions of 
these children and the identification of potential early signs of clinical complications 
in the future, will be highly important for future health care and potential further 
treatment optimization. Whereas follow-up of the normalized memory B-cell 
and T-cell populations will be important to define the stability of the beneficial 
effects of cART, the identified persistent defects might indicate potential pitfalls 
in the current treatment that could in the long term lead to clinical complications. 
Therefore, follow-up of these subclinical defective lymphocyte populations is 
highly important. 
Combined, the persistent, but still subclinical, defects identified in Chapter 7, 
might be signs of incomplete HIV control. CD4+ central memory and CD45RO+ 
effector memory T-cell populations might be preferentially infected and provide 
important HIV reservoirs that can be established in a little as 10 days after the 
onset of clinical symptoms.43-47  Though clearly speculative, the observed subclinical 
defects might suggest that CD4+ memory T cells are persistently depleted and 
that latent reservoirs in CD4+ memory T cells might not be fully eliminated by 
cART.48  Such a persistent reservoir and low-level ongoing virus replication, might 
subsequently trigger persistent CD8+ T-cell expansions, including the highly HIV-
related CD8+ intermediate differentiated effector memory T cells (Figure 1).1,2 The 
intestine has been described to be an important reservoir for HIV infection.43,49-51 
In line with this, we observed a severe decrease of intestinal-derived CD27-
IgA+ memory B-cell numbers in blood. Whether this population is reduced due 
to increased retention, lack of generation, or depletion of these cells in the 
intestine will require additional studies. Moreover, it will be highly interesting 
to study whether this population is affected as a direct result of ongoing local 
HIV-replication, of increased intestinal bacterial translocation after HIV-induced 
intestinal damage,49,52 or of the effect of the predominantly oral treatment on 
the integrity of the intestinal tissue. The latter might be tested in HIV-exposed, 
but HIV-uninfected individuals receiving post-exposure prophylaxis. Finally, the 
reduction of Vδ2+Vγ9+ T-cell numbers in HIV-infected children, which was partially 
due to impaired maturation of these cells in response to phospho-antigens,53-56 
might be an early predictor for potential mycobacterial complications and impaired 
anti-HIV responses.42,57 Altogether, detailed monitoring of these children will be 
needed to address the clinical relevance of these, still subclinical, defects at the 
long-term, but the populations identified here might provide important targets for 
longitudinal follow-up. 
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PlASTICITy IN THE CHIlDHOOD IMMuNE SySTEM uPON VIRuS 
ENCOuNTER
In Chapters 5 and 7, we observed that the CMV-, EBV- and HIV-associated CD8+ 
effector memory T-cell expansions in 6-year-old children did not affect the naive 
and central memory T-cell compartments. Furthermore, in CMV and EBV infection 
it, at the same age, did not result in the loss of vaccination responses against non-
related measles or tetanus infection. Moreover, infection before the age of 2 years 
induced smaller T-cell expansions than infection between 2-6y. In Chapter 6, we 
observed that EBV infection within the first two years of life resulted in an only 
transient decline of memory B-cell numbers around 24m that normalized before 
the age of 6y. Combined with the mostly asymptomatic nature of CMV and EBV 
infection in early childhood, and the potential protective effect of these viruses 
on the development of celiac disease (Jansen et al submitted) and allergies,58-60 
this might suggest only mild changes in immune homeostasis after childhood 
infection. However, it is important to realize that the studies in this thesis focused 
predominantly on quantitative measures, and less on functional responsiveness 
or the development of a broad repertoire of lymphocyte receptors. Even though 
our data in Chapter 5 suggests that effector memory T-cell populations did not 
increase in early CMV- and EBV-infected children between 2 and 6 years of age, 
long-term follow-up of these children will be essential to confirm the stability of 
this population and the associated mild changes in the composition of the immune 
system, without excessive accumulation of CD8+ effector memory T cells, the 
loss of naive cells or immunity against non-related pathogens. Furthermore, the 
reduction of memory B-cell numbers upon EBV-infection normalized before the 
age of 6 years and vaccination responses against measles and tetanus seemed 
normal. However, it needs to be investigated whether also the repertoire and 
responsiveness of this memory B-cell population fully normalized compared 
to EBV-uninfected children. When cell numbers normalize due to homeostatic 
proliferation, this might reduce the diversity and impair subsequent responsiveness 
of the memory B-cell population in EBV-infected children.  
The importance of a proper immune maturation might be even more clearly visible 
in perinatally HIV-infected children. In Chapter 7, we observed that the HIV-
infected children below 10y were treated at significantly younger age and showed 
less immune dysbalance than children >10y. Though current cART treatment is 
able to reduce the virus levels in serum to below the detection limit, and to recover 
a large part of the immune system, the extent of immune recovery was described 
to be inversely related to the patient’s age at the start of cART treatment.61,62 
(Reviewed in 63) Whereas the start of treatment early during immune maturation 
has been described to prevent the loss of humoral vaccination responsiveness, this 
responsiveness could not be restored by treatment started later during childhood.64 
Based on these beneficial effects of early treatment, current cART protocols 
changed in the last decade; whereas according to the 2006 guidelines cART had 
to be initiated in <11-months-old HIV-infected infants with clinical complications, 
CD4+ T-cell frequencies below 25% of the age-related normal frequency, CD4+ 
T-cell count <1,500 cells/ul, or a total lymphocyte counts below 4,000 cells/μl,65 
these recommendations have been updated, suggesting to initiate treatment in all 
HIV-infected children below 24 months of age (2010),66 or even in all HIV-infected 
children below 5 years of age (2013).67 Long-term follow-up of these early treated 
HIV-infected children will be essential to confirm whether the beneficial effects of 
early treatment might wane over time or persist into adulthood. 
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THE ClINICAl RElEVANCE OF uNDERSTANDING HERPESVIRuS 
IMMuNITy
In Chapter 4, we describe the large variation in herpesvirus seropositivity within 
populations with different ethnicities; the incidence of herpesvirus infection was 
significantly lower in the Western world compared to non-Western populations. 
Infection with CMV, EBV, HSV-1 and VZV are common, and might reach >50 
to even 100% seropositivity in the adult population in the Netherlands.68-73 
Genetic variation between different ethnic groups likely contributes to infection 
susceptibility. However, we described in Chapter 4, that a significant part of the 
difference in infection prevalence between ethnic groups could also be explained 
by differences in external determinants associated with (likely cultural) behavior. 
Lower socioeconomic situation and larger family size (more siblings) in certain 
ethnic population were associated to the increased prevalence of EBV and HSV-
1 infection, whereas the prevalence of CMV infection might be increased by 
more frequent breastfeeding over bottle feeding of infants. As a consequence, 
the smaller family size and use of bottle feeding in Western populations might 
delay or fully prevent infection. As especially infections with CMV and EBV have 
been associated with severe clinical complication in neonates, immunosuppressed 
individuals and elderly,74-83 the reduced prevalence of herpesvirus infection in the 
Western world might seem beneficial. 
However, we observed that a lack of CMV infection or seropositivity for less than 
2 herpesviruses was associate with an increased risk for the development of 
celiac disease autoimmunity (Jansen et al submitted), suggesting a protective 
effect of herpesvirus infection. A similar effect of herpesviruses has previously 
also been described for allergic diseases.58-60 Importantly, this protective effect 
might be limited to infection before the second year of life,60,84 and might require 
wild type infection and not vaccination.59 These observations are in line with the 
relatively limited immune disturbance that we observed upon early CMV and EBV 
infection in both the T-cell compartment (Chapter 5) and the B-cell compartment 
(Chapter 6), and are in line with the hygiene hypothesis. The increasing hygiene, 
smaller family size and increasing use of bottle feeding in the Western world, and 
the concomitant change in our microbiome and infection pressure in the Western 
population, is negatively correlated with the prevalence of allergic or autoimmune 
diseases.33,34
As a result of the diverse range of above-described clinical aspects to be considered, 
opinions on whether or not herpesvirus infection should be prevented by universal 
immunization are varying. Our data might argue against herpesvirus vaccination 
in young childhood (e.g. below 2 years of age) as herpesvirus infection at young 
age might be beneficial in priming immune maturation. However, as delayed 
infection poses important clinical risks, especially upon primary CMV infection 
during transplantation or pregnancy,74 delayed herpesvirus infection might be 
disadvantageous and should preferably be prevented. Therefore, immunization 
against especially CMV and EBV might prove beneficial in children that were not 
naturally infected during the first few years of life.
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THE uNIquE OPPORTuNITIES PROVIDED By lARGE COHORT 
STuDIES
The studies described in this thesis were performed in two unique population 
cohorts: the Generation R cohort and the Dutch vertically HIV-infected pediatric 
population cohort (HIV-cohort).85-87 Both cohorts are prospective population-
based cohort studies involving long-term follow-up of young children and include 
a detailed clinical or environmental characterization of the included individuals. 
The large size of the Generation R cohort enabled studies on clinically minor 
patient groups, which would otherwise be too small to be studied in detail. One 
of those opportunities was the inclusion of children with slightly delayed or lack 
of VZV infection. As VZV infection reaches nearly 100% in adults, and already 
>90% in 6-year-old children in the Netherlands,73 effects of VZV infection on the 
composition of the immune compartment could never be studied in detail before.88 
Moreover, in such studies, the effects of other persistent viruses, such as CMV and 
EBV, would need to be excluded. By studying this large Generation R population 
cohort, and focusing on 6-year-old children, we could identify 69 children being 
negative for HSV-1 and VZV. This allowed us, for the first time, to study the effect 
of VZV on the immune system (Chapters 5), while correcting our analyses for 
confounding effects that would otherwise interfere with proper interpretation of 
the data, including potential interference by CMV- and or EBV-associated effects. 
Thus, we showed that VZV did not affect memory T cells, in contrast to CMV or 
EBV. Consequently, VZV infection might be either relatively mild in terms of T-cell 
responses, or persistent T-cell expansions are only present locally and are not 
detectable in blood. 
Our studies on the HIV-cohort, including 69 children, enabled a detailed analysis 
of blood B and T cells (Chapter 7). This number of children, with different age 
between 0-23 years, made it possible to compare the effect of treatment in 
different age-groups. Furthermore, the detailed and longitudinal characterization 
of these children further enabled the discrimination between children with stable 
HIV suppression for >1y, children with suboptimal HIV suppression presenting 
low virus loads at the moment of sampling or detectable virus loads within the 
preceding year, and children that lacked virus suppression. Thereby we were 
able to correlate our findings to the presence of HIV in serum, and to define the 
relevance of optimal virus control. The detailed 8-color flow cytometry analyses 
of this large HIV-cohort enabled the identification of persistent immune defects, 
despite current cART protocols, that might provide important new targets for 
future studies (see Section “Persistent subclinical immune defects in HIV-infected 
children”)
CONCluDING REMARkS
A properly build immune system during the first few years of life is essential for 
long-term survival without the development of clinical complications. Persistent 
viral infections are known to have a strong impact on this immune maturation. 
The studies presented in this thesis combine both large-scale analyses on the 
complexity of immune maturation, and detailed immunological analyses on the 
origin, maturation or responsiveness of selected lymphocyte populations. Where 
large-scale cohort studies provide the unique possibility to analyze isolated 
determinants while excluding interference by the large variety of confounding 
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factors, only the addition of detailed cellular and molecular analyses will allow the 
study of immune maturation in its complete depth and complexity. 
Combined, the studies presented in this thesis stress the plasticity of the childhood 
immune system and its capability to control viral infection without large-scale 
immune dysfunction. This information will be important, not only for our basic 
understanding of healthy immune maturation, but might also contribute to 
our understanding of immune dysfunction during chronic immune stimulation. 
Furthermore, it might add to the ongoing debate of herpesvirus vaccination. In 
addition, the identification of persistent subclinical defects in selected lymphocyte 
populations in blood of cART treated HIV-infected children, might directly contribute 
to targeted long-term clinical follow-up of these children. 
It will be essential to continue combined epidemiological and detailed molecular 
immunological studies on the composition of the immune system in children under 
the influence of different inflammatory conditions or microbial colonization, as 
well as in children carrying different viral infections and being infected at different 
age. These studies will even further improve our understanding of what drives the 
maturation of the immune compartment during childhood and what defines its 
homeostasis. 
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During pregnancy, a fetus is protected from a large part of the pathogens of 
the environment. As a result, a newborn’s immune system is immature and 
unexperienced, and mainly composed of innate leukocytes and naive lymphocytes. 
Memory lymphocytes, and concomitant functional immunity, needs to be formed in 
response to various pathogen encounters. Most of the immune maturation occurs 
during the first few years of childhood, during which the child comes into contact 
with a large variety of pathogens. Though most of the pathogens are cleared, after 
which life-long immunity is generated, some viruses evade virus clearance and 
induce a state of latency and viral persistence. Due to their continuous presence 
and continuous pressure on the immune system, persistent viral infections are 
known to have a strong impact on the immune system of especially elderly. The 
research described in this thesis was set out to characterize immune maturation 
during early childhood, in response to various environmental determinants with a 
specific focus on persistent viral infections.  
In Chapter 2, we studied the dynamics of leukocyte subsets within the innate 
leukocyte, naive and memory B-cell and naive and memory T-cell lineages, 
and investigated which external determinants were associated with childhood 
leukocyte dynamics. We demonstrated that the dynamics of leukocyte subsets 
could be divided in four main age-related patterns, with functionally similar 
leukocyte populations following similar kinetics. Furthermore, the effect on 
immune dynamics by various external determinants related to prenatal maternal 
life style, maternal immune-mediated diseases, birth characteristics or bacterial/ 
viral exposure, were described. Our data confirms previously described effects 
of persistent Cytomegalovirus (CMV) and Epstein Barr virus (EBV) infections 
on memory B-cell and T-cell dynamics, and identified new effects, including the 
association between Herpes Simplex virus 1 (HSV-1) seropositivity and reduced 
naive B-cell numbers. Our large-scale analysis of all leukocyte subsets and various 
external determinants allowed for the identification of new determinants that can 
provide targets for studies on the molecular processes that regulate leukocyte 
development and immune responses. 
In Chapter 3, the effect of breastfeeding was studied in more detail in a cross-
sectional study on breastfed versus bottle-fed children at the age of 6, 14, 25 and 
72 months. We demonstrated a negative association between longer breastfeeding 
duration and the numbers of T-cell dependent CD27-IgG+, CD27+IgM+ and 
CD27+IgA+ memory B-cell populations at the age of 6 months. These effects 
disappeared after breastfeeding discontinuation. Furthermore, we demonstrated 
that breastfeeding exposure, independent of breastfeeding duration, had a 
positive effect on the size of the cytotoxic CD8+ T-cell compartment, potentially 
suggesting a lasting priming of CD8+ T-cell immunity via breastfeeding. Combined 
these observations might suggest that breastfeeding reduces the need for humoral 
immune responses, while priming cellular responses, thereby enabling step-wise 
immune maturation. 
In Chapter 4, we demonstrated the differences in infection prevalence for CMV, 
EBV and HSV-1 in populations with different ethnicities. The ethnic differences in 
EBV and HSV-1 prevalence could in part (up to 39%) be ascribed to socioeconomic 
position and factors related to life style. This might suggest an important 
involvement of horizontal transmission for EBV and HSV-1 infection, which would 
be related to factors such as family size or daycare attendance. Ethnic differences 
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in the prevalence of CMV infection were independent of socioeconomic position 
and factors related to life style. In contrast CMV infection seemed to be positively 
associated to breastfeeding, suggesting the involvement of vertical transmission 
from mother to child. 
CMV and EBV are associated with changes in immunological memory. Infected 
adults display persistent expansions of virus-specific effector memory T cells in 
both the CD8+ and the CD4+ T-cell lineages. In Chapter 5, we studied the memory 
T-cell compartment in detail in 6-year-old children with or without infection with 
CMV and/or EBV. We demonstrated similar virus-associated T-cell expansions as 
those described in adults. Furthermore, we demonstrated that these effects were 
independent of HSV-1 and Varicella Zoster virus (VZV) infection. However, in 
contrast to suggestions in elderly, CMV- and/or EBV-associated effector memory 
T-cell expansions in 6-year-old children did not result in a loss of the naive or 
central memory T cells, nor in a loss of vaccination responses against non-
related Measles or Tetanus vaccination. Moreover, in 6-year-old children infected 
before age 2 years, stable control of these persistent viruses was maintained 
with only limited effector memory T-cell expansions. This might suggest an only 
mild change in the CD8+ T-cell compartment upon childhood infection with CMV 
or EBV. These new insights into the immunomodulatory effects of herpesviruses 
in young children are important for our understanding of herpesvirus-associated 
immunosenescence in the elderly.
EBV has been shown to persist in memory B cells. Still, it is unclear whether 
persistent EBV infection results in altered B-cell memory. Therefore, in Chapter 
6, we studied persistence of EBV in the various memory B-cell subsets and the 
memory-B-cell compartments in children persistently infected with EBV. We 
demonstrated that, in adults, EBV was able to persist in all class-switched memory 
B-cell populations, independent of their germinal center dependent or independent 
origin. In addition, through extensive flowcytometric immunophenotyping in EBV-
infected children, we were able to demonstrate that EBV infection in the first 
year of life resulted in a reduction in the memory B-cell expansion that normally 
occurs at the age of 14 months. However, this reduction seemed transient as it 
normalized before the age of 6 years. Moreover, it did not seem to have long-term 
consequences on vaccination responses against tetanus and measles vaccination. 
Combined, this study demonstrates the  impact of EBV infection on immunological 
memory in young children, as well as the plasticity of the immune system to 
overcome this. 
With the introduction of combined antiretroviral therapy (cART), Human 
Immunodeficiency virus (HIV) infection is becoming a chronic instead of lethal 
disease, and perinatally HIV-infected children can reach adulthood with minimal 
clinical complications. However, long-term effects of persistent HIV infection and 
cART in children currently remain unclear. In Chapter 7 we studied a cohort HIV-
infected children and adolescents receiving cART. We demonstrated that cART 
is able to effectively reduce virus load in serum and restore total CD4+ T-cell 
numbers and many of the other HIV-related immune defects. Still, a selection 
of subclinical immunological defects was identified in blood of cART treated HIV-
infected children. These involved the CD4+ T-cell, CD8+ T-cell, TCRγδ+ T-cell 
and memory B-cell lineages, and were shown to be in part caused by defective 
immune maturation. A detailed understanding of the immunological conditions 
of HIV-infected children and the identification of potential early signs of clinical 
complications in the future, will be highly important for future health care and 
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potential further treatment optimization in these HIV-infected children. Though 
still subclinical, the identified defects might provide important targets for targeted 
clinical follow-up of the HIV-infected children.
Combined, the studies presented in this thesis underline the complexity of the 
childhood immune dynamics and identify various external factors associated with 
immune maturation, with a focus on breastfeeding and persistent viral infections. 
Moreover, these studies stress the plasticity of the childhood immune system 
upon viral infection with herpesviruses and the HIV virus. Children seem to 
control persistent herpesvirus infections without the negative effects that have 
been observed in elderly. This information will be important, not only for our 
basic understanding of healthy immune maturation, but might also contribute to 
our understanding of immune dysfunction during chronic immune stimulation. 
Knowledge on immune dynamics and the external determinants that shape the 
childhood immune system will provide more understanding of the processes that 
underlie the formation of long-lasting immunity without inducing destructive, 
excessive or insufficient immune responses.
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Het afweersysteem van de mens bestaat uit een complex geheel van cellen en 
moleculen. Het kan worden onderverdeeld in aangeboren afweer en verworven 
afweer. Aangeboren afweercellen functioneren direct na hun aanmaak en deze 
eigenschappen veranderen niet tijdens of na een afweerreactie. In tegenstelling, 
wordt de verworven afweer grotendeels gevormd als gevolg van contact met 
ziekteverwekkers. De verworven afweer bestaat uit B en T cellen. B en T cellen 
starten hun ontwikkeling als naïeve cellen die nog niet in contact zijn gekomen met 
een ziekteverwekker. Pas na contact met een ziekteverwekker zal een naïeve B of 
T cel gaan delen en uitrijpen tot effectorcellen die de ziekteverwekker bestrijden, 
of tot geheugencellen. Deze geheugencellen blijven lange tijd in het lichaam 
aanwezig en kunnen zich bij een volgend contact met dezelfde ziekteverwekker 
snel ontwikkelen tot een effectorcel. Daardoor kan de ziekteverwekker bij een 
volgend contact meestal snel uit het lichaam worden verwijderd voordat er 
ziekteverschijnselen ontstaan. In dit geval spreken we van immuniteit tegen deze 
ziekteverwekker. Het verworven afweersysteem past zich op deze manier als het 
ware aan aan de omgeving.
Tijdens de zwangerschap wordt een foetus in de baarmoeder beschermd tegen 
een groot deel van de ziekteverwekkers uit de omgeving. Daarom bestaat het 
afweersysteem in pasgeborenen voornamelijk uit aangeboren afweercellen 
en naïeve B en T cellen. Geheugencellen en bijbehorende immuniteit, zullen 
grotendeels gevormd worden na de geboorte als gevolg van contact met de vele 
verschillende ziekteverwekkers in de omgeving. De veelheid aan ziekteverwekkers 
die een kind vooral in de eerste levensjaren tegenkomt bepalen dus grotendeels 
de vorming van zijn afweersysteem. 
Hoewel de meeste virussen door middel van een afweerreactie worden verwijderd 
uit het lichaam, zijn sommige virussen in staat het afweersysteem te ontwijken en 
zich blijvend in het lichaam te ‘verschuilen’. Dit zijn zogeheten persistente virussen. 
Een aantal bekende persistente virussen zijn het humaan immunodeficiëntie virus 
(HIV), en leden van de herpesvirusfamilie, waaronder het cytomegalovirus (CMV), 
Epstein Barr virus (EBV), herpes simplex virus-1 (HSV-1) en varicella zoster virus 
(VZV). Doordat deze virussen continu in het lichaam aanwezig zijn, oefenen ze 
een sterke druk uit op het afweersysteem. Bij een deel van de ouderen beïnvloedt 
dragerschap van deze virussen het afweersysteem sterk, waardoor ze minder goed 
kunnen reageren op andere ziekteverwekkers, waaronder het influenza (griep) 
virus. Het is echter niet duidelijk of deze effecten al op jonge leeftijd ontstaan, 
of dat het afweersysteem bij jongeren anders reageert op deze virussen dan bij 
ouderen. Daarom was het doel van het onderzoek beschreven in dit proefschrift 
het bestuderen van de vorming van het afweersysteem in jonge kinderen en hoe 
infecties met persistente virussen deze vorming beïnvloeden. 
In Hoofdstuk 2 hebben we bestudeerd hoe de aantallen van de diverse typen 
afweercellen in bloed van kinderen veranderen tijdens de eerste 6 jaren van hun 
leven. Deze metingen zijn verricht binnen de Generation R Study waarin 10.000 
kinderen vanaf het eerste trimester van de zwangerschap worden gevolgd. 
Hierdoor zijn van veel kinderen gegevens van meerdere tijdspunten beschikbaar 
evenals vele sociale en biologische gegevens. Bij deze kinderen hebben we 
aangetoond dat de afweercellen in het bloed kunnen worden onderverdeeld in 4 
groepen op basis van de dynamiek in de cel aantallen. Hierbij volgden functioneel 
vergelijkbare afweercelpopulaties hetzelfde patroon. Deze grote Generation R 
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Study maakte het daarnaast mogelijk om te bestuderen welke omgevingsfactoren 
geassocieerd zijn met de dynamiek van afweercellen. We hebben hierbij gefocust op 
omgevingsfactoren die gerelateerd zijn aan 1) de levensstijl van de moeder tijdens 
de zwangerschap (bijvoorbeeld roken en alcoholgebruik), 2) de aanwezigheid 
van auto-immuunziektes of allergieën bij de moeder, 3) karakteristieken van de 
geboorte (bijvoorbeeld of een kind is geboren via een keizersnede of vaginale 
bevalling, of informatie over het geboortegewicht), of 4) het contact met 
bacteriën/virussen. Allereerst bevestigen onze resultaten eerdere bevindingen uit 
de literatuur over het effect van CMV en EBV op de verandering in de aantallen 
B en T geheugencellen. Daarnaast hebben we nieuwe effecten geïdentificeerd, 
zoals een verminderd aantal naïeve B cellen in bloed van HSV-1-geïnfecteerde 
kinderen. Onze grootschalige analyses van dit grote aantal leukocytenpopulaties 
en de vele omgevingsfactoren hebben het mogelijk gemaakt om nieuwe factoren 
te identificeren die kunnen worden gebruikt in vervolgstudies naar de processen 
die de vorming van het afweersysteem reguleren. 
In Hoofstuk 3 hebben we op de leeftijden van 6, 14, 25 of 72 maanden de 
effecten van borstvoeding en flesvoeding op het afweersysteem bestudeerd. Op 
de leeftijd van 6 maanden vonden we dat naar mate een kind langer borstvoeding 
kreeg, verschillende populaties binnen de B geheugencellen kleiner werden. Deze 
effecten waren niet meer detecteerbaar nadat de borstvoeding werd gestopt. 
Daarnaast hebben we gevonden dat kinderen die borstvoeding kregen, een 
vergrootte populatie van T geheugencellen hadden, namelijk de CD8+ centrale 
T geheugencellen. Dit effect was onafhankelijk van de hoe lang een kind 
borstvoeding kreeg. Samen, suggereren deze bevindingen dat een kind dankzij de 
beschermende werking van borstvoeding tijdelijk minder B geheugencellen hoeft 
te vormen, terwijl borstvoeding de vorming van T geheugencellen juist stimuleert. 
Mogelijk faseert het geven van borstvoeding de vorming van het afweersysteem 
door eerst de vorming van T geheugencellen te laten plaatsvinden en pas later de 
B geheugencellen. 
In Hoofdstuk 4 hebben we laten zien dat de frequentie van CMV, EBV en HSV-
1 infectie binnen een bevolking sterk afhangt van de etniciteit van de geteste 
groep mensen. Deze variatie tussen verschillende etnische groepen kon in het 
geval van EBV en HSV-1 infectie voor ≤39% worden verklaard door verschillen 
tussen de etnische groepen in de levensstijl en socio-economische status van 
de moeder. Dit hangt mogelijk samen met factoren zoals familiegrootte of het 
gebruik van kinderopvang en sluit aan bij eerdere bevindingen dat HSV-1 en 
EBV veelal horizontaal worden overgedragen door contact tussen familieleden 
of tussen kinderen op kinderdagverblijven. De verschillen in de frequentie van 
CMV infectie tussen verschillende etnische groepen waren niet afhankelijk van 
de socio-economische status of levensstijl van de moeder; CMV infectie kwam 
juist frequenter voor in bevolkingsgroepen die vaker borstvoeding gaven dan 
flesvoeding. Dit suggereert een rol voor de zogeheten ‘verticale overdracht’ van 
CMV van moeder naar kind. 
Een selectie van CMV- en EBV-geïnfecteerde ouderen hebben sterk toegenomen 
aantallen CMV- en EBV-specifieke T geheugencellen en een verminderde 
afweerrespons op vaccinaties tegen bijvoorbeeld influenza. Om te bepalen of CMV 
en EBV ook op jonge leeftijd zulke effecten geven, hebben we, in Hoofdstuk 5, 
T geheugencellen in detail bestudeerd bij 6-jaar-oude kinderen met of zonder 
CMV en/of EBV infectie. We hebben aangetoond dat CMV en EBV infectie elk 
resulteerden in een toename van een ander type T geheugencel, en dat beide 
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toenames aanwezig waren in dubbel-geïnfecteerde kinderen. Deze toenames 
waren onafhankelijk van infectie met twee andere herpesvirussen: HSV-1 
en VZV. In tegenstelling tot ouderen, leidden deze vergrote populaties van T 
geheugencellen bij kinderen niet tot verminderde aantallen naïeve T cellen of 
andere T geheugencellen, of tot het verlies van vaccinatieresponsen tegen de 
niet-gerelateerde ziekteverwekkers mazelen en tetanus. Het toegenomen aantal 
T geheugencellen was op 6 jarige leeftijd kleiner bij kinderen die al voor het 2e 
levensjaar waren geïnfecteerd met CMV of EBV, dan bij kinderen die op latere 
leeftijd waren geïnfecteerd. Onze resultaten suggereren dat er slechts een milde 
verschuiving ontstaat in de T-celpopulaties na infectie met CMV of EBV in de 
vroege kindertijd. Deze bevindingen zijn in tegenstelling met eerder beschreven 
sterke effecten van deze virussen op de T cellen in ouderen. Deze nieuwe inzichten 
in de effecten van herpesvirussen op het afweersysteem van jonge kinderen 
kunnen een belangrijk bijdrage leveren aan onze kennis over de herpesvirus-
geassocieerde veroudering van ons afweersysteem bij ouderen. 
In de literatuur is beschreven dat het EBV persisteert in B geheugencellen, maar 
het is niet bekend wat het effect daarvan is op de grootte en de verdeling van 
de verschillende B geheugencelpopulaties. Daarom hebben wij in Hoofdstuk 6 
bestudeerd in welke B geheugencelpopulaties EBV persisteert in het bloed van 
volwassenen. Daarnaast hebben we bestudeerd wat het effect is van persistente 
EBV infectie op de aantallen B geheugencellen in bloed van kinderen. We hebben 
aangetoond dat EBV in alle 6 typen B geheugencellen kan persisteren, maar dat 
de frequentie het hoogst was in de IgA+ en IgG+ subsets. Op de leeftijd van 
14 maanden waren de aantallen van deze B geheugencellen significant lager in 
het bloed van EBV-geïnfecteerde kinderen, in vergelijking met EBV-negatieve 
kinderen. Dit effect was kortstondig en op 6-jarige leeftijd waren de aantallen 
B geheugencellen in deze EBV-geïnfecteerde kinderen vergelijkbaar met die in 
EBV-negatieve kinderen en kinderen die pas tussen 14 maanden en 6 jarige 
leeftijd waren geïnfecteerd met EBV. Bovendien hadden de EBV infectie en de 
bijbehorende tijdelijke verlaging van B geheugencellen geen langdurig effect op 
vaccinatieresponsen tegen tetanus en mazelen. Hiermee hebben we voor het 
eerst een negatief effect gezien van EBV persistentie op B geheugencellen en 
hebben we vooral het vermogen aangetoond van het afweersysteem om deze 
gevolgen te herstellen. 
Infectie met HIV heeft een enorme invloed op het afweersysteem, maar dankzij de 
invoering van gecombineerde antiretrovirale therapie (cART) zijn de effecten veel 
kleiner dan voorheen. Veelal kunnen HIV-geïnfecteerde kinderen tegenwoordig 
de volwassen leeftijd bereiken zonder veel klinische problemen. Toch is het 
lange-termijn effect van HIV infectie en de bijbehorende cART behandeling nog 
onvoldoende bekend. In Hoofdstuk 7 hebben we het verworven afweersysteem 
bestudeerd in een groep met HIV-geïnfecteerde kinderen en jongvolwassenen 
die onder behandeling waren van cART. We hebben gevonden dat cART in staat 
was de hoeveelheid virus in het bloed te verlagen tot beneden de detectiegrens 
van de meettechniek. Als gevolg werden CD4+ T cellen niet massaal geïnfecteerd 
en waren deze aantallen vrijwel normaal. Daarnaast zorgde cART behandeling 
ervoor dat de aantallen B en T geheugencellen, en de meeste andere effecten van 
het virus op het afweersysteem, bijna volledig normaliseerden. Desalniettemin 
konden we een aantal subklinische defecten identificeren die niet verdwenen 
door de behandeling. Dit betrof onder andere een blijvend verlies van CD4+ T 
cellen, TCRγδ+ T cellen en B geheugencellen, en een blijvend toegenomen CD8+ T 
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celpopulatie. Een gedetailleerd beeld van de conditie van het afweersysteem van 
HIV-geïnfecteerde kinderen, en het herkennen van signalen die mogelijk wijzen 
op toekomstige klinische problemen, is uiterst belangrijk voor de gezondheidszorg 
en eventuele verdere optimalisatie van behandeling. Hoewel de geïdentificeerde 
defecten (nog) subklinisch zijn, kunnen de geïdentificeerde populaties mogelijke 
belangrijke targetpopulaties zijn voor immunologische monitoring van HIV-
geïnfecteerde kinderen. 
Gezamenlijk illustreren de studies in dit proefschrift de complexe dynamiek in 
het afweersysteem van jonge kinderen en het effect van persistente virussen 
hierop. Onze bevindingen benadrukken het vermogen van het afweersysteem van 
kinderen om een infectie met een persistent virus zoals de herpesvirussen of HIV 
onder controle te houden zonder de negatieve effecten die beschreven zijn bij 
ouderen. Deze informatie kan niet alleen bijdragen aan onze basale kennis over de 
vorming van het gezonde afweersysteem, maar kan mogelijk ook een belangrijke 
bijdrage leveren aan onze kennis over de disfunctie van het afweersysteem tijdens 
chronische (virus-gerelateerde) stimulatie. Bovenal zal deze informatie bruikbaar 
zijn bij het verder ontrafelen van de processen die de vorming van levenslange 
immuniteit reguleren zonder de vorming van ontoereikende, excessieve of zelfs 
destructieve responsen.
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AID  Activation-induced cytidine deaminase
AIDS   Acquired immunodeficiency syndrome
anti-TPO anti-thyroid peroxidase IgG
anti-tTG Anti-tissue transglutaminase IgA antibody
APC  Antigen presenting cell
BCR  B-cell receptor
BMI  Body mass index
cART  Combined antiretroviral therapy
CCR  Chemokine receptor
CD  Cluster of differentiation
CI  Confidence interval
CMV  Cytomegalovirus
CR  Complement receptor
CSR  Class switch recombination
D  Diversity
DC  Dendritic cell
EBV  Epstein Barr virus
FSC  Forward scatter
HIV  Human immunodeficiency virus
HLA  Human leukocyte antigen
HSC  Hematopoietic stem cell
HSV-1  Herpes simplex virus-1
Ig  Immunoglobulin
IgH  Immunoglobulin heavy chain
IgL  Immunoglobulin light chain
Igκ  Immunoglobulin kappa
Igλ  Immunoglobulin lambda
IL  Interleukin
INF  Interferron
J  Joining
KLRG1  Killer cell lectin like receptor G1
MHC  Major histocompatibility complex
NK cell  Natural killer cell
OR  Odds ratio
PD-1  Programmed death
SD  Standard deviation
SES  Socio-economic status
SHM  Somatic hypermutation
SSC  Side scatter
TI  T cell-independent
TD  T cell-dependent
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Tc  Cytotoxic T cell; CD8+ T cell
Tcm  Central memory T cell
TCR  T-cell receptor
Tem  Effector memory T cell
TemRA  CD45RO- effector memory T cell
TemRO  CD45RO+ effector memory T cell
TG2A  Anti-tissue transglutaminase IgA antibody
Th  Helper T cell; CD4+ T cell
TNF  Tumor necrosis factor
Treg  Regulatory T cell
V  Variable
VCA  Viral capsid antigen
VZV  Varicella zoster virus
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Britt, Jorn, Marieke, Edwin, Benjamin, Halima en Katharina. Sommigen heb ik 
hierboven al bedankt. Magda R., we started together on the FRET project, are now 
defending on two consecutive days, and even party together. Both of us struggled 
through the process of writing and finishing our thesis together. When you were 
stressed out, I would try to listen, but what happened most of the time is that I 
would freak out and you would listen and tell me that the world is not going to 
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alles onder controle. Je gaat bijna naar Australië en daarna je promotieonderzoek 
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